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General introduction and 
outline of thesis
Colorectal cancer is the third most common type of cancer and accounts for 10.2%of 
all cancers and 9.2% of cancer related deaths worldwide.(1) In the Netherlands, the 
specific incidence counted 9.412 for colonic cancer and 4.457 for rectal cancer in 2018 
respectively.(2) During the last decades the overall 5 year survival has been increasing 
due to advances in screening, early diagnosis, surgery and adjuvant therapy. Last years 
a similar five year overall survival is observed for colon and rectal cancer, respectively 
66% and 67% . Though the majority of research and developments have addressed 
rectal cancer due to higher local recurrence rate, difficulty of surgery in the lower 
pelvis and the more profound impact on patients quality of life . Three persistent major 
problems in rectal cancer are identified: functional impairment, local recurrence and 
difficult surgery reflected in high stoma and conversion rate. The descending colon 
(neorectum) is less capable to fully restore the reservoir function of the rectum and 
surgery and/or irradiation hampers the innervation of the pelvic floor, sphincter and 
urogenital organs resulting in functional complaints such as incontinence, frequent 
bowel movements and sexual dysfunction.(3, 4) In rectal cancer, locoregional recurrence 
occurs more frequently compared to colon cancer.(5) The bony constraints of the 
pelvis in combination with intra-abdominal adipositas limit access hampering safe and 
effective surgery which is reflected in conversion and substantial proportion of non-
restorative procedures (creation of an end-colostomy).(6) The funneling shape of the 
pelvis increasingly endangers a safe resection margin the lower the tumour is located. 
For low cancers, lymphatic draining is not only cephalic within the mesorectum but also 
to lateral pelvic lymph nodes. Treatment of recurrent rectal cancer is often palliative 
or in case of curative intent characterized by highly morbid multivisceral exenterative 
surgery.(7)
Over the past decades several major milestones can be identified which have improved 
the treatment outcome of patients with rectal cancer: sharp dissection along 
embryologic planes, laparoscopy and neo-adjuvant radiotherapy. However, defining the 
optimal strategy to treat rectal cancer in individual cases following these improvements, 
which are characterized by multidisciplinary involvement including neoadjuvant (chemo)
radiotherapy, have become less straight forward. In addition, shared decision making 
with patients based on individual preference in balancing trade-off between oncologic 
safety, treatment associated morbidity and quality of life have resulted in a need for 
tailored treatment strategies.(8)
From a surgical perspective the most renowned milestone has been the principle of total 
mesorectal excision (TME) which constitutes of sharp dissection along the embryological 
avascular “Holy” plane circumferencing the mesorectum with preservation of the 
autonomic nerves as popularized by Heald.(9) The local recurrence rate following 
TME for rectal cancer dropped to 3.7% at 5 years follow-up in his selected series of 
patients operated in Basingstoke and has consistently been reproduced in large trials.
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(10, 11) TME has become the gold standard for surgical resection of rectal cancer. A 
second surgical innovation has been the widespread use of minimal invasive approach, 
mostly laparoscopic, for colorectal cancer resections which results in faster recovery 
and similar long term outcome as demonstrated by the COLOR II trial.(12) Pathologic 
evaluation of the TME-specimen, which constitutes of the rectal tube surrounded by 
the fatty mesorectum containing the lymph nodes, is of paramount importance to 
assess the quality of surgery and identify patients at risk of local recurrence. Quirke 
and Nagtegaal have demonstrated the importance of the circumferential resection 
margin, i.e. distance between plane of dissection and malignant tumour cells, usually 
defined positive when within 1 millimeter and secondly, the quality of the specimen 
categorized by the extent of defects of the mesorectal envelope which is ideally covered 
by its shiny mesorectal fascia.(13, 14)
Another paradigm shift in the treatment of rectal cancer has been the introduction 
of neoadjuvant (chemo)radiotherapy. Radiotherapy aims to sterilize suspected or 
potential metastatic locoregional lymph nodes and/or downsizing of the primary 
tumour in case of a threatened margin to the mesorectal fascia. The Dutch TME trial 
has shown an improved local control for patients who underwent TME + neoadjuvant 
therapy compared to TME alone 2.4% versus 8.2% respectively (p <0.0001).(15) An extra 
paradigm shift has been the rectal preservation strategy as introduced by Habr-Gama 
et al.; for a minority of patients with locally advanced rectal cancer a complete clinical 
response after chemo-radiotherapy cancer is observed. Refraining from surgery and 
implementing a so-called ‘Wait and See’ strategy has been a popular a safe method(16, 
17) Albeit this concerns only a small portion of all rectal cancer patients it has opened 
the door to the concept of organ preservation and questions the dogma of radical 
mesorectal excision as only possibility for curative treatment of all rectal cancer beyond 
low risk early stage tumors.
The annual incidence of rectal cancer in the Netherlands in 2017, two years after 
the introduction of a nationwide screening program, comprised 4.436 patients.(2) 
Following this screening program a stage migration towards more early stage cancer 
has been observed: i.e an increase of smaller cT1/2 tumours.(18) Distinction between 
dysplastic adenomas and very early cancer can be difficult and endoscopic removal 
by the gastroenterologist will yield a proportion of cancerous tumours.[Moons/ backs 
T1] Also in more suspected lesions, a full thickness local excision can be considered as 
step-up approach. Technical advancements to facilitate access and visualization have 
increased the possibility to achieve a good quality full thickness local excision since the 
1980’s when professor G. Buess introduced the Transanal Endoscopic Microsurgery 
(TEM) allowing local excision of lesions located proximal (cephalic) from the anal canal.
(19) Further refinement by replacing the rigid tube (TEM) to a flexible platform by Atallah 
et al in 2020, where after the technique was named Transanal Minimally Invasive Surgery 
(TAMIS).(20) TAMIS helped to increase the indication of cases amendable for a local 
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procedure and improved the quality of the surgical excision as it requires conventional 
laparoscopic instruments and surgical skill.(20)
Avoidance of radical surgery in the pursuit of organ preservation for rectal cancer 
gains more interest of patients and physicians.(21) Similar to multimodal therapy for 
breast cancer, the adjunct of (chemo)radiotherapy either neoadjuvant or adjuvant 
in combination with more restrictive surgery (local excision) for other than locally 
advanced rectal cancer is increasingly investigated. The hypothesis is to sterilize 
possible metastasis in the mesorectum with radiotherapy and only locally excise the 
primary tumour. Currently, two randomized controlled trials evaluate the safety of local 
excision with respectively adjuvant or neo-adjuvant (chemo)radiotherapy compared to 
the gold standard of TME to evaluate whether promising results in terms of oncologic 
safety from cohorts with suspected selection bias can be reproduced.(22, 23)
In coherence with organ preservation strategies, patients that are subject to radical TME 
surgery often prefer sphincter preservation as restorative procedure. A proctectomy 
with creation of an end-colostomy has a higher impact on the quality of life compared 
to when an anastomosis is performed especially in young patients. (24) In 2009, Lacy 
and Sylla performed a revolutionizing new procedure nowadays known as Transanal 
Total Mesorectal Excision (TaTME) which has attracted the attention of the colorectal 
community ever since. The TaTME technique offers the technical ability to create a 
lower anastomosis, thus increasing the restorative and sphincter preservation rate. 
Furthermore, TaTME is suggested to offer improved access which could yield a lower 
conversion rate and better quality of the specimen with lower rate circumferential 
margin involvement and by endoluminal visualization more control of the distal margin. 
(25, 26) For restorative procedures, this technique enables a single-stapled circular 
anastomosis, in contrast to the conventional cross-stapled anastomosis in a pure 
laparoscopic approach. Omitting the stapled linear transection of the rectum at the 
pelvic floor which often requires multiple loads and the “dog-ears” after application 
of the circular stapler through the linear staple line could reduce the incidence of 
anastomotic leakage in theory. (27, 28) Nevertheless, the technique is complex which is 
reflected by a relative long learning curve of 40 to 45 cases based upon histopathologic 
and peri-operative outcomes. (29, 30) Furthermore, long-term oncologic outcomes have 
to be awaited before this new technique can be seen as an oncologically safe alternative 
to the current standard which is a laparoscopic approach.
OUTLINE OF THE THESIS
The first part of this thesis focusses on TAMIS local excision and organ preservation. 
Chapter 2 summarizes the available recommendations of national or international 




rectal cancer. Pathologic examination following local excision of an early rectal cancer 
may reveal risk factors. If such factors are present, the Dutch multidisciplinary guideline 
recommends formal radical resection also named completion surgery to reduce the risk 
of a local recurrence. The local recurrence rate following completion surgery, adjuvant 
chemoradiotherapy and refrained additional therapy but follow-up is compared in 
chapter 3. Early identification of potential candidates for rectal preservation is 
dependent on accurate staging. The accuracy of MRI staging with or without endorectal 
ultrasound for early rectal cancer in daily practice in the Netherlands is evaluated in 
chapter 4. In the context of shared decision making, physicians consider local excision 
in frail patients to avoid radical resection, balancing treatment related morbidity and 
oncologic safety. In chapter 5 the pros and cons of a local excision as palliative option 
in relation to alternative strategies are evaluated.
The second part of the thesis concerns the implementation of transanal minimal 
invasive surgery for total mesorectal excision whereas the first part concerned local 
excision. Chapter 6 summarizes the early experience of centers that published a cohort 
reporting their results with TaTME. In acknowledgement of the technical complexity of 
this technique a structured training pathway including on-site proctoring by surgeons 
experienced in TaTME was developed. In chapter 7 we describe perioperative 
morbidity and histopathologic outcomes of the first ten cases from twelve centers 
that completed this structured training pathway. In the first half of 2019 the occurrence 
of local recurrences following TaTME led to a national stop in Norway. Therefore, the 
oncologic outcomes of all 120 patients in the multicenter structured training cohort 
were externally audited in chapter 8 after signaling the occurrence of some early 
local recurrences in conjunction with the warning report from Norway. The long term 
local recurrence rate in a cohort of patients with a minimal interval of 3 years following 
index operation from the two centers starting TaTME in the Netherlands, Gelderse 
Vallei hospital and the VUmc, was studied in chapter 9. Extension of the bottom-up 
TaTME technique into a more advanced procedure which includes en-bloc resection of 
the pelvic floor and/or sphincter complex is named as a transperineal (extralevatory) 
abdominoperineal excision. In chapter 10 we describe the combined experience of 
five centers with this technique.
The results of this thesis are summarized and discussed in general in chapter 11 
followed by future perspectives on further evaluation and implantation of transanal 
surgery for rectal cancer.
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ABSTRACT
Background: The high morbidity associated with rectal resection for rectal cancer 
serves as an incentive for rectal preserving treatment strategies. This synopsis of 
national and international guidelines aims to determine current consensus and 
controversy among treatment recommendations for early rectal cancer. 
Methods: The databases PubMed, Embase, Trip database, national guideline 
clearinghouse, BMJ Best practice were systematically searched for relevant papers. 
Guidelines published before 2010 were excluded. The AGREE-II tool was used for quality 
assessment.
Results: Out of 2278 potential documents, 24 guidelines were included. Consensus 
exists for local excision of low risk T1 rectal cancer, although there is no uniformity how 
to stratify risk. It’s generally agreed that TME surgery is standard of care for all other 
stages. If rectal preserving alternatives are mentioned, this is mostly recommended 
only in patients unfit for radical surgery or in trial setting with a low level of agreement. 
Guidelines mostly lack any statement on assessing cN0, and surveillance protocols after 
local treatment. Clinical complete response after chemoradiotherapy is addressed by 
a minority of guidelines, mostly emphasizing the experimental status of a ‘watch and 
wait’ strategy or local excision of the scar.
Conclusion: Rectal preserving treatment strategies for rectal cancer, except for low risk 
T1 stage, are still considered experimental or only indicated in patients not suitable for 
standard care according to current guidelines and consensus statements, underlining 
the need for high quality studies. The definition of cN0 stage and surveillance of the 
preserved rectum are underexposed issues that need to be explored further.
WHAT DOES THIS PAPER ADD TO THE LITERATURE?
This guideline synopsis provides a systematic overview of national and international 
guidelines on rectal preserving treatment strategies, thereby identifying lacunae in 




The treatment of rectal cancer is rapidly developing towards a more patient tailored 
approach. Focus is also shifting from solely oncological control towards achieving a 
balance with optimal functional outcome and quality of life. The high morbidity and long-
term functional implications that are associated with radical surgery for rectal cancer 
have encouraged the development of treatment strategies that enable preservation 
of the rectum. Introduction of transanal approaches for local excision of early rectal 
lesions (i.e. Transanal Endoscopic Microsurgery (TEM)) and observing those patients 
who demonstrate clinical complete response after neoadjuvant chemoradiotherapy 
have contributed to this paradigm shift. Finally, the introduction of screening programs 
resulted in a migration towards earlier staged rectal cancers, thereby increasing the 
population of patients who may be treated with organ preservation strategies. There 
is considerable uncertainty and lack of standardisation in the approach to organ 
preservation and an urgent need to define standardized treatment strategies on an 
international level to facilitate an optimal balance between oncological control and 
treatment-related morbidity and sequelae in terms of functional outcome and quality 
of life.(1)
The pivotal publication of “watch and wait”(W&W) by Habr Gama et al. showed promising 
results for patients that achieved a clinical complete response following neoadjuvant 
chemoradiotherapy, and has led to various initiatives to investigate different strategies 
of rectal preservation.(2) However, there is still controversy whether these should be 
implemented as standard of care.
Local excision of low risk early rectal cancer is a commonly accepted rectal preserving 
treatment. However, defining the risk of an early rectal cancer is still debated. 
Intermediate and high risk early rectal cancers often pose a treatment dilemma as 
the increased risk of recurrence after local excision with or without neoadjuvant 
radiotherapy should be weighed against the morbidity associated with (completion) 
total mesorectal excision (TME).(3) The aim of this study is to systematically review 
national and international guidelines in order to provide an overview on the consensus 




A systematic search to identify regional, national and international guidelines and 
consensus documents on treatment of rectal cancer was performed. In collaboration 
with a clinical librarian, the search was carried out on November 5th 2015 using Medline 
(via Pubmed), Embase, Trip database, National Guideline Clearinghouse and BMJ Best 
21
Organ preservation in rectal cancer: a synopsis of current guidelines 
Practice databases. An update of the search was performed at June 2nd 2016 to include 
updates and/or recently published guidelines. Furthermore, websites of the Ministries 
of Health of several Western countries were searched manually.
Selection process
Guidelines written in English, Dutch, German, Scandinavian or Latin languages were 
included. Guidelines published prior to 2010 were excluded. Besides regional and 
national guidelines, consensus statements of multinational organisations (i.e. European 
Society of Medical Oncology or the European Association of Endoscopic Surgery) were 
included as well.
After removal of duplicates, retrieved references were independently screened by two 
reviewers (WAB, SO) on title and abstract using the online Covidence review manager 
(Covidence online review manager 2015, www.covidence.org). In case of disagreement, 
consensus was achieved by discussion. After this second round of screening, an 
additional check on duplicates, updates, addendums, and withdrawn status was 
performed. Full-text assessment of the remaining documents was performed 
independently by two reviewers.
The AGREE-II instrument was used for quality-assessment of the included guidelines.
(4) This instrument incorporates 23 items, which were scored independently by the 
two reviewers from 1 to 7, with 7 as the maximum score. A mean score of each paper 
was calculated, and those scoring 3.00 or less were deemed to be of low quality and 
were therefore excluded.
Data extraction
Data extraction and categorization were performed by WAB and SO and discussed to 
reach consensus. Topics of interest were rectal preserving treatment strategies per 
clinical/pathological stage, preoperative imaging of early rectal cancers, techniques 
of local excision, W&W after neoadjuvant chemoradiotherapy, and follow-up schemes 
after rectal preserving treatment.
Consensus and Level of Evidence
In order to reach consensus, at least two-thirds of the guidelines that made a relevant 
statement on a specific topic needed to have a similar recommendation on rectal 
preserving treatment strategies. For the conclusion statements, the highest level of 
evidence classified to the Oxford centre for Evidence-based Medicine Levels of Evidence 
2009 was retrieved from the included guidelines. (http://www.cebm.net/oxford-centre-
evidencebased-medicine-levels-evidence-march-2009/) If the included guidelines did 
not report their recommendations according to the Oxford classification, the level of 




Figure 1 Inclusion Flow-Chart
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RESULTS:
Literature search
The search resulted in a total of 2278 articles. After removal of duplicates, 1894 titles 
were evaluated for potential use, of which 1857 were excluded based on title or abstract. 
An additional 26 guidelines were retrieved by searching websites of ministries of 
health and surgical or oncological national societies, and by crosschecking references. 
Ultimately, 54 guidelines were assessed by full text for inclusion. Another 28 guidelines 
were excluded based on criteria as provided in Figure 1 (flowchart).
Quality – AGREE-II The remaining 26 guidelines that were assessed for quality consisted 
of 16 national guidelines [e01][e02][e03][e04][e06][e07][e08][e09][e11][e14][e17][e18]
[e19][e24][e25] [e27], eight consensus statements [e10][e12][e13][e15][e16][e20][e21]
[e22], and two sole chapters [e05][e26]. The mean score of the guidelines was 4.70. The 
Cuban[e04] and Danish[e05] guidelines were excluded due to a mean score of 2.21 and 
2.67 respectively. Eventually, a total of 24 guidelines were included.




Table 1 Included guidelines
Guideline Country Year
e1 Colorectaal carcinoom Netherlands 2014
e2 Cancer colorectal en la argentina Argentina 2011
e3 Guía de práctica clínica para la detección temprana, 
diagnóstico, tratamiento, seguimiento y rehabilitación de 
pacientes condiagnóstico de cáncer de colon y recto
Colombia 2013
e4 Consenso nacional de cáncer de recto (excluded) Cuba 2013
e5 Danish colorectal cancer group retningslinier Lokal 
tumorresktion i recum (excluded)
Denmark 2014
e6 Nasjonalt handlingsprogram med retningslinjer for 
diagnostikk, behnadling og oppfolging av kreft it tykktarm og 
endetarm
Norway 2015
e7 Thésuarus national de cancérologie digestive, ch 5 cancer du 
rectum
France 2013
e8 Evidence based guideline for colorectal cancer Germany 2014
e9 Protocolos clinicos e dretrizes terapeuticas em oncologica Brasil 2014
e10 Early rectal cancer: the europoean association for 
endoscopic surgery (EAES) clinical consensus conference
EAES 2015
e11 European guidelines for quality assurance in colorectal 




e12 Managment of patients with colorectal cancer: a 













e14 Consensus document for management of colorectal cancer India 2014
e15 Review of current best practice and priorities for research 
in radiation oncology for elderly patients with cancer: the 
International Society of Geriatric Oncology (SIOG) taskforce 
International 2014
e16 Practice parameters for early rectal cancer management: 
Italian society of colorectal Surgery guidelines
Italy 2015
e17 Management of early colorectal cancer New 
Zealand
2011
e18 National institute for Health and Care Excellence UK 2011/14
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Table 1 Continued.
Guideline Country Year
e19 SIGN Colorectal Scotland 2015
e20 ACR Appropriateness Criteria® Local Excision in Early Stage 
Rectal Cancer
USA 2015
e21 Practice Parameters for the management of Rectal Cancer 
(revised)
USA 2013
 ASCRS follow up   
e22 EURECCA colorectal: multidisciplinary management: 
European consensus conference colon &rectum
Europe 2014
e24 NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer USA 2015
e25 JSCCR guidelines 2014 for the treatment of colorectal cancer Japan 2014
e26 Early stage rectal cancer Canada 
(Alberta)
2013
e27 Cancer colorectal Adénocarcinome France 2012
SYNOPSIS
1.Staging
In the pre-treatment staging of rectal cancer, MRI and endorectal ultrasound (ERUS) 
have been described as imaging modalities. Local excision is only recommended in 
N0 stage rectal cancer, therefore staging with MRI to exclude lymph nodes suspected 
for metastasis is mandatory. Seven out of the 24 included guidelines, mentioned 
criteria for lymph node assessment based on MRI [e01][e10][e12][e13][e16][e21]
[e22]. Irregular border, signal heterogeneity and a round shape were named in all as 
morphologic characteristics associated with malignancy. Two guidelines mentioned a 
size >8 mm as a risk factor [e12][e22], and the Dutch guideline mentioned a size >5mm 
as a risk factor when concomitant suspicious morphologic features were observed 
[e1]. ERUS is superior in analysing depth of invasiveness for small rectal cancers, 
thereby differentiating between T1 and T2. MRI is superior to assess ingrowth into the 
mesorectal fat and mesorectal fascia. Therefore, MRI is recommended for larger lesions. 
This recommendation was mentioned in 14 guidelines [e06][e07][e08][e10][e12][e13]
[e14][e16][e17][e20][e21][e22][e26][e27]. In six guidelines MRI was recommended above 
ERUS, and that ERUS should be reserved for expert centres or solely when local excision 
is planned [e1][e3][e8][e11][e18][e19]. The NCCN guidelines (USA) did not differentiate 
between MRI or ERUS and stated that imaging should be performed according to 





 MRI and ERUS should be used complementary in the staging of rectal cancer. ERUS is 
superior when analysing depth of invasiveness in small superficial cancers, and MRI is 
superior for assessing mesorectal lymph nodes as well as ingrowth into the mesorectum 
and mesorectal fascia. Consensus. level of evidence: 2b.
2. Treatment based on clinical stage (cTNM)
cT1NOMO
Local excision for clinical staged cT1NOMO was advised in 13 of the included guidelines 
[e01][e03] [e06][e07][e10][e12][e14][e17][e20][e21][e22] [e24][e25]. Eight guidelines 
mentioned neo-adjuvant treatment for cT1-2 tumours followed by local excision as an 
alternative treatment strategy, but only in trial setting [e01][e03][e06][e8][e10][e11][e20]
[e21]. Additionally, the ESMO guidelines specifically mentioned contact radiotherapy 
or brachytherapy as an option for patients not fit for any type of surgery [e12]. Two 
guidelines advised TME for cT1N0M0, of which the Canadian guideline specifically 
mentioned that, if a patient consents with a higher risk on recurrence, a local excision is 
a viable option [e13][e26]. The NICE guideline from the United Kingdom stated that TME 
should be considered standard therapy for early rectal cancer as the evidence for all 
other treatment strategies is of inadequate quality [e18]. The European Union guideline 
refrained from recommendation based on cT1N0MO-stage [e11]. Six guidelines did not 
make a distinction between clinical- and pathological-staged rectal cancer separately, 
and therefore were not included in this analysis on clinical stage early rectal cancer 
[e02][e16][e09][e15][e19][e27].
Local excision is a safe approach for cT1N0M0 rectal cancer. Consensus, highest level of 
evidence: 1b.
cT2N0M0
None of the seventeen guidelines making a recommendation on this stage advised a 
local excision alone[e1][e3][e6][e7][e8][e9][e10][e11][e12][e13][e14][e15][e16][e21][e22]
[e24] [e25]. One consensus statement[e20] advised neoadjuvant treatment followed 
by local excision and 10 guidelines mentioned neoadjuvant therapy followed by local 
excision as an option in trial setting only, in patients not fit for surgery or in patients 
refusing a TME [e01][e03][e06][e07][e10][e11][e12][e15][e16][e21]. Six guidelines did not 
address this specific stage [e02][e17][e18][e19][e26][e27].
 For cT2N0M0 rectal cancer, TME should be considered standard of care. Consensus, 
highest level of evidence: 2b.
 Local excision following neo-adjuvant therapy can be offered in trial setting or for patients 
not fit for or refusing major surgery. Consensus, Level of evidence: 2b.
3. Definition of high risk pT1 rectal cancer
Six out of the 24 included guidelines did not make a categorisation into low or high 
risk pT1 rectal cancer based on tumour characteristics [e9][e14][e15][e17][e18][e19].
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Of the remaining guidelines, a pT1 tumour was defined as high risk in 13 out of the 
18 guidelines if the pathological examination revealed at least one of the following 
characteristics: poor differentiation, lymphatic- or venous-invasion and a resection 
margin of less than 1mm [e01][e02][e06][e07][e08][e10][e11][e12][e16][e21][e22][e24]
[e25]. Regarding margin status, the Argentinian guideline used a different cut-off of <3 
mm as high risk [e02]. A tumour size >3 cm was mentioned as an additional independent 
risk factor in six of the included guidelines [e1][e2][e7][e8][e17][e21].
Four of the included guidelines based the low/high risk classification of pT1 solely on SM-
classification [E3][e13][e26][e27]. In eight guidelines, SM-classification was mentioned as 
independent factor among the other characteristics (i.e. poor differentiation, lymphatic-, 
venous invasion) [e6][e7][e10] [e12][e16][e22][e24][e25]. Four of these eight guidelines 
mentioned SM3 as high risk and four classified anything higher than SM1 as high 
risk [e6][e7][e10][e16]. The German and the EURECCA guidelines stated that current 
evidence was of inadequate quality to include SM-classification in the definition of low 
or high risk pT1 rectal cancer [e8][e22]. In conclusion, 12 out of 18 guidelines mentioned 
SM-3 as indicator for high risk pT1.
Tumour budding was mentioned as independent characteristic of high risk in four of 
the included guidelines [e7][e11][e25][e27]. Tumour budding is classified into three 
grades, which is based on the amount of individual cells and small clusters of tumour 
cells that infiltrate the interstitium at the tumour resection margin. Grade 1 being less 
than 4 tumour cells within the microscopic field, grade 2 with 5-9 cells, and grade 3 with 
more than 10 cells [e25]. Grade 1 budding was considered to be low risk, and Grade 
2-3 budding was considered to be high risk pT1.
 A pT1 rectal cancer is defined as high risk if any of the following characteristics is 
mentioned in the pathology report: poor differentiation, lymphatic- or venous invasion, 
a clear resection margin of less than 1mm and sm3. Consensus, Level of evidence: 2b.
4. Treatment based on pathological stage (pT)
4a. pT1 Low risk (well-moderately differentiated, no venous invasion, no lymphatic inva-
sion, <3-4cm, SM1-2)
Following local excision or polypectomy of a low risk T1 rectal cancer, nineteen [e01]
[e02][e03][e06][e07][e08][e09][e10][e11][e12][e13][e14][e16][e19][e20][e22][e24]
[e25][e27] papers stated that no adjuvant therapy (completion surgery or (chemo-)
radiotherapy) was indicated. In five guidelines, there were no separate statements for 
risk categories of pT1, and adjuvant treatment after local excision was not mentioned 
[e15][e17][e18][e21][e26].





4b. pT1 high risk (poor differentiation, or venous invasion, or lymphatic invasion, or R1, or 
>3-4cm, or SM3)
Completion TME was recommended by 18 guidelines for high risk pT1 rectal cancer [e01]
[e02][e03][e06][e07][e08][e10][e11][e12][e13][e14][e16][e19][e20][e22][e24][e25][e27]. 
The Brazilian guideline [e09] advised adjuvant (chemo)radiotherapy, and nine other 
guidelines mentioned this as option in trial setting, or for patients not fit for or declining 
surgery [e07][e8][e10][e12][e13][e20][e22][e24][e27]. In addition, the French Thésaurus 
[e07] indicated contact radiotherapy as option for frail patients. Five documents [e15]
[e17][e18][e21][e26] did not clarify a specific advise on treatment for this stage.
 Standard of care after local excision/polypectomy of high risk pT1 is completion TME. 
Consensus, Level of evidence: 2b.
 Adjuvant (chemo)radiotherapy could be an alternative for completion TME in trial setting, 
or for patients unfit for surgery. Controversy, highest level of evidence: 3b.
4c. pT2
Seventeen guidelines [e01][e02][e03][e06][e07][e08][e10][e11][e12][e13][e14][e16][e19]
[e20][e22][e24][e27] recommended a completion TME after local excision of pT2 rectal 
cancer. Adjuvant radiotherapy was mentioned as an alternative for TME in the Brazilian 
guideline[e09] and considered as an alternative option in trial setting, or in patients 
not fit for surgery or declining surgery in 7 other guidelines [e07][e08][e09][e10][e12]
[e13][e20]. Six of the included papers did not make a statement on further treatment 
of locally excised pT2 rectal cancer [e15][e17]e18][e21][e25][e26].
 Standard of care after local excision of pT2 rectal cancer is completion TME. Consensus, 
Level of evidence: 2b.
 Adjuvant (chemo-)radiotherapy following local excision for pT2 rectal cancer is an 
alternative for completion TME in selected patients or in trial setting. Controversy, Level 
of evidence: 3b.
5. Treatment strategy for complete clinical response to neo-adjuvant treat-
ment (ycCR / ycT0)
W&W was mentioned by 8 guidelines in patients with a clinical complete response (cCR) 
after chemoradiotherapy that was indicated based on a clinically advanced stage. The 
Dutch guideline considered TME surgery as standard of care independent of response 
after chemoradiotherapy [e01], and W&W for ycCR should only be performed in trial 
setting. Two guidelines [e07][e15] postulated W&W for fragile patients or patients who 
refuse surgery. Five other guidelines [e08][e13][e18][e21][e24] mentioned the novel 
concept of close monitoring for ycCR but stated that there is no high-quality supporting 
evidence yet. None of the included guidelines incorporated an exact definition on how 
cCR is or should be defined.
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Excision of the scar in case of cCR should be considered according to 4 guidelines 
[e01][e13][e15][e16]. The French Thésaurus [e07] and EAES [e10] consensus statement 
proposed the excision of the scar in ycCR in the setting of a clinical trial. If local excision 
of a remaining scar after (chemo)radiotherapy has been performed, only one guideline 
specified the treatment strategy per specific ypT-stage. The Dutch guideline mentions 
that after local excision of the scar, surveillance can be considered in case of ypT0-1 
if discussed during a MDT meeting in a centre with expertise in rectal preserving 
treatment. Completion TME is advised in case of ypT2-3 by this guideline.
 W&W for ycCR with intensive surveillance by an experienced team can be considered, 
especially in frail patients and those refusing surgery, but should ideally be performed 
in the controlled setting of a trial. Local excision of the scar or small residual disease 
following (chemo)radiotherapy can be considered as alternative to TME surgery, with 
close surveillance for ypT0-1. Controversy, highest level of evidence: 3b.
6. Technique of local excision
A wide variety of different local excision techniques was described in the included 
guidelines: snare polypectomy, endoscopic mucosal resection (EMR), endoscopic 
submucosal dissection (ESD), transanal excision (TE), transanal endoscopic microsurgery 
(TEM), transanal minimally invasive surgery (TAMIS), posterior transphincteric resection, 
posterior proctectomy, and transcoccygial resection. TEM was the preferred technique 
for local excision according to 11 guidelines [e07][e08][e11][e12][e13][e14][e16][e20][e21]
[e22][e25]. Three guidelines considered TAMIS as equivalent [e01][e15] or alternative 
[e10] option for local excision. Endoscopic treatments (i.e. polypectomy, ESD and EMR) 
were indicated according to some guidelines [e06][e10][e18]. EMR is more commonly 
used for the resection of benign lesions and ESD is the preferred technique according 
to gastroenterologists if the lesion proved to be carcinoma and is small enough to 
be excised endoscopically. The European Commission guideline [e11] considered ESD 
inferior to TEM for rectal cancer. Conventional transanal excision was indicated as viable 
option in one guideline [e09], but was considered obsolete by 5 guidelines [e08][e11]
[e16][e20][e21]. Six guidelines [e03][e14][e17][e26][e27] did not specify which technique 
of local excision was advised.
 A minimally invasive surgical approach is preferred for local excision of early stage rectal 
cancer, using either TEM or TAMIS. Consensus, highest level of evidence: 2b.
7. Surveillance protocol following rectal preservation
Of the 24 included guidelines, five mentioned a surveillance protocol after local excision 
of early rectal cancer [e01][e03][e11][e12][e22]. None of the included guidelines 
mentioned a follow-up protocol following W&W. The Dutch guideline recommended 
endoscopic inspection of the scar and pelvic MRI every 3-6 months in the first 2 




sigmoidoscopy combined with digital exam up to five years. Independently of type of 
resection, 14 guidelines recommended a surveillance protocol after curative treatment 
of rectal cancer in general [e01][e02][e03][e07][e08][e09][e11][e12][e13][e19][e22][e24]
[e25][e27]. Although the differences were small, they all proposed a different follow-
up protocol. Six of these specifically stated that for pT1N0 and R0 resection, imaging-
modalities and CEA-testing were of no proven value [e01][e11][e12][e13][e14][e16].
 No uniform surveillance protocol following rectal preserving treatment of rectal cancer 
could be derived from the included guidelines. Endoscopic surveillance of the scar after 
local excision seems to be indicated. Controversy, highest level of evidence: 5.
DISCUSSION
This synopsis included 24 national and international guidelines or consensus documents 
with a statement on rectal preserving therapies for rectal cancer. Despite the growing 
attention and expanding application of this treatment strategy, this synopsis reveals 
that still only consensus exists for local excision of low risk T1 rectal cancer, although 
there is no uniformity how to stratify risk. It is generally agreed that TME surgery 
is standard of care for all other stages, and it is most commonly stated that rectal 
preserving alternatives should only be considered in patients unfit for radical surgery 
or in trial setting if mentioned at all. Unfit for surgery is never defined. Other topics 
with low level of agreement, reflecting the insufficient available evidence are MRI based 
lymph node assessment, W&W in complete responders after neoadjuvant therapy, 
definition and assessment of ycCR, and surveillance protocols after local treatment. 
Only a few guidelines included a statement on these topics. The original idea to conduct 
guideline synopses by the scientific committee of the ESCP was to identify the lacunae 
in the current evidence on specific topics and define areas of research. Therefore, these 
lacunae in rectal preserving treatment of rectal cancer will be discussed in the light of 
upcoming trials or the latest available evidence.
Emerging evidence and topics for further research
Despite the consensus achieved on the type of imaging that should be used for the 
assessment of rectal cancer, there was no consensus among the included guidelines 
regarding the definitions of clinical lymph node status if mentioned at all. The reported 
low sensitivity of 72-91% and 65-76% of endo-ultrasonography and MRI, respectively, 
has likely contributed to the observed variety among the guidelines (Topic 1).(5-8) 
Diffusion-weighted-MRI to assess nodal status has shown to increase the sensitivity 
and specificity. However, more prospective studies and uniformity in definitions are 
needed to increase the accuracy of preoperative staging modalities.(9, 10)
Consensus was observed on the approach of cT1N0M0 and pT1 low risk carcinomas, 
which can safely be treated with organ preserving local excision (Topic 2). Moreover, 
31
Organ preservation in rectal cancer: a synopsis of current guidelines 
the definition of characteristics associated with an increased risk on tumour 
recurrence (and therefore high risk pT1) was univocal among the guidelines regarding 
differentiation grade, lymphatic or venous invasion, resection margins and SM-
classification. Nevertheless, more recently used characteristics such as size of the 
carcinoma and tumour budding were not embedded in the majority of guidelines 
(Topic 3). A recent retrospective study and systematic review showed tumour budding 
to be an independent predictor for increased cancer recurrence.(11, 12) However, a 
more standardized method of assessment is needed before tumour budding can be 
implemented in current clinical practice.
Neoadjuvant radiotherapy for clinically staged cT1-3N0M0 should still only be applied in 
the controlled setting of a clinical trial. Neoadjuvant therapy that would otherwise not 
have been given for these stages, is associated with an increased risk of complications 
following surgery, long-term toxicity, and impaired functionality. These disadvantages 
should be weighed against the oncological safety and probability of preserving the 
rectum on the long term. Results of the recently published CARTS study showed 
that organ preservation with neoadjuvant chemoradiotherapy followed by TEM was 
possible in half of the patients with a cT1-3N0M0, but at the expense of a mortality 
rate of 3.6% related to the chemoradiotherapy and substantial overtreatment in those 
patients insufficiently responding.(13) In the UK TREC trial, cT1-2N0M0 patients were 
randomised between TME and short-course radiotherapy followed by TEM. Next to, 
the recently published GRECCAR-2 trial successfully randomised patients with good 
response to neo-adjuvant radiotherapy for a cT2-3 stage between local excision and 
TME.(14) These trials demonstrate the feasibility of randomising patients with early 
rectal cancer to standard TME surgery and a rectal preserving strategy. The upcoming 
multinational STAR-TREC trial will hopefully provide additional high quality evidence 
to enable evidence based treatment recommendations for rectal preservation based 
on clinical stage (Topic 4). As shown by Bach et al., a locally excised rectal lesion that 
is thought to be benign during preoperative work-up, is found to be malignant in up 
to 40% of the patients.(15) In the presence of high risk features these patients should 
undergo completion TME according to current guidelines as the associated risk of 
local recurrence is around 15, but might be as high as 42% if several risk factors are 
present (Topic 4).(15) The current evidence on adjuvant radiotherapy following local 
excision for this type of early rectal cancers is limited to small retrospective series 
with heterogeneous cohorts.(16) The currently recruiting TESAR Trial (NCT02371304) 
is aiming to provide the needed evidence for this subgroup of patients.(17)
cCR after neoadjuvant therapy is observed in 12% -to 30% of the patients but 
depends on several factors such as initial stage, type of neoadjuvant treatment and 
timing of response evaluation.(18, 19) Moreover, it is important to mention that in 
current literature, there is still substantial variation in the exact definition of a cCR. A 




and MRI seems to be most accurate in evaluating the response.(20) The exact criteria 
for cCR were, however, not assessed in the included guidelines. Reported studies on 
complete responders reflect a selected subgroup of patients with favourable tumour 
characteristics, which is important to keep in mind when interpreting the data. In 
a propensity matched analysis, Renehan et al. showed that 60% of the complete 
responders can be treated in an organ preserving manner.(19) Adequate surveillance 
is needed to detect the one third of patients with a local regrowth at a salvageable 
stage. It should be emphasised that the W&W strategy following cCR needs specific 
expertise and results should be closely monitored as part of a clinical trial or registry. 
Improving the clinical complete response rate in early rectal cancer is one of the 
research questions currently being addressed. Furthermore, there is a need to better 
define how (local excision, digital rectal examination, endoscopy, imaging), and at which 
interval from radiotherapy cCR should be assessed (Topic 5).
Few studies have directly compared TEM versus TAMIS for local excision of early cancers 
and both are recommended as local excision technique (Topic 6). One retrospective 
single-centre cohort study from Melin et al. compared 40 patients undergoing TEM 
with 29 patients that underwent a local excision with TAMIS.(21) They reported a non-
significant trend towards a higher involved margin rate of the TAMIS approach: 2.5% 
vs. 10.3%, respectively . As the basic principle of both surgical options is comparable, 
the additional value of an RCT on this topic seems limited.
Regarding surveillance protocols following organ preservation, the paucity found in 
standardized follow-up protocols among the included guidelines is inevitably a result 
of the limited evidence available. An intensified schedule, which includes endoscopic 
inspection of the scar and pelvic MRI for lymph node assessment, seems warranted 
following rectal preserving strategies. Frequency and duration have to be defined, also 
from a cost-effectiveness perspective.
CONCLUSION
Although rectal preserving treatment strategies for rectal cancer are mentioned to 
a certain extent in the majority of national and international guidelines, the exact 
boundaries and indications of use are still to be defined. Multiple trials are currently 
recruiting to define the optimal neoadjuvant treatment strategies, improve outcomes 
and further determine the exact definitions of early rectal cancer. Awaiting these 
results, rectal preservation should still be seen as an experimental treatment strategy. 
Uniformity in terms of lymph node assessment on imaging, surveillance protocols 
and risk assessment based on pathological examination is needed prior to definitive 
implementation into clinical practice.
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ABSTRACT
Background: After local excision of early rectal cancer, clinical dilemmas arise when 
balancing the risks of recurrence and treatment related morbidity, but few data are 
available to support shared decision-making. The aim of this meta-analysis was to 
determine oncological outcomes after local excision of pT1-2 rectal cancer followed by 
no additional treatment (NAT), completion total mesorectal excision (cTME) or adjuvant 
(chemo)radiotherapy (aCRT).
Methods: A comprehensive search was conducted in PubMed, Embase and the 
Cochrane Library. Primary outcome was local recurrence (LR). Statistical analysis 
included weighted average of proportions.
Results: Of 73 included observational cohort studies, 62 evaluated NAT, 13 cTME, and 
28 aCRT. The included studies comprised 4 793 patients. The LR rate for NAT in low-
risk pT1 tumors was 6.7% (95% CI 4.8-9.3). No LR occurred in low-risk pT1 tumors after 
cTME or aCRT. The LR rate for high-risk pT1 tumors was 13.6% (95% CI 8.0-22.0) for local 
excision only, 4.1% (95% CI 1.7-9.4) for cTME, and 3.9% (95% CI 2.0-7.5) for aCRT. The 
LR rate for pT2 tumors was 28.9% (95% CI 22.3-36.4) after NAT, 4.3% (95% CI 1.4-12.5) 
after cTME and 14.7% (95% CI 11.2-19.0) after aCRT.
Conclusion: Substantial risk of local recurrence has been reported for NAT after local 
excision, especially for high-risk pT1 and pT2 rectal cancer. Completion TME provides the 
lowest recurrence risk. The alternative, aCRT, showed comparable outcomes with cTME 
in high-risk pT1 tumors, but a higher risk in pT2 tumors. These findings may facilitate 




Screening programs for bowel cancer have resulted in a substantial shift towards 
earlier stages of colorectal cancer.(1, 2) Except for low-risk pT1 tumours, the current 
standard treatment for rectal cancer is a total mesorectal excision (TME) with or without 
neoadjuvant (chemo)radiotherapy depending on tumour stage.(3) This radical approach 
is associated with morbidity, long-term functional impairment and consequently a 
decrease in quality of life (QoL).(4, 5) The increased incidence of early lesions, treatment 
related morbidity and the impact of treatment on QoL create a clinical need for organ 
preservation, especially in patients with early rectal cancer.(3, 6)
Clinical staging by endoscopy, MRI, and endoscopic ultrasound (EUS) has shown low 
accuracy in distinguishing low-risk T1 from high-risk T1 or early T2 rectal cancers.(7, 
8) Therefore, local excision as initial diagnostic procedure is an attractive approach in 
early rectal cancer. This might turn out to be therapeutic in selected patients based on 
the histopathological results and is associated with low morbidity and good functional 
outcomes.(9) For high-risk pT1 tumours, local excision is not considered oncologically 
safe due to a higher risk of recurrence.(3, 10, 11) Despite the recommendations of 
guidelines, patients and physicians often refrain from completion TME (cTME) in case of 
high-risk tumours.(12) Clinical data supporting this strategy are scarce and relatively high 
recurrence rates have been reported.(11, 13-16) A promising organ sparing alternative 
after local excision is adjuvant (chemo)radiotherapy (aCRT), which is being evaluated in 
trials.(17) Solid long-term outcome data of all treatment options are essential to develop 
a valid clinical decision-making algorithm for both patients and physicians.
The aim of this meta-analysis was to provide an update on a previous meta-analysis 
and to evaluate the rising amount of data for the three treatment strategies after local 
excision of pT1-2 rectal cancer, namely no additional treatment (NAT), cTME, and aCRT.
(18) For these treatment strategies local recurrence rates, distant recurrence rates and 
both disease-free and overall survival rates were evaluated.
METHODS
Search strategy
The study was performed according to the Preferred Reporting Items for Systematic 
Reviews and Meta-Analysis (PRISMA) guidelines.(19) Comprehensive searches 
regarding the treatment options were performed in the bibliographic databases of 
PubMed, Embase and the Cochrane Library for NAT (Appendix S1) and for cTME and 
aCRT (Appendix S2). Compared with the previous meta-analysis, NAT was added as a 
treatment option and an additional subgroup analysis was performed regarding low- 
and high-risk pT1 tumours.(18) Literature searches were carried out on August 26th 2019 
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and contained all available records to the date of the search. Studies were reviewed for 
eligibility by two independent researchers and a third in case of discrepancies.
Studies were considered eligible if pT1-2 rectal carcinomas were included, treated with 
local excision followed by either NAT, cTME or aCRT, and met the following inclusion 
criteria: local recurrence rates were reported, a minimum of ten patients were included, 
articles were published since 1990 in the English language, and median length of 
follow-up was at least 36 months. Exclusion criteria were neoadjuvant treatment, 
distant metastasis at the time of local excision and studies that included patients with 
suspected nodal metastases on MRI. Studies that did not describe pT stage, treatment 
modality or distinction between colon or rectal cancer were considered ineligible. 
Animal studies, studies with overlapping data, reviews, and letters were excluded.
Quality assessment
In order to assess the quality of the included studies, the Methodological Index for 
Non-Randomised Studies (MINORS) instrument was used.(20) Each item was scored 
independently by two authors from 0 to 2 points; 0 indicating that it was not reported, 
1 indicating that it was inadequately reported and 2 indicating that it was reported 
adequately. In addition to the eight established elements, an item considering allocation 
bias was added to evaluate whether the treatment of choice was according to a protocol, 
to surgeon’s preference or whether the rationale was not described.
Outcome measures and statistical analysis
Primary outcome was local recurrence, defined as endoluminal recurrence or nodal 
recurrence in the pelvis. This included patients with isolated local recurrence as well 
as patients with distant metastases. Secondary outcomes were distant metastases, 
disease-free survival (DFS) and overall survival (OS). Subgroup analyses were performed 
to differentiate outcomes for tumour stage (pT1 vs. pT2). Additionally, the current 
meta-analysis added subgroup analysis regarding low- and high-risk pT1 tumours. 
Low- and high-risk tumours were analysed separately if the presence of risk factors 
was described. High-risk tumours were defined as tumours with at least one of the 
following histopathological risk factors: lymphovascular invasion, poor differentiation, 
deep submucosal invasion (sm3, Haggitt 4 or ≥1000 μm), tumour budding or positive 
resection margins (margin <1mm or tumour in resection plane).(21, 22) In low-risk 
tumours, these factors had to be absent. A weighted average of proportions was 
calculated using the generic inverse-variance method and a random effects model. 
After natural log transformation of the individual proportions final results were back 
transformed. Heterogeneity was assessed by the I2-statistic, an I2 of 75%-100% was 
determined as considerable heterogeneity, hence 75% was used as cut-off value.(23) 
One pooled analysis regarding NAT in pT2 tumours showed statistically significant 
heterogeneity (I2 55%, p<0.01) but was kept in the analyses. Due to heterogeneous 
and scarce reporting of OS and DFS, no weighted averages were determined for these 




included patients with other tumour stages than pT1-2, without specified survival rates. 
Disease-free survival was defined as survival without local or distant recurrence.
RESULTS
Included studies
The literature searches resulted in a total of 14 907 studies. The selection process 
according to the PRISMA guidelines is presented in figures 1 and 2. A total of 76 cohort 
studies were included in this systematic review and meta-analysis, compared to nineteen 
studies in the previous meta-analysis.(18) Sixty-two publications on local excision only 
were included, comprising 3 050 pT1 and 545 pT2 patients.(11, 13-16, 24-80) Thirteen 
studies reported outcomes of local excision followed by cTME, comprising 180 pT1 
and 70 pT2 patients.(11, 33, 35, 44, 56, 59-61, 73, 78, 81-83) Lastly, 28 studies on aCRT 
were included and contained 385 pT1 and 444 pT2 patients.(24, 28, 29, 32, 34, 35, 38, 
41, 42, 48, 52, 54, 59, 60, 63, 64, 67, 72, 74, 75, 84-91) For the subgroup analysis on 
low- and high-risk pT1 tumours a total of 29 studies were included regarding low-risk 
pT1 tumours without additional treatment, one study for cTME, and one for aCRT. The 
total amount of studies that described high-risk pT1 tumours were 19 for NAT, 7 for 
cTME, and 12 for aCRT. Twenty-nine of the 62 studies on local excision only described 
active surveillance during follow-up. For aCRT 14 of the 28 studies reported close 
follow-up schemes. Ten of the 73 (13.2%) included studies were prospective cohort 
studies. Eight prospective studies regarded NAT after local excision, one prospective 
study included cTME patients and three studies evaluated aCRT prospectively. Different 
local excision techniques were utilised in the included studies. For the NAT treatment 
group 52 of the 62 studies evaluated surgical modalities of local excision, five of the 62 
studies investigated endoscopic local excisions, and 5 studied either both or did not 
describe the local excision technique. For cTME nine out of thirteen studies evaluated 
surgical local excision, three studies investigated endoscopic local excision and one 
study included both surgical and endoscopic techniques. In studies regarding aCRT 24 
out of 28 studies evaluated surgical excision techniques, four studies investigated both 
surgical and endoscopic techniques or did not describe the utilised excision method. 
Detailed information concerning the characteristics of all included studies is provided 
in table S1-3 of the supplementary material.
Local recurrence rate
The local recurrence rate of patients with a pT1 tumour without additional treatment 
was 8.1% (95% CI 6.6-9.9) (Table 1). Completion TME after local excision of a pT1 tumour 
resulted in a local recurrence rate of 2.8% (95% CI 1.2-6.5). Weighted local recurrences 
for patients with a pT1 tumour receiving aCRT were 4.8% (95% CI 2.3-9.8).
For low-risk pT1 tumours, NAT showed a local recurrence rate of 6.7% (95% CI 4.8-9.3). 
No recurrences were reported after cTME and aCRT in patients with low-risk pT1 lesions, 
based on one study for each treatment strategy (Table 1).
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Figure 2 Flow chart of literature search: adjuvant (chemo)radiation or completion total mesorectal 
excision following local excision of early rectal cancer
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pT1 8.1 (6.6 – 9.9) 268 / 3 050 2.8 (1.2 – 6.5) 5 / 180 4.8 (2.3 – 9.8) 24 / 385
 pT1 LR 6.7 (4.8 – 9.3) 75 / 1 019 0 0 / 28* 0 0 / 1*
 pT1 HR 13.6 (8.0 – 22.0) 44 / 282 4.1 (1.7 – 9.4) 5 / 123 3.9 (2.0 – 7.5) 10 / 254
pT2 28.9 (22.3 – 36.4) 136 / 545 4.3 (1.4– 12.5) 3 / 70 14.7 (11.2 – 19.0) 66 / 444
LR: low-risk, HR: high-risk, NAT: no additional treatment, cTME: completion total mesorectal 
excision, aCRT: adjuvant (chemo)radiotherapy. *One study.
Weighted local recurrence rates of high-risk pT1 tumours were 13.6% (95% CI 8.0-22.0), 
4.1% (95% CI 1.7-9.4), and 3.9% (95% CI 2.0-7.5) for NAT, cTME, and aCRT, respectively.
In patients with a pT2 tumour, NAT was associated with an local recurrence rate of 28.9% 
(95% CI 22.3-36.4). This analysis showed significant heterogeneity (I2 55%, p<0.01) (Figure 
S1). After cTME, the local recurrence rate was 4.3% (95% CI 1.4-12.5). In pT2 tumours 
treated with aCRT, 14.7% (95% CI 11.2-19.0) of the patients had a local recurrence. Local 
recurrences were defined as patients with either local recurrence only or patients with 
both local and distant recurrence. These proportions are depicted in Table S4. Study 
specific local recurrence rates are reported in table S5-10 and figure S1-6.
Distant metastasis
The weighed distant metastasis rate in patients with pT1 tumours that underwent NAT 
was 3.4% (95% CI 2.5-4.6), for cTME the distant recurrence rate was 4.9% (95% CI 2.4-9.4) 
and for aCRT 5.0% (95% CI 3.0-8.3) (Table 2, Table S5-7, Figure S6-9). Distant metastasis 
rates for low- and high-risk tumours are described in table 2. In pT2 tumours, weighed 
averages of distant metastasis were 6.2% (95% CI 2.8-13.0) for NAT, 7.3% (95% CI 2.8-
17.8) for cTME, and 5.8% (95% CI 2.7-11.9) for aCRT.







pT1 3.4 (2.5 – 4.6) 101 / 2 658 4.9 (2.4 – 9.4) 8 / 165 5.0 (3.0 – 8.3) 14 / 280
 pT1 LR 3.2 (2.2 – 4.7) 25 / 783 3.6 1 / 28* 0 0 / 1
 pT1 HR 7.2 (3.6 – 13.9) 20 / 233 5.6 (2.5 – 11.8) 6 / 108 3.9 (1.9 – 7.5) 8 / 208
pT2 6.2 (2.8 – 13.0) 28 / 398 7.3 (2.8 – 17.8) 4 / 55 5.8 (2.7 – 11.9) 17 / 254
LR: low-risk, HR: high-risk, NAT: no additional treatment, cTME: completion total mesorectal 
excision, aCRT: adjuvant (chemo)radiotherapy. *One study.
Survival
Survival data are presented in table 3 and table S5-7. Five year DFS for local excision 




66.6%-97.0%) with two out of eight studies reporting 5 year DFS above 85%. Only one 
study reported a 5-year DFS rate of 81.4% after cTME. For aCRT in pT1 tumours the 5 
year DFS was reported in six studies (range 59%-100%) of which five reported DFS of 
more than 85%. For pT2 tumours 5-year DFS of NAT was reported in three publications 
as 64.8%, 80.5%, and 92.8%. One study reported a 3-year DFS of 100% after cTME. 
Four studies reported 5-year DFS rates for treatment with aCRT in pT2 tumours, which 
ranged from 58% to 78.2%.
The 5-year OS rate for NAT in pT1 tumours was reported in fifteen studies (ranged 
65.3%-100.0%), and exceeded 85% in one third of the studies. After cTME 5-year OS 
was 92.3%. Overall survival following aCRT was reported in six studies (range 63.0%-
98.0%), three out of six studies showed OS of over 85%. For pT2 tumours the 5-year OS 
rate in patients without additional treatment was reported in seven publications (range 
30.0%-94.7%), two of these studies described an OS rate of more than 85% (Table 3, 
S5-7). Five studies reported 5-year OS for pT2 tumours after aCRT (range 58%-93.3%), 
in two out of five studies OS exceeded 85% (Table 3, S5-7).
Table 3 Five-year overall and disease free survival rates
NAT n Reported 
survival 
>85%




DFS 66.6 - 97.0% 8 2 / 8 81.4% 1 59.0 - 100% 6 5 / 6
OS 65.3 - 100% 15 5 / 15 92.3% 1 63.0 - 98.0% 6 3 / 6
pT2
DFS 64.8 - 92.8% 3 1 / 3 100% * 1 58.0 - 78.2% 4 0 / 4
OS 30.0 - 94.7% 7 2 / 7 N.R. 58.0 - 93.3% 5 2 / 5
DFS: disease free survival, OS: overall survival, NAT: no additional treatment, cTME: completion 
total mesorectal excision, aCRT: adjuvant (chemo)radiotherapy, n: number of studies reporting 
this value. *: 3-year DFS.
DISCUSSION
This meta-analysis shows that patients who undergo NAT after local excision of pT1-2 
rectal cancer have a high risk of local recurrence, especially in high-risk pT1 and pT2 
lesions. The risk of local recurrence after aCRT for high-risk pT1 tumours seems to 
be similar to cTME. For pT2 tumours, aCRT seems less effective compared to radical 
surgery. This is the first meta-analysis evaluating the results of the three treatment 
options after local excision of rectal cancer, and may support both patients and 
clinicians in decision-making.
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Recently, Antonelli et al. reviewed local recurrence rates for pT1 colorectal tumours that 
were excised endoscopically without additional treatment. An overall recurrence rate 
of 9% for rectal cancer was reported.(92) This reported percentage of local recurrence 
is consistent with the outcomes of this review. The current data showed that high-risk 
pT1 is associated with a relatively high risk of recurrence of 13.6% after local excision 
only, which is consistent with other series.(46, 53) An older large cohort of Bach et 
al. showed an even higher percentage of 19% local recurrence for pT1 tumours. The 
relatively high 29% local recurrence rate for locally excised pT2 tumours in the study 
from Bach et al. corresponds to this study’s findings.(10) Other studies confirmed high 
local recurrence rates for pT2 cancer, and cTME is recommended.(93, 94) The data of 
aCRT after local excision in early rectal cancer are scarce. Most series are hampered by 
the lack of standardised histopathological evaluation distinguishing low-risk pT1 from 
high-risk pT1. Jeong et al. evaluated one of the largest cohorts of 83 patients, of whom 
3.6% had a local recurrence.(85) A review by Cutting et al. showed local recurrence rates 
that were comparable to this review, 5.8% for pT1 and 13.8% for pT2 tumours.(95) An 
earlier meta-analysis by this study group, not incorporating patients without additional 
treatment, reported a higher percentage of local recurrence of 10% in pT1 tumours, 
and similar results of 15% local recurrence for pT2 tumours.(18) The largest study of 
endoscopically resected tumours followed by cTME of Tamaru et al. included 56 pT1 
tumours and showed a local recurrence rate of 3.6%.(73) Borschitz et al. described the 
highest number of cTME’s after transanal endoscopic microsurgery and reported a local 
recurrence rate of 5.3% for high-risk pT1 tumours and 10% for pT2 tumours, which is 
higher than the pooled outcomes reported in the current review.(11)
The occurrence of distant metastases was comparable for the three treatment 
strategies, with averages between 3.4% and 5.0% for pT1 lesions and 5.8% to 7.3% for 
pT2 lesions. This is lower than rates reported elsewhere. In a study of locally excised 
pT2–3 rectal cancers, distant metastases were observed in 16 per cent at 3 years 
of follow-up of patients who underwent NAT or transanal endoscopic microsurgery 
followed by cTME.(96) In the previous review, the weighted average distant recurrence 
rate was 9 per cent in patients treated with aCRT or cTME.(18) It is not expected that 
the type of treatment influences the occurrence of distant metastasis, but it is more 
likely that local recurrence is associated with an increased risk of distant metastases. 
However, aspects as tumour biology and the occurrence of local recurrence may 
influence the risk of distant metastasis. These hypotheses cannot be confirmed based 
on this review, but are in line with other studies.(97, 98)
The intensity of surveillance of patients with NAT differed among the studies. About 
half of the studies reported endoscopic, MRI and/or EUS surveillance every three to 
four months during the first two or three years after local excision. A large share of 
studies (31 of 73) did not report specific follow-up schemes. Active surveillance of 




risk tumours. Unfortunately, the type (i.e. endoluminal or nodal) and stage of local 
recurrences were not reported in the vast majority of the included studies. Few 
studies have reported eligibility and outcomes of salvage treatment in case of local 
recurrence after local excision.(99-101) Based on this limited evidence, the proportion 
of patients deemed eligible for salvage surgery varies between 73% and 93%.(13, 100-
103) Salvage surgery is associated with more extensive procedures and low rates of 
sphincter preservation. Weiser et al. described a cohort of 50 patients that underwent 
salvage surgery; 55% of these patients required an extended pelvic resection.(104) 
Besides, in three studies regarding salvage treatment, in approximately two-thirds of 
the patients who underwent salvage surgery the sphincter could not be preserved.
(100, 101, 105) Moreover, in patients eligible for curative salvage surgery the survival 
rates are low. Several studies showed that 5-year OS rates after salvage treatment are 
around 50%.(100, 104, 106) Limited data is available on cancer specific survival after 
salvage treatment. Doornebosch et al. reported a 58% 3-year cancer specific survival 
and Vaid et al. a 53% 5-year cancer specific survival.(13, 103) A systematic review by 
Jones et al. reported a disappointing 5-year OS rate of 50% after salvage surgery as 
well, presumably due to the increased incidence of distant metastasis.(99) Conceivably, 
with adequate follow-up, local recurrences might be detected in an early stage. If case 
clear resection margins are achieved, 5-year OS was estimated at 59% by Weiser et al. 
In contrast to a 0% 5-year OS rate in incomplete resections.(104) While the data of the 
current review seem more robust than previous reports, a substantial gap remains 
regarding high-quality data and appropriate reporting of long-term outcomes of local 
treatment of early rectal cancer, which emphasizes the need for clinical trials.(18) The 
advantages and disadvantages (i.e. morbidity, function, and oncological outcomes) of 
the three treatment options should be contemplated for each patient individually. The 
increase in risk of recurrence that is accepted in order to preserve the rectum is unclear 
and may differ between patients and physicians. Eventually, the decision for rectum 
preserving treatment depends on both patient preferences and tumour characteristics, 
and should be based on shared decision-making.
An alternative strategy to accomplish organ preservation is neoadjuvant CRT, which 
has shown to downsize and even cause complete remission in over 50% of patients.
(107, 108) However, patients without complete remission will require TME surgery. This 
implies that neoadjuvant CRT led to overtreatment of these non-or partially responding 
patients and likely resulted in increased morbidity. More importantly, since clinical 
staging by imaging has shown to lack accuracy this treatment strategy incorporates 
patients with low-risk tumours as well, who could have been treated with local excision 
only.(7, 8) For this reason, a strategy that consists of local excision of small lesions 
without signs of risk factors on preoperative imaging seems more attractive. Based on 
the histopathological risk factors, additional treatment can be patient tailored.
47
LR rates after cTME, adj CRT or wait after local excision of pT1-2 rectal cancer; a meta-analysis
The current meta-analysis is based upon extensive data, including 73 studies, compared 
to nineteen in the previous meta-analysis.(18) Besides the newly added third treatment 
strategy, NAT, which included 62 studies, the number of studies evaluating cTME and 
aCRT doubled to thirteen and 28 studies, respectively. Yet, this study was limited by 
the heterogeneous character of the included studies and selection bias in allocated 
treatment. A variety in follow-up protocol, follow-up length, sample size and type of 
adjuvant treatment was observed. In some studies, patients underwent radiotherapy 
without concurrent chemotherapy. Besides, NAT was often allocated to patients 
unfit for surgery or patients that refused additional treatment and presumably led 
to selection bias. Due to the variability in follow-up, local recurrence rates were not 
correlated to follow-up length or protocols. Despite these methodological differences 
it was decided to perform a pooled analysis. Quality assessment according to the 
MINORS checklist revealed that almost ninety percent of the included studied was 
carried out retrospectively (Table S11-12). A large amount of studies did not describe 
the histopathological inclusion criteria in detail. The definitions of histopathological risk 
factors varied, for instance some studies reported a margin of <1mm as a risk factor, 
whereas other studies defined this by carcinoma in the resection plane. Moreover, 
deep submucosal infiltration was determined to be a histopathological risk factor. 
However, more recent evidence shows that deep submucosal invasion only is not a 
strong risk factor in multivariate analysis for lymph node metastases.(109) Nevertheless, 
this subgroup analysis for low- and high-risk pT1 tumours was performed because 
it provides important information in clinical decision-making, and reporting overall 
local recurrence rates only would have led to additional bias. Data of pT2 tumours are 
heterogeneous and will likely include a proportion of patients with nodal disease due to 
underreporting of inclusion criteria and suspected nodal involvement on preoperative 
imaging. Besides, in studies on NAT and aCRT patients with unidentified nodal disease 
might have been included, whereas these patients were excluded in studies on cTME. 
These issues may have influenced the outcomes. Survival data were not reported 
sufficiently enough to pool and might have been influenced by the selection of patients 
for each treatment strategy. For these reasons only ranges could be described and 
no conclusions could be drawn based on the available data. A potential confounder 
is the method of local excision. The majority of included studies evaluated surgical 
local excision techniques. Further research is needed to study differences in outcomes 
within and between surgical and endoscopic techniques of local excisions.(110, 111) In 
addition, the location of local recurrence (i.e. endoluminal, mesorectal or lymph node 
involvement), was generally not reported, but is of value in decision-making for salvage 
treatment. Despite these limitations, it was attempted to minimize heterogeneity by 
sustaining strict inclusion criteria and by reporting data for the included subgroups only.
This meta-analysis is the largest set of data evaluating treatment options after local 
excision. The current data shows that local excision only cannot be recommended 




alternative for high-risk pT1 tumours, although for pT2 tumours a relatively high local 
recurrence rate is observed. Completion TME surgery for overall pT1 and pT2 tumours 
is associated with lowest risk for recurrence. Data from high-quality trials with long-term 
outcomes and sufficient sample sizes are awaited to define the exact value of the three 
options after local excision of high-risk pT1 and pT2 lesions.(17)
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INTRODUCTION
Local excision is a well-accepted organ preserving method for early rectal cancer 
with substantial lower morbidity and impact on quality of life compared to radical 
surgery. However, only rectal cancers staged as a T1 tumor limited to the superficial 
third of the submucosa (sm1) and less than 3 cm in diameter without signs of poor 
differentiation, lymphatic or vascular invasion, budding or clustering in the final 
pathology are oncologically safely treated with radical local excision (1). These tumors 
have local recurrence rates of less than 5%. Small locally excised lesions with more risk 
factors as budding, poor differentiation and lymphovascular invasion or even T2 lesions 
have been associated with relatively high recurrence rates (2-4). Due to the increased 
recurrence rate, most guidelines recommend completion radical surgery after local 
excision of high risk lesions (5).
Local excision for palliation could be considered in patients who are either too fragile 
for or who refuse radical surgery. This seems to be a valuable option for those that 
have symptomatic bleeding, changed defecation or even incontinence. However, local 
excision alone for higher risk tumors in the rectum is not without risks. The relatively 
high recurrence rate within 2-3 years is a substantial problem, since recurrences are 
often symptomatic. Combining local excision with radiation for palliative reasons could 
be an option, but unfortunately data to support this theory are scarce.
Other organ preserving strategies after local excision of high risk lesions are being 
investigated in prospective cohorts and randomized trials. A potential curative option 
is adjuvant chemoradiation (CRT) following local excision, which has proven to decrease 
local recurrence rates and offers acceptable morbidity with organ preservation. The 
other option is no further therapy, but instead offer close surveillance with salvage 
radical surgery if a local recurrence presents itself (about 20%).
Several combinations of local excision, radiotherapy, chemotherapy and/or close 
observation are being investigated for treatment of higher staged tumors. The aim 




Treatment with solely local excision offers the lowest burden for patients, since it 
is a minimally invasive technique and results in low morbidity and colostomy rates. 
You et al. reported an overall 30-day morbidity rate of 5.6% compared to 14.6% for 
radical resections, because of less gastrointestinal and infectious complications, with a 
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consequent shorter hospital stay after local excision. (6) However, the question remains 
whether it is a sufficient treatment since local excision only treats the primary tumor and 
not the potential remaining tumor cells in the mesorectum. The clinically pathological 
features such as depth of submucosal invasion, differentiation, lymphovascular invasion, 
budding, and clustering are related to recurrence, whether endoluminal or within the 
mesorectum. When local excision is carried out, the surrounding muscular wall and 
mesorectum are left untreated. Therefore, tumor cells are potentially left behind where 
they may propogate and eventually develop into a clinically detectable local recurrence.
Many cohorts and population-based studies have provided data concerning oncological 
outcome after local excisions for T1 and T2 tumors. A meta-analysis of local excision as 
sole treatment, covering all published data from 1990 to 2018, revealed local recurrence 
rates of 10% in 2120 patients with a T1 tumor, and 32% in 357 patients with a T2 tumor 
as shown in Table 1 [Tuynman et al in preparation (7)]. Distant failures occurred in 6% 
of 1805 patients, and 12% of 230 patients with respectively T1 and T2 tumors. The 
substantial increase in recurrences of T2 tumors indicates the reduced effectiveness 
of local excision for more advanced early rectal cancer.




















n = number of patients included in this analysis; LE = local excision; adjuvant = (chemo)radiation 
The recurrence rates after local excision of T3 cancer are expected to be even higher 
and are the reason that local excision for T3 is not supported by clinical guidelines as 
treatment strategy with curative intent. As expected, data is scarce concerning this 
group of advanced disease. Some publications report a few cases of patients who 
refused radical surgery or were deemed unfit for major surgery. In seven publications 
which address this subject, an overall recurrence rate of 68% (15 of 22 patients) was 
reported (8-14).
This increase in recurrences might be an acceptable clinical outcome if a radical 
resection is not desirable nor possible in frail patients who present unacceptably 
high risk of perioperative morbidity and mortality. Therefore, expected longevity and 
predicted survival rates are important factors when a deliberate choice for a sub-
standard operation is carried out by performing local excision. Allaix et al. (15) reported 
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5-year survival rates of 76% in 32 patients after TEM, and 96% of 33 patients after 
anterior resection or APR. However, radical resection was indicated in all patients. 
Those who underwent a TEM procedure were either not fit for surgery or refused 
radical surgery. A meta-analysis showed overall 5-year survival rates of 65% to 100% for 
T1 tumors, and 30% to 95% for T2 tumors (7). The majority of all recurrences appears 
within 3 years after initial treatment. Salvage treatment usually consists of major surgery 
or less effective radiotherapy, and it is often associated with complications.
In conclusion, local excision for rectal cancer is accompanied by low morbidity rates and 
good functional outcome. However, it is also associated with poor oncological outcome 
in high risk tumors which increases with tumor (T) stage. In case of low risk T1 tumors, 
local excision alone is a viable and accepted treatment strategy.
Local excision with adjuvant therapy
Especially for infirm patients, local excision is an attractive strategy compared to 
radical surgery concerning morbidity. Therefore, other additional options to improve 
the associated oncological compromise have been studied. One of these explored 
options is addition of adjuvant (chemo)radiation following local excision. This might 
increase oncological outcomes including survival, while still offering organ preservation.
A meta-analysis reported average local recurrence rates of 7% in 278 patients with 
T1, and 16% in 382 patients with T2 tumors (Table 1). Distant recurrence rates were 
5% in 214 patients, and 7% in 254 patients with respectively T1 and T2 tumors (7). In 
particular, it was noted that recurrence rates of T2 tumors decreased remarkably with 
the addition of adjuvant therapy compared to local excision alone. Overall recurrence 
rate of local excision with adjuvant (chemo)radiation of T3 tumors was 38% (12 of 32 
patients) (8, 9, 12, 14, 16-19).
A United States National Cancer Database analysis showed a 5-year survival rate of 
79.7% for T2N0M0 tumors, similar to radical surgery (20). After exclusion of 90-day 
mortality, survival was significantly worse than after radical surgery. Others report 
5-year overall survival rates are 63% to 98% for T1 tumors, and with 61% to 93% 
slightly lower for T2 tumors (7). Compared to local excision alone, the survival benefit 
of adjuvant therapy seems to be substantial for T2 tumors. However, due to serious 
heterogeneity of the studies, direct conclusions cannot be established. Nevertheless, 
the addition of adjuvant CRT after local excision seems to be a promising strategy as 
tailored approach for tumors at high risk of recurrence, such as T1 tumors with risk 
features or T2 tumors.
The TESAR trial, was initiated in 2015 to gain insight into the oncological and functional 
outcome of local excision with adjuvant chemoradiotherapy (21). In this study, local 




is followed by randomization of patients between either adjuvant chemoradiotherapy 
or completion TME. The hypothesis is that both treatments offer similar recurrence and 
survival rates, while adjuvant chemoradiation offers better quality of life and functional 
outcome. The trial remains ongoing at the time of this writing.
Summarized, addition of adjuvant therapy to local excision potentially improves 
recurrence rates and survival in locally excised rectal cancer staged as T1 with risk 
features or T2 tumors. T3 tumors seem to benefit from adjuvant therapy as well, but 
oncological outcome remains poor with high recurrence rates.
Neoadjuvant therapy followed by local excision
The incorporation of neoadjuvant chemoradiotherapy and subsequent local excision 
is a possible treatment strategy. Neoadjuvant therapy might lead to downstaging 
and shrinkage of the primary lesion, which could enable local excision of what were 
initially larger tumors. More importantly, such a protocol targets the mesorectum via 
irradiation, which could sterilize occult nodal disease.
Local recurrence rates of 7-17% have been reported for T2 and T3 tumors treated with 
neoadjuvant chemotherapy prior to local excision (22-24). This is substantially lower 
than the previously mentioned rates of local excision alone, and slightly better than 
adjuvant therapy. Focusing on survival, an American National Cancer Database analysis 
revealed 5-year overall survival of 76.1% for T2N0M0 tumors (20). This was similar to 
radical surgery, and local excision with adjuvant chemoradiation. Allaix et al. reported 
a comparable 5-year survival rate of 77,8% in 11 patients, which was equal to local 
excision alone (15). Based on these numbers, neoadjuvant and adjuvant therapy seem 
to be equally effective strategies.
However, morbidity of neoadjuvant treatment is highly underestimated. Local 
excision after neoadjuvant chemoradiation is associated with higher risk of wound 
dehiscence (61% vs. 23%), post procedural pain (52% vs. 15%), and an increase of 
hospital readmissions (44% vs. 7%) compared to local excision alone (25). Another 
series reported the increase in wound-related morbidity following TEM (26). This series 
by Marks et al. included 43 patients with neoadjuvant therapy, of whom 36 received 
chemoradiation. The remaining 7 patients were deemed not fit for chemotherapy, 
and therefore underwent radiotherapy only. In total, 11 (25.6%) patients suffered 
wound complications. None of the 19 patients treated with TEM alone had wound 
complications.
Despite the increased short-term morbidity associated with neoadjuvant therapy, 
the promising oncological outcomes account for ongoing studies on this subject. An 
example is the multicenter international randomized STAR-TREC trial (27). In this study, 
small cT1-3 N0 lesions are randomized between primary TME and rectal preserving 
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therapy. In the rectal preservation arm, neoadjuvant chemo-radiotherapy is followed 
by local excision in case of good clinical response. In case of complete clinical response, 
cross-over to a Watch and Wait regime is offered. The hypothesis behind this protocol is 
that chemoradiation could be sufficient as sole treatment for early stage rectal cancer.
This hypothesis is supported by the group of Professor Angelita Habr-Gama (São 
Paulo, Brazil) among others. They described complete responses up to 22.4% of the 
irradiated tumors, omitting the need for surgery and enabling a Watch and Wait follow-
up regimen (28, 29). In another publication, they reported improvement of absolute 
survival after chemoradiotherapy alone in the setting of complete clinical response, 
compared to incomplete responses to neoadjuvant therapy followed by radical surgery 
in octogenarians (age 80), regardless of whether they were fit or if they had significant 
comorbid conditions (30). Absolute survival advantage, after chemoradiotherapy 
without versus with radical surgery, was 10.1% for fit octogenarians, and 13.5% for 
comorbid octogenarians after one year.
In summary, the addition of neoadjuvant chemoradiation appears to improve 
oncological outcome of local excisions. However, the increased morbidity after 
neoadjuvant radiotherapy requires caution. Complete responses after chemoradiation 
are found in less than one of four patients. Nevertheless, this might offer opportunities 
to improve survival and organ preservation, if the good responders can be identified.
Palliative Radiotherapy
The administration of short course radiotherapy can be regarded in an attempt to avoid 
surgical intervention. Radiotherapy is often used for palliative relieve of symptoms 
associated with tumor growth, such as pain, obstruction, bleeding, or tenesmus. A 
systematic review was performed in 2014 to assess the efficacy of radiotherapy on 
palliation (31). Improvement of symptoms occurred in 75% of patients. However, all 
included studies used different dosages.
More recently, a study was published administering 5 fractions of 5 Gy in 5 days for 
palliation of locally advanced rectal cancer (32). They reported reduction or resolution 
of pain in 87.5%, and of bleeding in 100% of cases. Colostomy free rates were 100% 
after 1 year, 71.4% after 2 years, and 47.6% after 3 years. Toxicity of this dose was low.
Endorectal brachytherapy has been shown to be effective in patients with inoperable 
tumors and in the palliative setting. When used as a boost, it seems to improve the 
pCR (complete response) but does not impact recurrence rates or overall survival. Local 
administration of radiotherapy by brachytherapy for palliation, is an option whose use 
is derived from experience with prostate and cervical cancer. Brachytherapy as local 




In a study by Hoskin et al., fifty patients with either inoperable or incurable tumors 
were treated with brachytherapy as sole treatment or as a boost to external beam 
radiotherapy (EBRT)(33). A clinical response was achieved in 75% of all patients, 
including 14 complete responses. Median survival for patients treated with definitive 
EBRT and brachytherapy boost was 25 months and 7 months for patients treated 
with a palliative intent. Of the 28 patients with rectal bleeding at presentation, 57% 
achieved a complete clinical resolution with a median response duration of 10 months. 
The HERBERT trial also examines the efficacy of the combination of EBRT followed by 
high-dose-rate endorectal brachytherapy boost in elderly and medically inoperable 
patients with rectal cancer. The first results have shown that response occurred in 
29 of 33 patients (87.9%), with 60.6% complete response (CR). The local progression 
free survival and overall survival rates were 42% and 63%, respectively, at 2 years (34).
In conclusion, radiotherapy as sole treatment for infirm and otherwise inoperable 
patients seems to be a valid option as palliative treatment with significant improvement 
of tumor related symptomology. The combination of external beam radiotherapy with 
endoluminal brachytherapy shows especially high response rates. More data on long-
term outcome after radiotherapy is needed to evaluate toxicity.
Radical surgery
Currently, radical surgery following the principal of total mesorectal excision (TME) 
remains the best available treatment of rectal cancer, in terms of oncological outcome. 
However, the risk of anastomotic leakage is substantial with 3-10%, which might be 
catastrophic, particularly in frail, elderly patients (35). Therefore, resection with creation 
of an end-colostomy (Hartmann’s procedure) might be a valid option in this setting.
From an epidemiological standpoint, the majority patients diagnosed with rectal cancer 
are older than 75 years of age. Therefore, a significant subset may be considered 
for palliative treatment rather than curative-intent therapy due to frailty, severe 
comorbidities and/or reduced life expectancy. A systematic review by Manceau et 
al. concluded that severity of comorbidities had more influence on postoperative 
complications than advanced age (35). This suggests that age on its own should not 
be a discriminator.
Unfortunately, few studies report exclusively on this older, comorbid population. 
Postoperative 30-day mortality in patients with colorectal cancer aged between 75-84 
years, is approximately 9%. For patients older than 85 years of age, 30-day mortality 
is 20%, which increases when surgical intervention is performed in the emergent 
setting (36, 37). Mamidanna et al. described a higher 30-day mortality of 31% which 
increased to 51% at 12 months follow up in patients older than 80 years (38). However, 
this data includes procedures with restoration of bowel continuity. Survival rates in 
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younger patients are more promising. For T1 rectal cancer, 5-year overall survival is 
approximately 80%, and for T2 tumors 77% (6, 20, 39).
In conclusion, radical surgery offers the best oncological outcome. By opting for a 
Hartmann procedure, anastomosis related morbidity and mortality could be avoided 
in high-risk patients, whilst still maintaining superior oncological outcomes.
CONCLUSION; TAILORING PALLIATIVE TREATMENT
Local excision is associated with low morbidity rates, but when compared to radical 
resection, local excision has inferior oncological outcome for rectal tumors other than 
low risk T1. Although theoretically attractive, addition of neoadjuvant (chemo)radiation 
results in relatively high morbidity. Local excision with tailored adjuvant treatment 
seems to be a promising option for T1 and T2 tumors. Local excision alone for tumors 
staged T2 or higher stage seems to be associated with unacceptably high recurrence 
rates that could be very symptomatic. Therefore, local excision is not advised as part 
of palliative treatment.
The best treatment should be highly tailored to each individual patient and discussed 
with the patient, the family, and a multi-disciplinary tumor board. If it is only for short-
term symptom relief, short course radiotherapy might be the best option. If next to 
low morbidity, a recurrence free period is also of relevance, a more invasive treatment 
strategy might be the best option. This could include local excision with adjuvant 
therapy for T1-2 tumors. As an alternative, endoluminal brachytherapy with or without 
external beam radiotherapy could be administered for palliative treatment of rectal 
cancer. For patients who are deemed medically fit to tolerate radical surgery and want 
optimal oncological control, then radical surgery seems to be the best option. For 
patients where the risk of anastomotic leak is unacceptably high, rectal extirpation 
without configuration of an anastomosis (with permanent end-colostomy) seems to 
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ABSTRACT
Background: Adequate MRI based staging of early rectal cancers is essential for 
decision making in an era of organ-conserving treatment approaches. The aim of this 
population-based study was to determine the accuracy of routine daily MRI staging 
of early rectal cancer, whether or not combined with endorectal ultrasound (ERUS).
Method: Patients with cT1-2 stage rectal cancer who underwent local excision or total 
mesorectal excision (TME) without downsizing (chemo)radiotherapy were selected from 
the Dutch ColoRectal Audit, between 1 January 2011 and 31 December 2018. Accuracy 
of imaging was expressed as sensitivity, specificity, and positive- and negative predicting 
value (PPV/NPV).
Results: Of 7 382 registered patients with cT1-2 stage rectal cancer, 5 539 patients 
were included (5 288 MRI alone, 251 MRI + ERUS; 1 059 cT1 and 4 480 cT2). Patients 
with pT1 were overstaged by MRI alone in 54.7% (792/1 448) and by MRI and ERUS in 
31.0% (36/116). Understaging of pT2 occurred in 8.2% (197/2 388) and in 27.9% (31/111), 
respectively. MRI alone overstaged pN0 in 17.3% (570/3 303) and the PPV of cN0 stage 
was 76.3% (2 733/3 583). Of the 834 patients with a pT1N0 stage, potentially suitable 
for local excision, 253 patients (30.3%) were correctly staged as cT1N0, and 484 (58.0%) 
and 97 (11.6%) patients were overstaged as cT2N0 and cT1-2N1, respectively.
Conclusion: Dutch population-based analysis of patients who underwent local excision 
or TME surgery for cT1-2 rectal cancer with preoperative MRI staging reveals substantial 





Rectal cancer management depends on clinical locoregional staging as performed 
by endoscopy, endorectal ultrasound (ERUS) and magnetic resonance imaging (MRI). 
The decision-making process to treat rectal cancer patients either with rectal sparing 
local excision or radical excision with or without the addition of preoperative (chemo-)
radiotherapy (RT) is dictated by clinical staging and identification of risk factors such 
as T-stage, suspicious lymph nodes and extramural venous invasion.(1) The use of MRI 
for determining indication for preoperative radiotherapy and extent of subsequent 
rectal resection in patients with intermediate or high risk rectal cancer has significantly 
influenced rectal cancer care worldwide.(2)
Introduction of bowel cancer screening programs has resulted in stage migration with 
an increase in early stage rectal cancer, i.e. cT1-2N0 stage.{logan 2013} This opens 
opportunities for organ preservation, avoiding substantial morbidity and decrease 
in function associated with radical rectal resection.(3) But, to safely aim for an organ 
preservation strategy, correct patient selection with optimal staging is a prerequisite.
{logan 2013} Superficial lesions (T1) without risk features and/or suspicious lymph 
nodes might be considered suitable for upfront local excision as part of an organ 
preserving strategy. However, the final pathology result might reveal a more advanced 
tumour stage or presence of adverse features leading to a completion total mesorectal 
excision (TME) or adjuvant chemoradiotherapy (CRT) within current trials.(4, 5) Another 
approach aiming at organ preservation for patients with early cancer is upfront (C)RT 
with subsequent response assessment and tailored further treatment (e.g. TME surgery, 
local excision, watch and wait strategy) within current trials. Although this approach is 
promising, a substantial proportion (about 50%) of patients is at risk for overtreatment, 
especially given the current limitations in clinical staging.(6, 7)
To avoid both under- and overtreatment, optimising clinical staging is of utmost 
importance. MRI based staging of rectal cancer has proven its value in more advanced 
stages of the disease, but is known for its limited accuracy in early rectal cancers 
and assessment of lymph node status.(8)The diagnostic value largely depends on MRI 
scanning protocols and experience of the radiologist. In early lesions, the addition of 
ERUS has been advocated to improve clinical staging, but this seems highly operator 
dependent.(9) At present, population-based data on the accuracy of clinical tumour 
and nodal staging of early rectal cancer in daily practice is lacking.
Therefore, the aim of this population-based study was to determine the diagnostic 
accuracy of routine MRI staging in patients who underwent local excision or TME 
surgery for cT1-2 rectal cancer, whether or not combined with ERUS, and with trends 
over time.
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METHODS
Data were derived from the Dutch ColoRectal Audit (DCRA). This audit collects detailed 
information on the patient, tumour, treatment and short-term (≤90 days) outcome 
characteristics of all patients undergoing resection for primary colorectal cancer in the 
Netherlands. Specific details of the DCRA regarding data collection, data quality, data 
validation and methodology have been published previously.(10)
Patient selection
All patients who underwent local excision or TME surgery for primary cT1-2 staged rectal 
cancer and were registered in the DCRA between January 1st, 2011 and December 31th, 
2018 were potentially eligible. Only patients who were staged by MRI, with or without 
ERUS, were included. Exclusion criteria were downsizing therapy (e.g. short course 
radiotherapy (SCRT) with delayed surgery or CRT), a registered (y)pT0 stage, emergency 
surgery, staging by other modalities than MRI ± ERUS. Patients who underwent SCRT 
with immediate surgery (SCRT-IS; ≤2 weeks interval to surgery) were considered eligible. 
For this study, no ethical approval or informed consent was required under Dutch law.
Data extraction and outcome parameters
The following data were extracted from the DCRA-database: patient- and tumour 
characteristics, diagnostic- and staging characteristics, and procedural characteristics. 
Data on ERUS was available in the DCRA dataset until 2017. Removal of this variable 
was related to the low uptake of ERUS at a national level and registration burden. 
Pathological T and N-stage were extracted as the gold standard for comparison with 
radiological staging. Overstaging and understaging of staged rectal cancer patients was 
defined as higher pTN stage compared with cTN stage, for understaging and lower pTN 
stage compared to the cTN stage for overstaging, respectively. Outcome parameters 
included sensitivity, specificity, positive predictive value (PPV) and negative predictive 
value (NPV) of the preoperative MRI for tumour- and nodal staging.
Dutch colorectal cancer guidelines
The Dutch colorectal cancer guideline of 2008 was revised in 2014.(11, 12) For cT staging 
of rectal cancer, both Dutch guidelines stated that for non-superficial tumours, MRI is 
recommended as part of the standard work-up. ERUS can be considered in addition 
to MRI for differentiating between T1 and T2 stage. Regarding nodal staging, the Dutch 
guideline of 2008 stated that lymph nodes with a size of >5 mm on MRI should be 
considered suspicious for nodal metastasis. The revised guideline of 2014 stated that 
nodal disease should be considered in lymph nodes with a size of 5-9 mm and the 






Descriptive statistics were used to describe baseline characteristics which were defined 
as absolute numbers of cases and percentages. Staging was evaluated for patients who 
underwent MRI alone, and those who underwent combined imaging by MRI and ERUS. 
To calculate diagnostic performance of imaging, cT and cN staging was compared with 
pT and pN staging. For T-staging, both local excisions and TME were included, and only 
TME was included for analysis of N-staging. Sensitivity, specificity, PPV and NPV were 
calculated for cT1 and cT2 and cN0, cN1 and cN2 stage with 95% confidence intervals 
(CI). These outcome parameters were also calculated per year, graphically plotted, and 
analysed for time trends using the Linear-by-Linear Association test for the total study 
period (2011-2018) and comparing two time periods (<2014 vs. ³2014) for revision of the 
National colorectal cancer guideline in 2014. Regarding N-staging, nodal positivity (N+) 
was used without discriminating N1 from N2 stage. P-values of <0.05 were considered 
statistically significant. Statistical analyses were performed in SPSS 24.0 Statistics for 
Windows (Armonk, NY: IBM Corp).
Table 1. Patient-, tumour- and treatment characteristics for patients with cT1-2 rectal cancer 
diagnosed by MRI ± ERUS in the period from 2011-2018, who subsequently underwent TME 
surgery without downsizing preoperative radiotherapy.
Patient Count Percentage
Sex Male 2 997 61.9
Female 1 848 38.1
Missing 2
Age <75 3 508 72.4
≥75 1 336 27.6
Missing 3
ASA I - II 4 000 82.5
III+ 846 17.5
Missing 1
Charlson score 0 2 619 54.0
1 1 044 21.5
2+ 1 184 24.4
BMI <30 3 889 81.6
≥30 879 18.4
Missing 79
Preoperative MRI staging MRI 4 700 97.0
MRI including ERUS 147 3.0
Distance from anus* ≤5 cm 1 564 33.7
6-10 cm 1 820 39.3
≥10 cm 1 252 27.0
Missing 211
cT score cT1 577 11.9
cT2 4 270 88.1
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Table 1. Continued.
Patient Count Percentage
cN score cN0 3 746 77.4
cN1 942 19.5
cN2 81 1.7
cNX  / unknown 69 1.4
Missing 9
cM score cM0 4 542 93.9
cM1 82 1.7
cMX / unknown 215 4.5
Missing 8
Neoadjuvant radiotherapy No 3 227 66.6
SCRT-IS 1 620 33.4
Procedure (L)AR 3 115 64.3
APR 1 044 21.5
Hartmann 578 11.9
Other** 110 2.3
 pT stadium pT1 1 057 21.8
pT2 2 331 48.1
pT3 1 403 28.9
pT4 56 1.2
pN stadium pN0 3 465 71.5
pN1 1 046 21.6
pN2 294 6.1
pNX / unknown 42 0.9
CRM Positive (≤1mm) 119 2.7
Negative 4 222 97.3
Number of lymph nodes retrieved ≤10 1 060 21.9
>10 3 779 78.0
Unknown 8 0.4
Number of positive lymph nodes 0 3 492 72.1
1-3 1 034 21.4
>3 317 6.5
Missing 4
# Percentages for the variables are calculated out of the total number of actual results available, 
excluding the missing values.
ASA = American Society of Anaesthesiologists-Classification, BMI = Body Mass Index, 
MDT= multidisciplinary meeting, MRI = Magnetic Resonance Imaging, Multidisciplinary Team, cT 
stage = clinical tumour stage, cN stage = clinical nodal stage, SCRT-IS = Short Course Radiotherapy-
Immediate Surgery (≤2 weeks), pT stage = pathological tumour stage, pN stage = pathological 
nodal stage.
* Note: this was not defined in the DCRA until 2016 and mostly based on endoscopic measurement 
of the distance to the anal verge, while since 2016 this is defined as the distance to the ARJ on 
sagittal MRI





A total of 7 382 patients with cT1-2 rectal cancer, were identified between 2011 and 
2018. Patient selection is displayed in Supplement Figure 1. During the study period, 
the use of MRI for clinical staging in this patient population increased from 90.4% (2011) 
to 92.6% (2018). A total of 5 539 patients remained for final analysis after exclusion of 
preoperative (chemo)radiotherapy with an interval of >2 weeks to surgery, emergency 
setting and staging by other means than MRI ± ERUS. Staging was performed by MRI 
alone in 5 288 patients, and 251 patients had combined imaging by MRI and ERUS. 
The use of ERUS in combination with MRI increased from 0.2% in 2011 to 5.4% in 2017. 
Clinical T stage was cT1 in 19.1% (n=1 059) and cT2 in 80.9% (n=4 480). The patient-, 
tumour- and treatment characteristics of the included patients are displayed in Table 1, 
stratified for type of surgery. The median number of examined lymph nodes increased 
from 11 lymph nodes in 2011 to 15 lymph nodes in 2018 (Supplement Figure 2). The 
proportion of pN+ remained similar over time (median 28%), as well as the total number 
of positive lymph nodes in case of pN+ (median 2).
Diagnostic performance for tumour staging
The diagnostic performance of preoperative MRI alone and with the addition of ERUS 
was assessed per tumour and nodal stage for each year in the period from 2011-2018 
and shown in Table 2. Of 942 patients with a cT1 stage, 656 patients (69.6%) had a pT1 
stage, 197 (20.9%) a pT2 stage and 85 (9.0%) a pT3 stage. Of 4 346 patients with a cT2 
stage, 792 patients (18.2%) had a pT1 stage, 2 191 (50.4%) a pT2 stage and 1 311 (30.2%) 
a pT3 stage. Overstaging of pT1 tumours occurred in 54.7% and under staging of pT2 
tumours in 8.2%. The sensitivity and specificity of MRI alone were 45.3% and 97.6% for 
T1 tumours, and 91.8% and 25.7% for T2 tumours, respectively (Table 3). Overall, staging 
of cT1-2 rectal cancer by MRI alone was accurate in 2 847 patients (53.8%); 792 patients 
(15.0%) were clinically overstaged, and 1 649 (31.2%) were clinically understaged. When 
combining the results of cT1-2 tumours evaluated by MRI alone, 26.4% had pT3 stage 
and 1.1% pT4 stage.
In patients who were staged by both MRI and ERUS, overstaging of pT1 occurred in 
31.0% (36/116) and understaging of pT2 in 27.9% (31/111). Sensitivity and specificity of 
combined MRI and ERUS was 69.0% and 72.6% for T1 tumours, with corresponding 
percentages of 72.1% and 61.4% for T2 tumours, respectively.
The trends for sensitivity, specificity, PPV and NPV per individual clinical tumour stage 
over the study period are demonstrated in Figure 1. The PPV of MRI for staging cT1 
tumours showed a significant increase of 32.1% in 2011 compared to 2018 (p<0.05). 
NPV showed a significant decrease from 89.6% to 80.7% in the same timeframe (p<0.05) 
(Figure 1a). For cT2 tumours, the specificity showed a significant increase of 9.4% from 
2013 to 2018 (p<0.05) and a significant increase of PPV of 4.5% from 2012 to 2018 
(p<0.05) (Figure 1b).
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Figure 1A. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value 
(NPV) of MRI for diagnosis of cT1 rectal cancer over time (2011-2018).
*Statistically significant difference (p<0.05) tested over the total study period.
Figure 1B. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value 
(NPV) of MRI for diagnosis of cT2 rectal cancer over time (2011-2018).




Table 2a. Clinical versus pathological tumour- and nodal staging by MRI alone
Clinical versus pathological tumour staging
pT1 pT2 pT3 pT4 Total
cT1 656 197 85 4 942
cT2 792 2 191 1 311 52 4 346
Total 1 448 2 388 1 396 56 5 288
Clinical versus pathological nodal staging
pN0 pN1 pN2 pNX Total
cN0 2 733 672 178 32 3 615
cN1 524 311 89 6 930
cN2 46 15 18 0 79
cNX 36 24 3 4 67
Total 3 339 1 022 288 42 4 691*
MRI = Magnetic Resonance Imaging, cT stage = clinical tumour stage, cN stage = clinical nodal 
stage, pT stage = pathological tumour stage, pN stage= pathological nodal stage. *Note: 9 cases 
of cN/pN were missing.
Table 2b. Clinical versus pathological tumour- and nodal staging, by MRI + ERUS
Clinical versus pathological tumour staging
pT1 pT2 pT3 Total
cT1 80 31 6 117
cT2 36 80 18 134
Total 116 111 24 251
Clinical versus pathological nodal staging
pN0 pN1 pN2 Total
cN0 106 22 3 131
cN1 10 1 1 12
cN2 1 0 1 2
cNX 2 0 0 2
Total 119 23 5 147
MRI = Magnetic Resonance Imaging, cT stage = clinical tumour stage, cN stage = clinical nodal 
stage, pT stage = pathological tumour stage, pN stage= pathological nodal stage.
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Table 2c. Diagnostic accuracy of clinical staging of combined T and N stage, by MRI alone.
Pathological tumour and nodal staging versus clinical staging
pT1N0 pT2N0 pT1-2N1 Total
cT1N0 253 87 47 387
cT2N0 484 1 312 289 2 085
cT1-2N 97 279 177 553
Total 834 1 678 513 3 025*
MRI = Magnetic Resonance Imaging, cT stage = clinical tumour stage, cN stage = clinical nodal 
stage, pT stage = pathological tumour stage, pN stage= pathological nodal stage. *Note: 1 675 
(35.6%) patients were staged as T3-4N0-2.
Tumour staging for local excisions
In patients who were staged by MRI alone and underwent a local excision, overstaging 
of pT1 occurred in 23.5% (100/426) and understaging of pT2 in 45.2% (66/146) 
(Supplement Table 1). For the local excision group, sensitivity and specificity of MRI 
alone was 76.5% and 56.2% for T1 tumours, and 54.8% and 74.9% for T2 tumours, 
respectively (Supplement Table 2).
For patients who underwent local excision and were staged by MRI and ERUS, 
overstaging of pT1 occurred in 12.3% (10/81) and understaging of pT2 in 59.1% (13/22). 
Sensitivity and specificity of MRI and ERUS was 87.7% and 39.1% for T1 tumours, and 
40.9% and 87.8% for T2 tumours, respectively (Supplement Table 2).
Diagnostic performance for nodal staging
Preoperative nodal staging was available for 4 769 (98%) TME patients. Missing cN 
stage in this patient population decreased from 3.5% in 2011 to 0.7% in 2018. Overall 
nodal stage was accurate in 3 066 patients (65.4%) by MRI alone; 977 (20.8%) were 
clinically understaged, and 570 (12.2%) were clinically overstaged (Table 2a). Using MRI 
alone, accuracy of a cN0 stage was 69.0%, with corresponding sensitivity of 82.7% 
and specificity of 33.8%. Overstaging of pN0 occurred in 17.3% (570/3 303), and 
understaging of pN1-2 in 66.3% (850/1 283). Combined MRI with ERUS resulted in 131 
patients with a cN0 stage, of whom 25 patients had a pN1-2 stage (19%). Accuracy for 
cN0 stage by MRI with ERUS was 75.2%, with corresponding sensitivity of 90.6% and 
specificity of 10.7% (Table 2b).
Within this population of cT1-2 rectal cancer TME patients assessed by MRI, a decreasing 
trend in diagnosis of cN1-2 disease was observed after revision of the guideline in 2014 
(Figure 2). The sensitivity of nodal staging by MRI showed a significant increase from 74.0 
percent in 2012 to 87.6 percent in 2018 (p<0.05). For PPV, a significant decrease from 




showed a significant decrease of specificity over the total study period (p=0.031) and 
comparing the two-time periods, <2014 and ³2014 (p=0.039).
Diagnostic accuracy of combined tumour and nodal staging by MRI
The clinically relevant combined staging of T and N stage was evaluated (Table 2c). Of 
the 834 patients with a pT1N0 stage, potentially suitable for local excision only, 253 
patients (30.3%) were correctly staged as cT1N0, 484 (58.0%) patients were overstaged 
as cT2N0 and 97 (11.6%) patients were overstaged as cT1-2N1 (Table 2c). In 387 patients 
with cT1N0 stage, 5.2% (n=87) of the patients were incorrectly stages as pT2N0 stage 
and in 9.2% (n=47) of the patients as pT1-2N1 stage. Patients with pT1-2N1 stage, were 
correctly staged by MRI alone in 34.5% (n=177).
Table 3a. Accuracy of MRI alone (sensitivity, specificity, positive predictive value (PPV), and 
negative predictive value (NPV))
Accuracy MRI alone tumour staging (% (95% CI))
Sensitivity Specificity PPV NPV Accuracy
cT1 32.3 (29.4-35.3) 94.2 (93.4-94.9) 60.6 (56.7-64.2) 83.3 (82.7-83.9) 80.7 (79.5-81.8)
cT2 94.2 (93.1-95.1) 16.8 (15.4-18.4) 50.8 (50.3-51.3) 76.0 (72.4-79.2) 53.7 (52.3-55.2)
Accuracy MRI alone nodal staging (% (95% CI))
Sensitivity Specificity PPV NPV Accuracy
cN0 82.7 (81.4-84.0) 33.8 (31.2-36.4) 76.3 (75.5-77.0) 43.2 (40.6-45.8) 69.0 (67.7-70.4)
cN1 31.2 (28.3-34.1) 82.9 (81.6-84.1) 33.7 (31.1-36.3) 81.2 (80.6-81.9) 71.7 (70.3-73.0)
cN2 6.3 (3.8-9.8) 98.6 (98.2-98.9) 22.8 (15.0-33.0) 94.1 (93.9-94.2) 92.9 (92.1-93.6)
MRI = Magnetic Resonance Imaging, CI = confidence interval, cT stage = clinical tumour stage, cN 
stage=clinical nodal stage, pT stage = pathological tumour stage, pN stage= pathological nodal 
stage, PPV= Positive predicting value, NPV= Negative predicting value.
Table 3b. Accuracy of MRI + ERUS (sensitivity, specificity, positive predictive value (PPV), and 
negative predictive value (NPV))
Accuracy MRI + ERUS tumour staging (% (95% CI))
Sensitivity Specificity PPV NPV Accuracy
cT1 25.7 (12.5-43.3) 79.5 (70.8-86.5) 28.1 (16.7-43.4) 77.4 (73.4-81.0) 66.7 (58.4-74.2)
cT2 79.8 (69.9-87.6) 24.1 (13.9-37.2) 61.7 (57.4-65.9) 43.8 (29.6-59.0) 57.8 (49.4-65.9)
Accuracy MRI + ERUS nodal staging (% (95% CI))
Sensitivity Specificity PPV NPV Accuracy
cN0 90.6 (83.8-95.2) 10.7 (2.3-28.2) 80.9 (78.6-83.0) 21.4 (7.5-47.7) 75.2 (67.3-82.0)
cN1 4.4 (0.1-22.0) 91.0 (84.4-95.4) 8.3 (1.2-40.1) 83.5 (82.0-84.8) 77.2 (69.6-83.8)
cN2 20.0 (0.5-71.6) 99.3 (96.1-99.9) 50.0 (6.8-93.2) 97.2 (95.7-98.2) 96.6 (92.1-98.9)
MRI = Magnetic Resonance Imaging, CI = confidence interval, cT stage = clinical tumour stage, cN 
stage=clinical nodal stage, pT stage = pathological tumour stage, pN stage= pathological nodal 
stage, PPV= Positive predicting value, NPV= Negative predicting value.
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Figure 2. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value 
(NPV) for clinical mesorectal lymph node staging based on MRI (cN0 and cN1-2 vs. pN0 and pN1-2) 
in patients with MRI based cT1-2 rectal cancer for each year (2011-2018).
Note: cN stage plotted in all surgically resected rectal cancer patients. Confidence Intervals (CI) 
are depicted for Sensitivity, specificity, PPV, and NPV values.
*Statistically significant difference (p<0.05) tested over the total study period.
DISCUSSION
In this Dutch population-based study during the period 2011-2018, among 7 382 
patients with a registered cT1-2 stage rectal cancer, 9% and 66% of patients underwent 
local excision and TME after MRI staging without downstaging preoperative therapy, 
respectively. Within this combined population, 12% of the patients also underwent 




rectal cancer was disappointing. The diagnostic value of preoperative MRI showed some 
improvements in tumour- and nodal staging over time, but still indicating potential 
areas for improvement. The accuracy of MRI based clinical staging for pT1 patients 
was 70%, and patients with a pT2 cancer were understaged in 8%. Most striking was 
the overstaging of pT1 tumours in 54% when using MRI alone, and still a 31% when 
ERUS was added to the MRI. On the other hand, patients with a cT1 tumour appeared 
to be pT1 in 70% and pT2 in 21%. Accuracy of cN0 stage was 69%, overstaging of pN0 
occurred in 17.3%, and understaging of pN1-2 in 66.3%. Of the 834 patients with a 
pT1N0 stage, only 253 patients (30.3%) were correctly staged by MRI as cT1N0 and 484 
(58.0%) patients were overstaged as cT2N0, indicating the potential role for upfront 
local excision.
In the present study, the diagnostic value of MRI for tumour- and nodal staging 
was specifically determined for the early tumour stages. Most studies reporting on 
diagnostic performance of MRI include all stages of rectal cancer. The meta-analysis 
from Al-Sukhni et al., including 21 studies, and Bipat et al., including 90 studies, 
demonstrated overall sensitivities ranging from 69-87%, and specificities of 75-82% for 
T-staging by MRI.(13, 14) Preoperatively treated rectal cancer patients with downsizing 
therapy were excluded in the meta-analysis by Zhang et al., comprising a total of 35 
studies.(15) Subgroup analyses for T1 and T2 tumours showed sensitivities of 58% and 
80% (45.3% and 91.8% in our study) and specificities of 97% and 74% (97.6% and 25.7% 
in our study), respectively. In accordance with our results, a high specificity of cT1 stage 
and a high sensitivity for cT2 stage were found.
The diagnostic value of nodal staging by MRI remains subject of debate. The revised 
Dutch colorectal cancer guideline of 2014 specifically included more strict criteria 
to consider a lymph node positive on MRI.(12) Remarkably, a significant decrease 
of specificity for nodal staging (p=0.039) was observed, meaning that an increased 
tendency towards overstaging was observed over time in this population of early rectal 
cancers, despite current guideline recommendations. In a study by Zhou et al. including 
52 patients with T1-3 stage rectal cancer, preoperative nodal staging by MRI revealed an 
accuracy of 59.6%, sensitivity of 56.5% and specificity of 82.8%.(16) Balyasnikova et al. 
evaluated 65 early rectal cancer patients and reported an accuracy of 84%, PPV of 71% 
and NPV of 90% for MRI based nodal staging.(17) Our study confirms the overstaging 
by MRI for nodal disease in this specific group with early tumours with 56% of the cN1 
being pN0. A possible explanation of overstaging might be based on the use of size 
criteria for nodal staging and hospital variation in guideline adherence. Overstaging 
of positive nodal disease when using >5 mm as a size criterion, which was a guideline 
recommendation stated in the colorectal cancer guideline of 2008, has been reported 
in 30-40%.(18) In the TESAR-trial, a trial investigating the therapeutic options after local 
excision of early rectal cancer with risk features, lymph nodes are considered benign 
with a size smaller than 10 mm independent of morphologic features.(5)
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Radiologists have a learning curve to become proficient in staging of early rectal cancer 
by MRI. Rafaelsen et al. found a higher sensitivity (96% vs. 77%, p<0.05) and specificity 
(74% vs. 40%, p<0.05) when comparing more experienced gastrointestinal radiologists 
to general radiologists when assessing all stages of rectal cancer.(19) This implies that 
specific training programs and accreditation for radiologists is likely to improve the 
accuracy of early rectal cancer staging.(20) Furthermore, tumour staging improves with 
the use of higher field strength MRI and review of images ideally by consensus of two 
or more expert radiologists.(15, 16) Recently, the national SPECC (significant polyps and 
early colorectal cancer) initiative in the UK expressed the need to improve staging of 
early rectal cancer, which includes better focus on standardization of MRI protocols, 
consensus guidelines, (size) criteria used for nodal staging, structured MRI reporting, 
and increasing the performance and experience in smaller centres.(3, 20)
The European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus 
document explicitly mentions the role for (additional) ERUS, given its superior diagnostic 
performance for differentiating T1 from T2 tumours. (21) In the present study, the 
addition of ERUS only slightly improved nodal staging in comparison with MRI alone, and 
showed overstaging of pT1 and understaging of pT2, but numbers were small because of 
the restricted use of ERUS in the Netherlands. As these modalities are complementary 
to each other, the encountered accuracy should be interpreted as such and not as sole 
accuracy of MRI or ERUS. A recent study showed that ERUS outperformed MRI in overall 
T, T1, T3 and overall nodal staging (p<0.01).(22) These results support the thought that 
ERUS is better in detecting smaller lesions in the thinner colorectal wall (submucosa 
and serosa) in contrast to the muscularis propria (T2) at which level the MRI performs 
better. However, Mondal et al. showed no benefit of ERUS in patients’ selection for 
local therapy, with <10% change of management when ERUS being considered next to 
clinical, endoscopically and MRI staging findings.(23)
Given the diagnostic difficulties in MRI staging as found in current analysis, the upfront 
chemoradiotherapy strategies for patients have a risk of overtreatment since many 
small T1 will be included which could treated with local excision only. The potential of 
upfront (chemo)radiotherapy as organ preservation is currently investigated in the 
setting of an international controlled trial.(6, 24)Another more pragmatic strategy aimed 
at organ preservation for cT1-2 tumours with limited size is a diagnostic/therapeutic 
local excision. Exact histopathology will reveal the final staging, and for the majority, 
a radical local excision with endoscopic submucosal dissection (ESD) or transanal 
minimally invasive surgery (TAMIS) already constitutes definitive treatment for the low 
risk T1 tumours. If the final pathology shows intermediate-risk early cancers (high-risk 
pT1 or low-risk pT2), additional treatment options should be considered: completion 
TME surgery, adjuvant chemoradiotherapy or close surveillance including MRI for local 
and/or nodal regrowth, however these two last mentioned options are to this date 




by ESD or TAMIS for all cT1-2 tumours requires patient as well as surgeon and MDT 
education. Patients should be aware of the possibility that completion TME is advised 
after final pathology reveals high risk features. However, completion TME is regarded as 
a slightly riskier procedure because it is associated with higher morbidity and colostomy 
rates, and risk of incomplete specimens, compared to primary TME.(25) However, these 
increased risks seems less evident with transanal TME.(26) In addition, the potential 
problems of subsequent completion surgery should be considered before deciding on 
local excision, and full thickness excisions should be avoided in those areas at risk for 
breach of completion TME surgery (anterior rectum and close to the sphincter). The 
alternative therapeutic approaches, adjuvant chemoradiotherapy and close surveillance 
with endoscopy and MRI, are the experimental arms in the ongoing TESAR trial.(5, 24)
The strength of this population-based study is that it offers real life data concerning 
the diagnostic accuracy of the preoperative assessment of MRI staging of early rectal 
cancer in daily practice in the Netherlands. However, some limitations of this study need 
to be addressed. Patients who underwent endoscopic polypectomy of a T1 cancer, or 
were referred to dedicated units in pursue of a rectal preserving strategy were not 
included, which might have influenced overall diagnostic accuracy of MRI and ERUS. 
The decision-making process regarding the use of an additional ERUS for staging, was 
not registered in the DCRA dataset. Furthermore, no data was available regarding the 
different MRI protocols used to stage rectal cancer in the centres. Also, the current 
available variables in the DCRA do not allow for analyses on the percentage of patients 
that eventually could have been spared TME surgery based on all currently known high 
risk features to guide this decision, or needed completion TME if routine upfront local 
excision would have been implemented.
This large population-based study demonstrates the diagnostic value of preoperative 
MRI in patients who underwent local excision or TME surgery for early rectal cancer 
in routine daily practice in the Netherlands between 2011 and 2018. This revealed a 
substantial rate of overstaging of pT1N0 tumours, which eliminated the option of an 
organ-preserving approach instead of TME surgery in eligible patients.
Acknowledgements
The authors would like to thank all surgeons, registrars, physician assistants and 
administrative nurses that registered all the patients in the DCRA, the Dutch ColoRectal 
Audit.
Data-availability
The data, analytic methods, and study materials of this study are accessible from 
the Dutch ColoRectal Audit (DCRA) but are not publicly available. The data is made 
accessible to other authors upon reasonable request and with permission of the Dutch 
ColoRectal Audit.
83
MRI cT1-2 rectal cancer staging accuracy: a population-based study. 
REFERENCES
1. Costa-Silva L, Brown G. Magnetic resonance imaging of rectal cancer. Magn Reson Imaging 
Clin N Am. 2013;21(2):385-408.
2. Patel UB, Taylor F, Blomqvist L, George C, Evans H, Tekkis P, et al. Magnetic resonance 
imaging-detected tumor response for locally advanced rectal cancer predicts survival 
outcomes: MERCURY experience. J Clin Oncol. 2011;29(28):3753-60.
3. Morino M, Risio M, Bach S, Beets-Tan R, Bujko K, Panis Y, et al. Early rectal cancer: the 
European Association for Endoscopic Surgery (EAES) clinical consensus conference. Surg 
Endosc. 2015;29(4):755-73.
4. Borstlap WAA, van Oostendorp SE, Klaver CEL, Hahnloser D, Cunningham C, Rullier E, et al. 
Organ preservation in rectal cancer: a synopsis of current guidelines. Colorectal Dis. 2017.
5. Borstlap WA, Tanis PJ, Koedam TW, Marijnen CA, Cunningham C, Dekker E, et al. A multi-
centred randomised trial of radical surgery versus adjuvant chemoradiotherapy after local 
excision for early rectal cancer. BMC Cancer. 2016;16:513.
6. Stijns RCH, de Graaf EJR, Punt CJA, Nagtegaal ID, Nuyttens J, van Meerten E, et al. Long-term 
Oncological and Functional Outcomes of Chemoradiotherapy Followed by Organ-Sparing 
Transanal Endoscopic Microsurgery for Distal Rectal Cancer: The CARTS Study. JAMA Surg. 
2019;154(1):47-54.
7. Rullier E, Rouanet P, Tuech JJ, Valverde A, Lelong B, Rivoire M, et al. Organ preservation for 
rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 
trial. Lancet. 2017.
8. Moreno CC, Sullivan PS, Mittal PK. MRI Evaluation of Rectal Cancer: Staging and Restaging. 
Curr Probl Diagn Radiol. 2017;46(3):234-41.
9. Patel RK, Sayers AE, Kumar P, Khulusi S, Razack A, Hunter IA. The role of endorectal 
ultrasound and magnetic resonance imaging in the management of early rectal lesions in 
a tertiary center. Clin Colorectal Cancer. 2014;13(4):245-50.
10. Van Leersum NJ, Snijders HS, Henneman D, Kolfschoten NE, Gooiker GA, ten Berge MG, et 
al. The Dutch surgical colorectal audit. Eur J Surg Oncol. 2013;39(10):1063-70.
11. Landelijke richtlijn Rectumcarcinoom (2.0) [Internet]. 2008 [cited 26 January 2020]. Available 
from: https://www.nvgic.nl/file/2017/06/Richtlijn-rectumcarcinoom.pdf.
12. Landelijk Richtlijn Colorectaal Carcinoom (3.0) [Internet]. 2014 [cited 26 January 2020]. 
Available from: https://www.nhg.org/sites/default/files/content/nhg_org/uploads/.
13. Al-Sukhni E, Milot L, Fruitman M, Beyene J, Victor JC, Schmocker S, et al. Diagnostic accuracy 
of MRI for assessment of T category, lymph node metastases, and circumferential resection 
margin involvement in patients with rectal cancer: a systematic review and meta-analysis. 
Ann Surg Oncol. 2012;19(7):2212-23.
14. Bipat S, Glas AS, Slors FJ, Zwinderman AH, Bossuyt PM, Stoker J. Rectal cancer: local staging 





15. Zhang G, Cai YZ, Xu GH. Diagnostic Accuracy of MRI for Assessment of T Category and 
Circumferential Resection Margin Involvement in Patients With Rectal Cancer: A Meta-
Analysis. Dis Colon Rectum. 2016;59(8):789-99.
16. Zhou J, Zhan S, Zhu Q, Gong H, Wang Y, Fan D, et al. Prediction of nodal involvement in primary 
rectal carcinoma without invasion to pelvic structures: accuracy of preoperative CT, MR, and 
DWIBS assessments relative to histopathologic findings. PLoS One. 2014;9(4):e92779.
17. Balyasnikova S, Read J, Wotherspoon A, Rasheed S, Tekkis P, Tait D, et al. Diagnostic accuracy 
of high-resolution MRI as a method to predict potentially safe endoscopic and surgical 
planes in patients with early rectal cancer. BMJ Open Gastroenterol. 2017;4(1):e000151.
18. Balyasnikova S, Brown G. The MRI assessment of SPECC (significant polyps and early 
colorectal cancer) lesions. Colorectal Dis. 2019;21 Suppl 1:19-22.
19. Rafaelsen SR, Sorensen T, Jakobsen A, Bisgaard C, Lindebjerg J. Transrectal ultrasonography 
and magnetic resonance imaging in the staging of rectal cancer. Effect of experience. Scand 
J Gastroenterol. 2008;43(4):440-6.
20. Taylor FG, Swift RI, Blomqvist L, Brown G. A systematic approach to the interpretation of 
preoperative staging MRI for rectal cancer. AJR Am J Roentgenol. 2008;191(6):1827-35.
21. Beets-Tan RGH, Lambregts DMJ, Maas M, Bipat S, Barbaro B, Curvo-Semedo L, et al. Magnetic 
resonance imaging for clinical management of rectal cancer: Updated recommendations 
from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) 
consensus meeting. Eur Radiol. 2018;28(4):1465-75.
22. Chan BPH, Patel R, Mbuagbaw L, Thabane L, Yaghoobi M. EUS versus magnetic resonance 
imaging in staging rectal adenocarcinoma: a diagnostic test accuracy meta-analysis. 
Gastrointestinal endoscopy. 2019;90(2):196-203 e1.
23. Mondal D, Betts M, Cunningham C, Mortensen NJ, Lindsey I, Slater A. How useful is 
endorectal ultrasound in the management of early rectal carcinoma? Int J Colorectal Dis. 
2014;29(9):1101-4.
24. Borstlap WA, Coeymans TJ, Tanis PJ, Marijnen CA, Cunningham C, Bemelman WA, et al. 
Meta-analysis of oncological outcomes after local excision of pT1-2 rectal cancer requiring 
adjuvant (chemo)radiotherapy or completion surgery. Br J Surg. 2016;103(9):1105-16.
25. Eid Y, Alves A, Lubrano J, Menahem B. Does previous transanal excision for early rectal cancer 
impair surgical outcomes and pathologic findings of completion total mesorectal excision? 
Results of a systematic review of the literature. J Visc Surg. 2018;155(6):445-52.
26. Roodbeen SX, Penna M, Arnold S, Wynn G, Warusavitarne J, Francis N, et al. A nationwide 
study on the adoption and short-term outcomes of transanal total mesorectal excision in 
the UK. Minerva Chir. 2019;74(4):279-88.
85









TaTME compared to LaTME for mid and 
low rectal cancer; current evidence.
SE van Oostendorp, TWA Koedam, C Sietses, HJ Bonjer, JB 
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ABSTRACT
Background: Transanal Total Mesorectal Excision (TaTME) is potentially the answer to 
refractory challenges in rectal cancer surgery. The surgical dissection in the deep pelvis 
is facilitated by a down to up approach with modern laparoscopic techniques. Potential 
benefits are decrease in short-term morbidity including anastomotic leakages, in 
conversion and colostomy rate, and better quality of specimens including less R1 rates. 
Long-term oncological outcome data is lacking and needs to be reviewed thoroughly. 
Initial (comparative) series show promising results, however there is a lack of audited 
data and comparative data between Laparoscopic TME(LaTME) and TaTME. This review 
compares available data of LaTME and TaTME.
Methods: A systematic review was performed in PubMed to identify papers reporting 
TaTME series with minimal 15 patients. A comparative set of recent large RCT data on 
laparoscopic TME was constructed. Weighted averages were derived from the extracted 
data. Primary endpoints were short-term morbidity, anastomotic leakage, conversion, 
pathological outcomes and local recurrences(LR).
Results: The search yielded 1.093 papers, of which after the selection process resulted 
in the inclusion of 23 series on TaTME. To make a comparison, the four latest RCT’s on 
LaTME were identified as a referential group. The international TaTME registry paper was 
presented separately to make a third comparative group. Average morbidity 31.5% and 
39.6% and anastomotic leakage 6.9% versus 8.0% both in favor of TaTME. Conversion 
rate was 2.0% versus 15.7% for TaTME and LaTME respectively. Complete mesorectal 
integrity 86.2% vs 81.5% and CRM+ 4.6% vs. 7.9%. Five urethral injuries (0,7%) were 
reported. Long-term outcomes of local recurrences were reported in a minority of 
studies with heterogeneous follow-up intervals.
Conclusion: This review summarizes the data and potential benefits of TaTME. 
Compared to LaTME, TaTME decreases short-term morbidity, conversion, suboptimal 
quality of the specimen and involved CRM rate. Due to concerns about underreporting 
of poor outcomes, a well-designed randomized controlled trial with quality assurance 





Transanal total mesorectal excision (TaTME) is the potential answer to refractory 
challenges in the surgical resection of mid and low rectal cancer. Since the first reports 
of this approach by its pioneers in 2010, the technique has gained wide attention in 
the surgical community.(1, 2) The technique facilitates dissection of the very distal 
rectum and mesorectum providing excellent view of the anatomy in the deep pelvis. 
Especially difficult cases (e.g. obese, male patients with bulky distal tumors) seem to 
benefit from the transanal approach. Nevertheless, no randomized evidence is present 
to support any benefits. Also, in systematic reviews as well as reported in registries 
the benefits of TaTME compared to LaTME seem modest and long-term oncological 
outcome is awaited.(3-5) Current problems in TME surgery are short-term morbidity 
including anastomotic leakage, conversions to open surgery in 10-25%, unintended 
end colostomies, poor specimen quality, circumferential resection margin involvement, 
distal margins rates and local recurrences.
Laparoscopic TME surgery is associated with substantial short-term morbidity of 30-
40%. This includes anastomotic leakage rates around 8%.(6, 7) The conversion rate in 
LaTME is still above 10% as reported in recent trials and even with robotic surgery this 
percentage remains between 10 and 20 percent, especially in obese patients.(8-11) 
Conversion to open surgery occurs due to difficult dissection and is associated with 
higher morbidity and worse oncological outcome.(12-15)
Currently an increase focus is seen towards sphincter preserving therapy.(16, 17) The 
open intersphincteric resection and transanal dissection creates the possibility of 
saving the sphincter avoiding end colostomies, but laparoscopic TME still results in a 
relatively high rate of APR, which has negative impact on quality of life. Transanal minimal 
invasive access with high-quality images creates the potential to achieve a higher rate of 
sphincter saving procedures. Nevertheless, data regarding unintended AP resections 
are scarce and only within a randomized comparison it will be possible to evaluate this 
aspect. High-quality surgery with respect to the embryological avascular planes aims 
to achieve an intact mesorectal envelope and offers good local control, especially with 
neoadjuvant radiotherapy if indicated.(18, 19) An involved circumferential resection 
margin remains a concern since this is a substantial risk factor for LRs. Laparoscopic 
surgery with an intent for TME result in an involved circumferential resection margin 
of 17% as is shown in national registries.(20) Potentially the mesorectum is not totally 
removed in TME surgery as shown by the presence of residual mesorectum in 40% 
upon evaluation by MRI 6 months after surgery in 46.9%.(21)
The TaTME technique could improve outcomes for patients with mid and low rectal 
cancer overcoming the limitations of dissection the angulated rectum deep within the 
pelvis.(1, 12) Especially the known difficult LaTME resection will probably benefit from 
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the TaTME approach such as male sex, low tumor, high BMI and bulky or anteriorly 
situated tumours.(22) In these situations deep mesorectal dissection, safe resection 
margins (both distal and circumferential) and safe stapled transection, without the need 
for multiple firings, may not be achieved requiring conversion to open surgery.(12, 20) 
Furthermore, in (ultra)low anterior resections for tumours situated close to but not 
grown into the pelvic floor, the rate of end-colostomy (APR) for technical considerations 
outstands the rate in which it is an oncological necessity.(16) TaTME may overcome 
these challenges by improved visualization and ergonomics. By enabling a more precise 
distal dissection in the embryological planes, theoretically the autonomic nerves can 
be preserved possibly leading to improved functional outcomes.(23, 24)
In this review we focus to current evidence of laparoscopic rectal surgery and TaTME 
with respect to morbidity including anastomotic leakage, conversion, colostomy, 
involved resection margins and local recurrences.
METHODS
We performed a PubMed search with a similar syntax as recently published to identify 
studies, published since January 2005, reporting on outcomes of TaTME.(4) The final 
search was performed at 25 January 2018 with the following syntax:
((((excision*[tiab] OR resection*[tiab] OR TME[tiab] OR TaTME[tiab] OR TAMIS[tiab] 
OR NOTES[tiab] OR proctectom*[tiab]) AND (transanal*[tiab] OR trans-anal*[tiab])) 
OR ((excision*[ot] OR resection*[ot] OR TME[ot] OR TaTME[ot] OR TAMIS[ot] OR 
NOTES[ot] OR proctectom*[ot]) AND (transanal*[ot] OR trans-anal*[ot]))) AND 
((((“Neoplasms”[Mesh] OR neoplas*[tw] OR tumor*[tw] OR tumour*[tw] OR cancer*[tw] 
OR malignan*[tw] OR oncolog*[tw] OR carcinom*[tw] OR adenocarcinom*[tw]) AND 
(“Rectum”[Mesh] OR rectum[tiab] OR rectal[tiab] OR colorect*[tiab] OR mesorect*[tiab])) 
AND (“surgery”[Subheading] OR surgery[tiab] OR surgical[tiab] OR operati*[tiab])) OR 
(“Rectal Neoplasms/surgery”[Mesh:noexp])))
For this paper, case-series, cohorts and comparative studies, with a minimum of 15 
patients that underwent Transanal TME for rectal cancer were included. The transanal 
approach had to be an endoscopic technique, therefore papers on open transanal 
approach (TaTa) were excluded. Moreover, animal and cadaver studies were not 
included. Language in which the cohorts were reported was restricted languages with 
the Latin alphabet.
The international registry of TaTME was isolated from the other retrieved series on 




other that rectal cancer such as IBD, completion proctectomy and Hartmann reversal.
(25)
In addition, to provide the most recent evidence from randomized clinical trials 
regarding laparoscopic TME, data from the laparoscopic arms of large, n= >200, multi-
center RCT’s published after 01-01-2015 were isolated and recorded.
Primary endpoints were type of surgery, morbidity, anastomotic leakage, defined as 
(partial) dehiscence, intraoperative complication as urethral injury, intraoperative 
bleeding, stoma-rate, conversion, clinicopathological parameters as quality of the 
mesorectum, circumferential resection margin and distal margin involvement and 
long-term oncological outcome as LRs.
Statistical analysis
Because a minority reported comparative data on TaTME and laparoscopic TME, 
no direct comparative meta-analysis could be performed. Instead, for the retrieved 
laparoscopic and TaTME studies, a separate weighted average was provided for the 
retrieved baseline characteristics and outcomes. The calculated weighted percentages 
and crude data (events and adjusted total population per outcome) of the laparoscopic 
TME and retrieved TaTME series, as well as the TaTME registry are presented in tables.
For the primary endpoints, if possible, a separate weighted average of the proportions 
was determined by means of the generic inverse-variance method. This is a method for 
aggregating multiple effect sizes to minimize the variance of the weighted average, giving 
more weight to the effect of large studies than to small ones. Analyses were performed 
with the inverse-variance method, using a random-effects model. Heterogeneity was 
assessed by use of the I2 statistic. The software used for statistical analysis was R 
version 3.2.2 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
The PubMed search on TaTME resulted in 1093 papers. Selection by title/abstract 
excluded 1058 studies which resulted in 35 papers for full text analysis. Of those, nine 
papers were excluded for N= < 15.(26-34) Other reasons of exclusion were the use of 
another technique or non-availability of full-text for two other articles.(35, 36) Eventually, 
24 papers on TaTME were included in this paper, of which overlap existed by 2 papers 
from the same clinic.(37, 38) Since the latter paper focused on pathological outcomes, 
from this paper only the pathological data were extracted; quality of mesorectum, 
CRM and DRM positivity (38). Because of its unique design the TaTME registry was not 
pooled with the other series in the meta-analysis.(25) Figure 1 flowchart and Appendix 
Table 2 search results.
93
TaTME compared to lapTME for mid and low rectal cancer – current evidence
Figure 1 Flow-chart of flowchart of TaTME search
The selection of the open/robotic versus laparoscopic TME multicenter RCT’s with an 
arm of N= >200 resulted in the ROLARR, COLOR II, ALaCaRT and ACOSOG Z6051.(8, 9, 
39-41)
TaTME series and registry
The 23 included TaTME cohorts varied in design and inclusion criteria and reported 
clinical and pathological outcomes of 1107 patients, Appendix Table 3 TaTME.(37, 38, 
42-62) Fourteen single center series (37, 43-47, 51, 53-55, 57-60), of which one published 
2 papers (37, 38), 7 dual or multicenter (42, 48, 50, 53, 56, 61, 62) and one paper of an 
implementation pathway(49) were included. One of the single center papers included 
solely advanced or recurrent low rectal cancers.(59) Furthermore, for the pathological 
data of the largest single center experience, Hospital Clinic, we extracted the data of 




rectal cancer varying from <5 to 15 centimeter from the anal verge, however some 
included a few benign cases. Due to heterogeneous inclusion criteria regarding intent 
for continuity; pooling for APR or LAR rate could not be performed. Table 1 weighted 
averages. Baseline characteristics, Surgical and postoperative outcomes of the TaTME 
series can be found online: http://ales.amegroups.com/public/system/ales/supp-
ales.2018.04.02-2.pdf.
The TaTME registry encompasses 1594 patients who received an anastomosis after 
TaTME, of which 1540 procedures were for rectal cancer, and in the appendix an 
additional 161 abdominoperineal resections were reported.(25)
Table 1 – weighted averages
Outcome TaTME Laparoscopic TME Registry
Baseline
Population N= 1107 1411 1594
Male sex 65.3% (710/1088) 65% (923/1411) 68% (1080/1594)
Age (years, RoM) 63.7 (55.0 - 70.0) 64.7 (57.7 - 66.8) 63.7
BMI (RoM) 26.2 (24.2 - 29.5) 26.3 (26.1 - 27.0) 26.3
Neoadj treatment 65.3% (680/1041) 61.9% (874/1411) 56% (895/1594)
Surgery
Colostomy (definite) 7.4% (75/1007) 27.0% (378/1398) 12% (211/1755) *
Conversion 2.0% (22/1083) 13.7% (192/1403) 5.6% (90/1594)
Duration of surgery (min, RoM) 249.1 (166 - 368.6) 242.9 (210 - 266) 252 (30 - 733)
Intraoperative complications 4.2% (36/865) 12.1% (141/1164) 30.6% (487/1594)
  Intraoperative bleeding 1.7% (10/585) 3.5% (41/1164) 4.2% (67/1594)
  Urethral injury 0.7% (5/694) NR 0.8% (12/1594)
Pathology
Mesorectal integrity
Complete 86.2% (871/1010) 81.5% (1139/1398) 85.5% (1193/1540)**
Partial 12.6% (111/1010) 11.9% (166/1398) 10.8% (150/1540) **
Incomplete 2.8% (25/1010) 4.1% (58/1398) 3.4% (47/1540) **
CRM Positive 4.6% (51/1118) 7.9% (102/1290) 4.1% (60/1451)
DRM Positive 0.7% (7/1013) 1.0% (7/702) 0.7% (10/1445)
Postoperative outcomes
Short-term morbidity (30 day) 31.% (317/100) 39.6% (462/1167) 34.8% (555/1594)
Anastomotic Leakage (30 day) *** 6.9% (67/975) 8.0% (88/1104) 7.8% (124/1594)
Length of stay (days, RoM) 7.5 (4 - 4) 7.9 (7.3 - 8.2) 8 (2-94)
Mortality (30 day) 0.6% (7/110) 0.9% (13/1407) 0.6% (9/1594)
*, included 161 APR; **, minus 54 benign; ***, defined as dehiscence. RoM, range of reported 
means or medians; DRM, distalresection margin; CRM, circumferential resection margin; BMI, 
body mass index; TaTME, transanal total mesorectal excision; LaTME, laparoscopic TME.
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Laparoscopic TME
The laparoscopic TME arms of the before mentioned RCT’s covered short-term and 
pathological outcomes of 1411 patients.(8, 9, 39-41) Only the COLOR II trial reported 
the long-term outcomes: 5% local recurrences after 3 years.(39) Patient demographics 
were comparable, but Fleshman et al. reported an neo-adjuvant therapy rate of 98% 
which was rather high compared with the 46-59% rate reported by the other trials, 
Appendix Table 4 LaTME.(41)
The 4 studies reported an abdominoperineal resection(APR) percentage of 11-29%, and 
had a weighted colostomy rate of 27%, table 1 weighted averages. Conversion to open 
surgery was done in 13.7% and laparoscopic TME resulted in 8% anastomotic leakage. 
The retrieved crude data can be found in Appendix Table 4 LaTME.
Short-term morbidity and anastomotic Leakage
The reported short-term morbidity (30-day) of the retrieved TaTME series varies 
between 8.7% and 52% with a weighted average of 31.5% versus an average of 39.6% 
short-term morbidity in laparoscopy. Table 1 weighted averages In the meta-analysis of 
short-term morbidity, an average rate of 0.32 (95% CI 0.28 – 0.36, I2= 25.8% ) of TaTME 
versus 0.39 (95% CI 0.33 - 0.46, I2= 80.6% ) laparoscopy was calculated, but with serious 
risk at heterogeneity for laparoscopic TME. Figure 2a and 2b.
The incidence of anastomotic leakage, defined as (partial dehiscence) was more or less 
equal for weighted average of laparoscopic (8.0% ), TaTME (6.9%) and the Registry (7.8%), 
table 1 weighted averages. Interestingly, anastomotic failure, including pelvic abscess, 
fistula and sinus reached 15.8 % if the 30- day was extended to 3 months.(25) The meta-
analysis of the weighted average of the proportions can be found in figure 3a and 3b.
For TaTME specific intraoperative complications such as pelvic (sidewall or prescaral) 
bleeding and urethral injury, 10 (1.7%) and 5 (0.7%) cases were reported. The 
international TaTME registry report 4.2% intraoperative bleeding and 0.8% (n=12) 
urethral injuries, table 1 weighted averages. The 30.6% intraoperative complication rate 
included technical aspects, such as difficulties with the transanal platform.(25)
Conversion
Conversion to open surgery is encountered less frequently in TaTME, 2.0% versus 13.7%. 
The registry reports an intermediate conversion rate of 5.6 percent. Table 1 weighted 
averages. Meta-analysis by inverse variance with a random effects model resulted in 
a 0.03 (95% confidence interval 0.02-0.05) rate of conversion in TaTME with low risk of 
heterogeneity (I2 = 0%), Figure 4a. In laparoscopic TME this was 0.13 (95% CI 0.09-0.16, 




Figure 2 Morbidity Meta-analysis of the single proportions by inverse variance with a random 
effects model. Proportions are shown with 95% CI. (A) TaTME morbidity; (B) LaTME morbidity. 
TaTME, transanal total mesorectal excision; LaTME, laparoscopic TME.
Colostomy
The four RCT’s of laparoscopic TME encompassed an average of 20% abdominoperineal 
resection (APR) for TME surgery, with a definitive stoma rate of 27%. Table 1 weighted 
averages and Appendix Table 4 LaTME. The retrieved TME series varied in inclusion criteria 
for APR’s, intersphincteric TME and low anterior resections. Therefore, an average 
APR-rate could not be calculated, but the reported definitive stoma rate was 7.6%. 
The registry paper focused on anastomotic leakage and excluded APR’s. However, 
the supplement stated 161 registered APR’s leading to an 12% definitive stoma rate in 
which also total proctocolectomies or completion proctectomies for benign indications 
were included.(25)
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Figure 3 Leakage Meta-analysis of the single proportions by inverse variance with a random 
effects model. Proportions are shown with 95% CI. (A)TaTME leakage; (B) LaTME leakage. TaTME, 
transanal total mesorectal excision; LaTME, laparoscopic TME.
Irradicallity
The integrity of the mesorectum, defined by Quirke, was complete in 81.5% in 
laparoscopy and 86.2% in TaTME. See table 1 weighted averages. Distal resection margin 
positivity was 1.0% and 0.7% for LaTME and TaTME respectively. The weighted rate 
of a positive circumferential resection margin (CRM), was 7.9% versus 4.6% in the 
Laparoscopic TME and TaTME groups respectively. See table 1 weighted averages. For 
the pathological outcomes of the latest paper from the group of Lacy et al. was used.(38)
Meta-analysis of complete mesorectum and CRM+ for both approaches are shown in 
Figures 5a-5b and 6a-6b. The percentage of complete is 86% vs 80% in the transanal 




The weighted average of the proportions shows a positive CRM of 0.08 (95% CI of 
laparoscopic 0.06 – 0.11, I2=58%) in laparoscopy compared to 0.06 in TaTME (95% CI 
0.04 – 0.07, I2=0).
Figure 4 Conversion Meta-analysis of the single proportions by inverse variance with a random 
effects model. Proportions are shown with 95% CI. (A) TaTME conversion; (B) LaTME conversion. 
TaTME, transanal total mesorectal excision; LaTME, laparoscopic TME.
Local recurrence
Local recurrence(LR) rate was reported 5% the 3-year follow-up paper in COLOR II-
trial (39). None of the other laparoscopic TME trials reported 3-year follow-up yet. 
Neither the TaTME papers reported 3 years follow-up with LR percentages. However, 
an incidence of 17 local recurrences was reported. (37, 46, 51, 59, 61, 62). Of these 17 
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local recurrences, 5 were reported by Rouanet et al. who included locally advanced 
rectal cancer or local recurrences in his TaTME-series.(59)
Figure 5 Mesorectum complete Meta-analysis of the single proportions by inverse variance 
with a random effects model. Proportions are shown with 95% CI. (A) TaTME mesorectum com-
plete; (B) LaTME mesorectum complete. TaTME, transanal total mesorectal excision; LaTME, lap-
aroscopic TME.
DISCUSSION
This is the latest systematic review of all the cohorts larger than 15 patients, describing 
the short-term results of TaTME. Because the comparison with LaTME is most important 
in evaluating the potential benefits of TaTME and comparative prospective clinical trial 
are still lacking we have added the result of the 4 latest randomized trials evaluating 
LaTME. TaTME compared to LaTME is beneficial in terms of conversion rate and clinico-




colostomy (APR) rate and local recurrences could was not reliably reported by the 
retrieved studies, due to design and lack of long-term follow-up.(37, 38, 42-62) Before 
widespread implementation can be justified, careful evaluation is warranted because 
morbidity has not decreased, and the rate of local recurrence is still a concern and 
needs thorough evaluation in an RCT with quality control of surgery and data.(63)
The short-term overall morbidity in TaTME was 31.5% which is beneficial compared to the 
registry data of 34.8% and pooled LaTME of 39.6%. This 31.5% rate of the TaTME cohorts 
must be interpreted with caution since morbidity was not reported in a standardized 
way such as the Clavien-Dindo classification. A concern in (laparoscopic) rectal cancer 
surgery remains anastomotic leakage which was 8% in the latest laparoscopic RCT 
data. It was imposed that leakage could be decreased by TaTME as a consequence 
of a new way of making an anastomosis without the need for cross stapling leaving 
dog-ears which are prone to ischemia.(25, 64) However, the current data do not 
suggest a decrease with a reported 30-day leak rate 7%. The open rectal stump which 
results after the dissection needs to be fused with the descending colon to create the 
anastomosis. This can be performed either by a hand sewn colo-anal anastomosis for 
very low anastomosis or by a stapled colo-rectal anastomosis with a circular stapling 
technique with the aid of a second purse string to close up the open rectal stump, 
which is described in detail in the 2016 paper in Techniques of coloproctology.(64) 
TaTME potentially leads to more bacterial load as showed by Velthuis et al. and needs 
further investigation of the rate of anastomotic failure or pelvic abscess.(65) The 
registry reported an anastomotic failure rate of 15.7% when late complications of the 
anastomosis such as fistula, chronic abscess or presacral sinuses were included.(25) 
These numbers are comparable to the anastomotic leak rate, defined as not only early 
dehiscence but includes presacral abscess or sinus, which builds up to 20% beyond 
the 30 day cut-off.(6)
This paper shows a promising conversion rate of 2% in TaTME in the cohort series 
compared to 5.6% in the TaTME registry compared to 12.2 - 16.6% for LaTME as reported 
in the ROLARR and laparoscopic arms of the COLOR II, ALaCaRT and ACSOG-Z6501 
trials.(8, 9, 40, 41) The main reasons for conversion to open surgery are extensive 
adhesions, intra-operative complications such as major bleeding, the inability to make 
progress in sharp dissection of the mesorectal envelope or to achieve a clear distal 
margin below the tumor.(12) Risk-factors that contribute to difficulty are male sex, high 
body mass index(BMI) , visceral obesity, narrow pelvis, bulky tumours or more advanced 
stage of the tumours and these patients might be candidates for a down to up approach 
of mesorectal excision.(10, 11, 66)
The average 20% APR-rate in laparoscopic TME surgery for rectal cancer as stated 
before impacts quality of life. This extensive procedure with resection of the sphincter 
complex is not always required from oncological point of view, which is mostly the 
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risk of CRM+ due to ingrowth in the sphincter complex or m. levator ani, but is also 
performed for technical reasons such as the inability to get a satisfactory distal margin 
intraoperatively.(16) Definitive colostomy–rate is even higher, adding some sphincter 
sparing Hartmann procedures without restoration of bowel continuity. TaTME enables 
lower sphincter saving, or intersphincteric, dissections with a colo-anal anastomosis in 
selected cases.(16) Unintended APR rate resulting in end colostomy was an endpoint 
which could not be evaluated. The RCT series did not report the incidence of planned 
versus unplanned; one study reported an end colostomy rate of 79,7% in LaTME for 
the low rectum(0-5 cm from the AV).(9)
The circumferential resection margin positivity, an important predictor of local 
recurrence, was found to be less frequently involved in TaTME.(67) This can be 
contributed by improved visualization of the surgical plane and improved ergonomics 
in the dissection of especially the lower (meso)rectum.(1, 2)
The integrity of the mesorectal envelope surrogates surgical quality by pursuing a 
smooth specimen which is correlated to local recurrence.(68) This review shows that 
TaTME results in better mesorectal integrity for TaTME as shown in table 1 weighted 
averages. Positive distal resection margins are rarely encountered since the tumor can 
be directly visualized by the transanal endoscopic view.(4) Furthermore, in case of a 
stapled anastomosis, the donuts of the EEA-31 hemorrhoid stapler add an extra 16 mm 
margin in addition to the original specimen.(64) Local recurrences are not well reported 
in the TaTME cohorts. Overall, 17 local recurrences were reported with a varying follow-
up (9.7-29.0 months). The registry has not reported long-term oncological outcome and 
will probably underreport this fact because of the voluntary non-audited design. The 
trial data of LaTME reports a 5% local recurrence rate at 3-year follow-up.(39)
The lack of long-term outcome underlines the importance of a prospective trial with 
quality assurance and with auditing of the long-term data. Potentially tumor spill due 
to inadequate closure of the rectum or due to seeding due to manipulation could be a 
concern of the TaTME technique.
The cohorts and registry contain unaudited data and publication bias, therefore 
concern has risen about unreported poor outcomes. Urethral injuries have been 
mentioned at symposia and training sessions frequently, but fail to be equivalently 
reported in manuscripts.(4, 25, 69) Other potential injuries such as side wall injury 
with the risk at major haemorrhage or autonomous nerve injury and a too low stapled 
anastomosis resulting in poor outcomes are also concerns especially in the learning 
curve. These potential disastrous complications warrant restraint of wide-spread 





Although this review contains the most up-to-date overview of the available data 
substantial limitations are present which precludes any conclusion about the value 
of TaTME. Only cohort data with selection bias, publication bias and lack of audit. 
The registry data contains similar bias since data is missing and no audit of the data 
is present. Comparing RCT with cohort data is only presented due to lack of other 
comparative data and only serves as an indication. RCT’s often have better results 
compared to registries since the learning curve is less an issue whereas the TaTME 
data is biased by a learning curve which has shown to be associated with increased 
morbidity and worse specimens. The learning curve of laparoscopy has been set 
at 50-60 patients previous decade, measured by conversion and morbidity.(72, 73) 
Koedam et al. analyzed the individual learning curve of a surgeon starting TaTME, and 
concluded is achieved after 40 cases and 60 more are required to get to the level 
competent to teach others.(77)
To shorten this learning curve, a training pathway has been designed which covers 
e-learning, live surgery, hands on cadaver course and on-site proctoring.(32, 70, 71) The 
international TaTME consensus meeting on the design of a training-pathway concluded 
due to the technical demanding aspect of TaTME this approach should be reserved for 
dedicated colorectal surgeons who have extensive experience in both laparoscopic 
colorectal surgery and TAMIS for local excision.(70) The results of the Australian & 
New Zealand training and implementation program that were included in this review 
reported the outcomes of 12 surgeons that performed 108 cases TaTME for rectal 
cancer with a 5.4% anastomotic leak rate, 1.9% CRM+, 0% DRM+ and an intact TME 
specimen in 107 cases (98.2%) suggesting high quality surgery.(49)
Another need is quality assurance to ensure proficiency and safety and avoid patients 
and results of trials to be hampered by suboptimal performance of not sufficiently 
trained surgeons.(74, 75) A well designed trial with these components, in order to 
capture the real advantage and potential harms of a technique within a training pathway 
and a patient safety environment, avoids underreporting of poor outcomes and a 
randomized trial is best suited to rule out bias of excellence centers.
It is well recognized that randomization often discourages patients and surgeons which 
are in favor of one technique but no other trial design yet has been able to reproduce 
the level of evidence an adequately powered and executed RCT provides.(76)
CONCLUSION
Continuous cohort reports on TaTME indicate a benefit in conversion rate compared 
to laparoscopic TME and potential increase in sphincter preservation. However, 
morbidity including anastomotic leakage and by this novel approach introduced specific 
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complications as urethral or pelvic side-wall injury need prospective audit. A significant 
learning curve is present in the implementation and hampers fair comparison. Long-
term oncological outcome does not seem to improve so far but randomized controlled 
trial with proper quality assurance is best suited to provide data on short-term 
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ABSTRACT
Background: Transanal Total Mesorectal Excision (TaTME) is a new complex technique 
with potential to improve the quality of surgical mesorectal excision for patients with 
mid and low rectal cancer. The procedure is technically challenging and has shown 
to be associated with a relative long learning curve which might hamper widespread 
adoption. Therefore a national structured training pathway for TaTME has been set up 
in the Netherlands to allow safe implementation. The aim of this study was to monitor 
safety and efficacy of the training program with 12 centers.
Methods: Short term outcomes of the first ten TaTME procedures were evaluated 
in 12 participating centers in the Netherlands within the national structured training 
pathway. Consecutive patients operated during and after the proctoring program 
for rectal carcinoma with curative intent were included. Primary outcome was the 
incidence of intraoperative complications, secondary outcomes included postoperative 
complications and pathological outcomes.
Results: In October 2018, 12 hospitals completed the training program and from each 
center the first 10 patients were included for evaluation. Intraoperative complications 
occurred in 4.9% of the cases. The clinicopathological outcome reported 100% for 
complete or nearly complete specimen, 100% negative distal resection margin and the 
circumferential resection margin was positive in 5.0% of patients. Overall postoperative 
complication rate was 45.0%, with 19.2% Clavien-Dindo ≥ III and an anastomotic leak 
rate of 17.3%.
Conclusions: This study shows that the nationwide structured training program for 
TaTME delivers safe implementation of TaTME in terms of intraoperative and pathology 
outcomes within the first ten consecutive cases in each center. However, postoperative 
morbidity is substantial even within a structured training pathway and surgeons should 




Transanal total mesorectal excision (TaTME) has been proposed as a potentially 
better alternative to the laparoscopic standard TME for mid and distal rectal cancer.
(1-4) The bottom up approach for the deep pelvic region increases exposure and 
facilitates the distal mesorectal excision. Especially those difficult cases such as obese 
patients, low rectal cancer and (male) patients with a narrow pelvis seem to benefit 
from this approach.(5, 6) TaTME has been introduced in 2010 and has had enthusiastic 
uptake throughout the world.(7, 8) Current evidence from non-randomized studies 
shows that the TaTME technique for mid and low rectal cancer has similar short term 
clinical outcomes compared to laparoscopic TME (Lap TME) in terms of complications 
including anastomotic leakage, margin involvement and specimen quality. Especially the 
conversion rate seems to benefit from TaTME compared to Lap TME (2% versus 12%) 
as shown in both registry and systematic reviews.(8, 9) The circumferential resection 
margin (CRM) involvement after TaTME has shown to be slightly lower as observed in 
conventional or robotic TME in pooled analysis by weighted averages: 4.6% versus 7.9% 
versus 5.1% respectively.(8-10) However, direct comparison in large trials have yet to 
confirm this difference and demonstrate oncological safety. Within the international 
TaTME registry, a relative high percentage of intraoperative and postoperative 
complications has been presented including an anastomotic failure rate of 15.7%.(9, 
11) Since the TaTME has only recently been introduced a learning curve is probably 
partly a reason for the relative high morbidity rate. TaTME seems technically demanding 
because of the required single port surgery skills and due to a different approach to 
the anatomy: down-to-up.(12) The traditional landmarks are missing and surgeons 
inexperienced in this technique may encounter TaTME specific related complications. 
A well trained TaTME surgeon might show benefits, but for those less trained and 
capable surgery by TaTME will probably result in worse short- and long-term outcomes. 
A meta-analysis of TaTME cohorts showed a quality difference in low- versus high-
volume centers, indicating a potential learning curve.(2, 12)
The technical challenges and accompanying learning curve of the TaTME technique 
resulted in the off sprout of dedicated courses all over the world. In the Netherlands 
a structured training pathway was set up in 2014 including a multiple step program 
of e-learning, didactic courses, detailed anatomy instruction, observation of a TaTME 
live procedure, a hands-on cadaver workshop and the first cases proctored by TaTME 
experts. The current training pathway was set up to ensure adequate skills to participate 
in the COLORIII study, an international multicenter study evaluating the TaTME technique 
in terms of short- and long- term outcome powered upon oncological safety.
The aim of the present study was to capture the safety, clinical and pathological 
outcomes of the implementation of TaTME in centers within the structured training 
pathway by collecting the data from the first ten patients in each participating center.
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MATERIALS AND METHODS
Training pathway
The education and training pathway was set up in The Netherlands in 2014 as a 
structured program for postgraduate colorectal surgeons with known experience in 
laparoscopic TME surgery who had the intention to implement the TaTME technique 
in their center. In order to successfully introduce the TaTME technique minimal pre-
requisites were set out in order to enter the pathway. 1. Adequate skills and experience; 
prior training and experience in laparoscopic rectal cancer surgery with at least 
50 laparoscopic TME cases. 2. Prior TAMIS experience; knowledge and skills of the 
transanal single port technique. 3. Case volume; the number of TaTME cases a year 
should be at least 20 /year /center to ensure sufficient exposure of the entire team. 
4. Adequate medical instruments including a continuous air insufflation system, an 
adequate transanal platform and the possibility to perform a two-team approach.
This training program comprises of a 2-day hands-on course in which a maximum of 
ten surgeons can participate enabling intensive interaction and individual tutoring. The 
course incorporates three different elements; didactic sessions, live TaTME surgery and 
a hands-on training including box trainers and a cadaveric course. Didactic sessions 
included topics as theoretical background of TaTME, extensive pelvic anatomy by an 
anatomist, procedure specific pitfalls (urethral injury, wrong plane of dissection e.g.), 
patient selection, setup of surgical equipment and step-by-step procedure training. 
Part of the education was available online (www.rectalcancersurgery.eu and www.
iLappSurgery.com). The second part consisted of a multidisciplinary team (MDT) 
discussion of a case and a live TaTME case, performed at the Amsterdam University 
Medical Centers – location VUmc. Both surgeons and scrub nurses were invited as 
observers and technique was interactively demonstrated with informed consent of 
the patients.
The third part of the training was a full day hands-on training including box-training 
for the single port technique skills and training the purse string. The final part was to 
practice an entire TaTME procedure on a cadaver in pairs, with experienced faculty 
providing help. At time of writing over 200 surgeons from all over the globe have 
participated in one of our 22 courses since its launch in 2014.
The implementation of the technique in the center of the trainees was done by a 
structured clinical proctoring program until adequate proficiency was reached in 
agreement with the proctor to proceed alone. The group of proctors consists of eight 
surgeons who have each performed over 50 cases of TaTME and are trained in surgical 
education. Patients were informed to undergo a proctored TaTME. After each case 




an additional case of proctoring could occur in order to guarantee the quality as much 
as possible.
In October 2018, hospitals that have successfully completed the proctoring program 
were approached to share the data of the first ten TaTME procedures performed on 
patients with rectal cancer with curative intent. All of the 12 hospitals that were eligible 
to participate in our study agreed on participation.
TaTME Surgical procedure
The technique has been highly standardized as previously described.(13) First, the 
laparoscopic transabdominal phase starts with standard medial to lateral mobilization 
of the splenic flexure. Next the patient is positioned in Trendelenburg and a medial 
to lateral approach to the sigmoid and rectum is performed, after the ligation of the 
superior artery including sigmoidal branches with preferably sparing of the left colic 
artery. Thereafter the dissection is continued in the TME plane dorsally, both sides 
laterally and the beginning anteriorly. Identification of ureters and hypogastric plexus 
and nerve bundles has been mandatory. After ligation of the vessels, the transanal 
phase is started simultaneously with insertion of the transanal port and establishing 
pneumorectum with abdominal clamping of the distal sigmoid to avoid a pneumocolon. 
After closure with a purse string of the rectum below the tumor and ideal above the 
anorectal junction, the rectal tube is rinsed with povidone-iodine solution. After a 
full-thickness endoscopic transection of the rectum is achieved, the posterior TME 
plane, anterior plane and both lateral planes are dissected, the latter with the help 
of abdominal retraction of the rectum. Anastomosis is preferably constructed with a 
circular stapling technique either side-to-end or end-to-end, specimen retraction is 
preferably done by a pfannenstiel incision.
Patients
The Medical Ethics Review Board of the VU Medical Center in Amsterdam approved the 
study protocol and waived the need for informed consents. The first ten consecutive 
patients from each participating hospital with clinical suspicion of rectal cancer in 
whom a TaTME was performed with curative intent were eligible for this study. In 
October 2018, 12 hospitals completed our proctoring program and were all willing 
to participate in this study. All participating surgeons followed the structured TaTME 
training in the VU medical center prior to the proctoring program. Data were provided 
anonymously by the participating surgeon and checked by research assistants. No 
cases were excluded and all cases were consecutively. For the evaluated cases, all 
data was collected anonymously with entry as case numbers. In order to calculate 
the distance from the anal verge (AV) when only distance from anorectal junction was 
provided, the tumor distance measured from the anorectal junction was corrected by 
adding four centimeters for males and females.(14-17) The part of the rectum in which 
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the tumor was situated was defined by distance from the AV as 0-6 cm, 7-11 cm 12-15cm 
for low, mid and high rectum respectively.(15)
Outcomes
Primary outcomes were intraoperative complications. Secondary outcomes included 
operation time, conversion to laparotomy and postoperative complications, length 
of stay and pathological outcomes (e.g. circumferential and distal resection margin, 
completeness of mesorectum according to classification of Quirke et al.).(18) In order to 
show a potential learning curve, outcomes of the first five procedures were compared 
to the outcomes of the sequential five procedures.
Statistical analysis
A p-value <0.05 was considered statistically significant. For analysis of comparing 
results between the first and sequential five procedures, Chi-Square test (Fisher’s 
exact test when appropriate) in case of categorical variables and Students T-test in 
case of continues variables were used. Mann-Whitney U test was used for continuous 
variables that were not normally distributed. Statistical analysis was performed using 
SPSS version 22 for Windows and Mac (SPSS, Chicago, Illinois, USA).
RESULTS
Baseline characteristics
A total of 120 patients was included of which 53 operated with attending proctor and 67 
without attending proctor. Baseline characteristics are shown in Table 1. The majority 
of patients was male (n = 91, 75.8%). The mean BMI was 26.9kg/m2 (standard deviation 
(SD) 4.0) and age 65.4 years (SD 9.9). Tumors were located in the lower rectum in 45%, 
middle rectum in 46.7% and upper rectum in 8.3% (Mean 6.9 cm from AV). Patients 
received either radiotherapy (n=41, 34.2%), chemoradiotherapy (n=36, 30.0%) or no 
neoadjuvant treatment (n=43, 35.8%). The majority of tumors was classified as cT3 
(73.7%) on MRI in the preoperative work-up. When comparing the first and sequential 
cohort of 60 patients, ASA classification was significantly higher in the second group 
(p= 0.021) Remaining baseline characteristics did not differ significantly.
Operative details
Table 2 shows the intraoperative outcomes of all patients. Transanal TME with primary 
anastomosis and diverting ileostomy was performed in 64.1% of patients (n= 77). 
In one patient a transverse loop colostomy was performed due to clinical signs of 
obstruction prior to the TaTME. The most common anastomotic technique performed 
was mechanical stapling (94.9%) with a side-to-end or end-to-end anastomosis in 36.7% 
and 63.3% of patients respectively. Mean operative time was 293 minutes (SD 93.4). 




Table 1 Patient characteristics
Structured training 
program n=120
Sex Male 91 (75.8)
Female 29 (24.2)
BMI (mean) (±SD) 26.9 (±4.0)
Age (years) (mean) (±SD) 65.4 (±9,9)
History of abdominal surgery No 91 (75.8)
Yes 29 (24.2)
History of transanal surgery No 115 (95.8)
Yes 5 (4.2)
ASA I 25 (21.4)
II 75 (64.1)
III 17 (14.5)
Missing data 3 (2.5)
Tumor height (AV) (cm) (mean) (±SD) 6.9 (±3.1)




Missing data 2 (1.7)
Mesorectal fascia involvement No 97 (82.2)
Yes 21 (17.8)
Missing data 2 (1.7)
Preoperative therapy None 43 (35.8)
RT 41 (34.2)
CRT 36 (30.0)
Numbers in parentheses are percentages, unless mentioned otherwise
Abbreviations: BMI = Body Mass Index (kg/m2), SD = standard deviation, ASA = American 
Society of Anesthesiologists, cm = centimeters, AV = anal verge, RT = radiotherapy, 
CRT = chemoradiotherapy
Two of this six complications occurred during the transanal phase (1.7%); a rectal 
perforation and difficulty dissecting the right lateral plane resulting in completing the 
dissection laparoscopically. Two pelvic bleeding, iatrogenic injury to the small bowel and 
combined ureter and bladder injury occurred in four patients during the laparoscopic 
phase (3.3%). In 5 out of 120 cases (4.2%) conversion to laparotomy was necessary, 
due to portal hypertension, a combined ureter and bladder injury, difficulties due to a 
BMI of 40 in combination with a small male pelvis and difficulty mobilizing the splenic 
flexure during the laparoscopic phase. The fifth conversion was done due to a difficult
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Type of surgery LAR 110 (91.7)
Intersphincteric 10 (8.3)
Anastomosis No 22 (18.3)
Yes 98 (81.7)
Stoma type None 20 (16.7)
Diverting ileostomy 77 (64.1)
Colostomy^ 23 (19.2)
Technique anastomosis Hand sewn 5 (5.1)
Stapled 93 (94.9)
Type anastomosis Side-to-end 36 (36.7)
End-to-end 62 (63.3)
Specimen removal Pfannenstiel 68 (57.6)
Transanally 31 (26.3)
Stoma site 3 (2.5)
Laparotomy 5 (4.2)
Small transverse incision 11 (9.3)
Missing data 2 (1.7)
Operative time (min) (mean) (±SD) 293.0 (±92.6)
Blood loss (ml) (median) (range) 100.0 (0-4050)
Conversion* 5 (4.2)
Intraoperative events Urethral injury 0 (0.0)
Pelvic bleeding 2 (1.7)
Rectal perforation 1 (0.8)
Small bowel injury 1 (0.8)
Ureter injury 1 (0.8)
Technical problems# 1 (0.8)
Numbers in parentheses are percentages, unless mentioned otherwise
^ includes 1 in situ loop transversostomy
* includes 1 early conversion
# Complete unilateral dissection, unable to safely progress contralateral
Abbreviations: LAR = low anterior resection, SD = standard deviation, min= minutes, 
ml = milliliters
transanal phase; an inability to find a safe lateral plane due to a combination of a 
curved anatomy and the initial transanal unilateral dissection with connection to the 




without attending proctor, the latter with attending proctor. In summary, intraoperative 
complications occurred twice during the abdominal phase (1.7%), and in four cases 
(3.3%) during the transanal phase. For the non-converted cases, specimen removal was 
mostly performed through a pfannenstiel incision (57.6%) and secondly by transanal 
extraction (26.3%).




Hospital stay (days) (median) (range) 7 (3-43)
Postoperative complications CD None 66 (55.0)
Minor (CD I-II) 31 (25.8)
Major (CD ≥ III) 23 (19.2)
IIIa 7 (30.4)
IIIb 16 (69.6)
Anastomotic leakage <30 days^ 17 (17.3)
Anastomotic treatment^ Endosponge 5 (5.1)
Temporary ileostomy 4 (4.1)
Unintended colostomy 4 (4.1)
Suture 2 (2.0)
Drainage 1 (1.0)
Novel anastomosis 1 (1.0)
30-day mortality 0 (0.0)
Numbers in parentheses are percentages, unless mentioned otherwise
^ Only patients selected with anastomosis (n=98)
Abbreviations: CD = Clavien-Dindo classification
Postoperative outcomes
Median hospital stay was reported as 7 days (range 3 - 43) (Table 3). Overall 
postoperative morbidity rate was 45.0% (n=54). Major complications within 30 days, 
graded as Clavien-Dindo IIIa or IIIb were seen in 19.2% (n=23) of patients. No Clavien-
Dindo gr IV or V complications were reported. A primary anastomosis was performed 
in 81.7% of the cases(n=98) of whom 17 patients (17.3%) encountered anastomotic 
problems. Treatment in these cases occurred by colostomy (4), diverting ileostomy (4), 
resuture (2), drainage (1), novel anastomosis (1) and endosponge (vacuum therapy) (5). 
Four patients with a primary end colostomy developed a presacral abscess despite of 
the absence of an anastomosis which was treated by transanal drainage (2), CT-guided 
drainage (1) and endosponge (1). Overall, twenty patients had anastomotic problems or 
presacral abscesses of which 81% (n=17) was seen in patients with primary anastomosis.
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Table 4 Pathology reports
Structured training 
program n=120





Quality of specimen (Quirke)^ Complete 107 (89.2)
Nearly complete 13 (10.8)
Incomplete 0 (0.0)
CRM involvement 6 (5.0)
DRM involvement* 0 (0.0)
Lymph nodes harvested (mean) (±SD) 17.0 (±7.2)
Lymph nodes positive (median) (range) 0 (0-7)
Numbers in parentheses are percentages unless mentioned otherwise
^From Quirke et al. Lancet 2009 (reference 18)
*1 missing patient
Abbreviations: CRM = circumferential resection margin, DRM = distal resection margin, 
SD = standard deviation
Pathologic outcomes
The quality of specimens according to Quirke’s classification was complete or nearly 
complete in all patients (89.2% and 10.8% respectively). A positive circumferential 
resection margin (tumor invasion <1mm from non peritonealized surface of the rectum) 
was reported in 5.0% of patients. Distal resection margins was negative (>1mm) in all 
120 patients.
Short-term training
No significant differences in operative time between the first cohort of proctored and 
second cohort of unproctored five procedures per center were found (283.6 and 302.5 
minutes respectively, p=0.266). (Table 5) In both groups three intraoperative adverse 
events occurred suggesting no major increase in intraoperative difficulties resulting in 
visceral injuries or an increase in conversion rate. A complete specimen (Quirke) was 
excised more frequently in the second cohort which was a significant difference; 80.0% 
versus 98.3% for procedure 1-5 and 6-10 respectively (p = 0.001). The circumferential 
resection margin involvement was slightly higher in the second half of procedures (1.7% 
versus 8.3%) but this did not reach significance. Postoperative morbidity was equal for 
the first and second cohort as can be seen in table 5. Severe short-term morbidity, 
defined as Clavien-Dindo ≥ III, was equally distributed. Moreover, anastomotic problems 









Sex (male) 45 (75.0) 46 (76.7) .831
BMI (mean) (±SD) 26.5 (±3.5) 27.3 (± 4.5) .269
Age (years) (mean) (±SD) 64.9 (± 10,3) 66.0 (± 9.5) .540
ASA I 15 (26.3) 10 (16.7) 0.017
II 39 (68.4) 36 (60.0)
III 3 (5.3) 14 (23.3)
Tumor height (AV) (cm) (mean) (±SD) 6.7 (3.1) 7.1 (3.0) 0.519
Tumor stage T1 3 (5.1) 3 (5.1) 1000*
T2 12 (20.3) 11 (18.6)
T3 43 (72.9) 44 (74.6)
T4 1 (1.7) 1 (1.7)
Mesorectal fascia involvement No 49 (83.1) 48 (81.4) .810
Yes 10 (16.9) 11 (18.6)
Preoperative therapy None 18 (30.0) 25 (41.7) .406
RT 22 (36.7) 19 (31.6)
CRT 20 (33.3) 16 (26.7)
Type of surgery LAR 53 (88.3) 57 (95.0) .186
Intersphincteric 7 (11.7) 3 (5.0)
Operative time (min) (mean) (±SD) 283.6 (±80.1) 302.5 (±103.6) .266
Conversion 1 (1.7) 4 (6.8) .207*
Intraoperative complications 3 (5.0) 3 (5.1) .1000*
Hospital stay (days) (median) (range) 8 (3-43) 7 (3-25) .521*
Postoperative complications CD None 31 (51.7) 35 (58.3) .750
Minor (CD I-II) 17 (28.3) 14 (23.4)
Major (CD ≥ III) 12 (20.0) 11 (18.3)
Anastomotic leakage <30 days^ 9 (18.8) 8 (16.0) .719
Quality of specimen (Quirke)# Complete 48 (80.0) 59 (98.3) .001
Nearly complete 12 (20.0) 1 (1.7)
Incomplete 0 (0.0) 0 (0.0)
CRM involvement 1 (1.7) 5 (8.3) .207*
Numbers in parentheses are percentages, unless mentioned otherwise
^ Only patients selected with anastomosis (n=98)
* Fisher’s Exact Test or Fishers-Freeman-Halton Test or Mann-Whitney U Test
# From Quirke et al. Lancet 2009 (reference 18)
Abbreviations: BMI = Body Mass Index (kg/m2), SD = standard deviation, ASA = American Society 
of Anesthesiologists, RT = radiotherapy, CRT = chemoradiotherapy, LAR = low anterior resection, 
min = minutes, CD = Clavien-Dindo classification, CRM = circumferential resection margin
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Sex (male) 75.8 67.4 67.8 65
Age (years) (mean) 65.4 63.8 63.7 64
BMI (mean) 26.9 26.1 26.3 26.1-27
Neoadjuvant (c)RT 64.2 73.0 56.1 61.9
Tumor height (cm) (AV) (mean) 6.9 6.5 4.0$ NA
cT3 or cT4 75.4 69.3 69.0 NA
Conversion 4.2 2.7 5.6 13.0
Anastomotic leakage 17.3 NA 15.7 7.9
pT3 or pT4 50.0 45.1 43.5 NA
Quality of specimen 
(Quirke)&
Complete 89.2 89.7 85.8 87.0
Nearly complete 10.8 9.0 10.8 13.0
Incomplete 0 1.3 3.4 4.0
Missing 9.7 6.0
CRM involvement 5.0 4.5 4.1 8.0
DRM involvement 0.0 NA 0.7 NA
All numbers are percentages, unless mentioned otherwise
^ From Deijen et al. Tech Coloproctology 2016 (reference 2)
* From Penna et al. Ann Surg 2018 (reference 9)
# From van Oostendorp et al. Annals of lap and Endoscop Surg 2018 (reference 8)
$ Median from anorectal junction
& From Quirke et al. Lancet 2009 (reference 18)
Abbreviations: TaTME = Transanal Total Mesorectal Excision, Lap TME = Laparoscopic 
Total Mesorectal Excision, BMI = Body Mass Index (kg/m2), (c)RT = (chemo)radiotherapy, 






This study shows the outcome data during the initial phase of a structured TaTME 
training and proctoring curriculum in the Netherlands in 12 centers, and within each 
center the first ten patients resulting in a total of 120 patients. We have demonstrated 
that the implementation within a structured training pathway is relatively safe with 
a low rate of intraoperative complications of 4.9% and good quality of resection and 
specimen. The resection quality as addressed by pathology showed that complete or 
nearly complete specimen was obtained in 100%, similar to negative distal resection 
margin. Circumferential resection margin was positive in 5.0% of patients. Postoperative 
complications according to Clavien-Dindo ≥III occurred in 19.2%. These results suggest 
that the structured training pathway does result in safe introduction of the technique 
without major intraoperative complications and safe results comparable to those 
obtained from laparoscopic TME surgery.(8, 19)
Compared to the international TaTME registry, especially the intraoperative event rate 
seems low; the registry reports 30.6% intraoperative adverse events rate, of which 
a vast majority (18%) regarded technical problems leaving 12.6% to visceral injuries 
(1.8%) of which 12 urethral injuries (0.8%), incorrect dissection planes (5.7%) and pelvic 
haemorrhage (4.2%).(9) Concern exists for underreporting since publications bias of 
cohort studies is present and rumors about intraoperative complications as urethral 
injury, pelvic sidewall injury, rectal tube perforation and venous CO2 embolisms are 
discussed at conferences and courses frequently but fail to be represented in the 
available literature. The proctor guided implementation of TaTME in the current series 
showed that intraoperative complications were encountered in 5.0% and conversion 
to laparotomy was necessary in 4.2%, suggesting that a proctor based introduction 
potentially lowers the frequency of intraoperative difficulties and adverse events. 
To illustrate this, no injuries to the urethra (0%) occurred and visceral injury was 
encountered in 3 of 120 cases (2.5%). An incorrect dissection plane was reported in one 
patient (0.8%) which is considerably lower than the 5.7% of the previously mentioned 
registry. Abbott et al.(20) recently published the results of implementing TaTME Australia 
and New Zealand using a training pathway which includes on-site proctoring and 
showed a safe introduction with low conversion rate (3%), no intraoperative visceral 
complications but did report two rectal wall perforations.
Postoperative morbidity was reported as 45% overall complications, including 19.2% 
major complication and 17.3% leakage rate. Although the structured training seems 
to provide intraoperative safety the postoperative event rate is high. Several reasons 
may account for this. First, all pelvic abscess and subclinical leaks were included and 
regarded as a anastomotic leakage. Second this is audited cohort data from multicenter 
cohort within a learning curve. Most likely the learning curve is associated with 
prolonged operating time and bacterial spill may negatively influence morbidity rate.(12, 
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21) It is shown that he learning curve of TaTME is associated with an increase in major 
surgical postoperative complications (Clavien-Dindo ≥III) in the first forty cases.(12) In 
this study the anastomotic leak rate was 27.5% for the first 40 cases and decreased 
to 5% for the next forty cases. In addition, the international registry data also shows 
a relative high anastomotic leak rate; 15.7%.(9, 12) Similar leakage rates have been 
reported by the Dutch national audit (90 days; 20%).(9, 22-24) The delayed leak and/or 
presacral abscess potentially may come as a consequence of the open rectal stump 
which raises a concern for bacterial contamination as demonstrated by Velthuis et 
al.(21) but needs further prospective investigation. Third reason for the experienced 
relative high morbidity is the selected patient group with 45% distal tumors and 64.2% 
was treated with neoadjuvant therapy. These distal tumor resections are more prone 
to morbidity.
Within the included centers no difference in intraoperative complications, postoperative 
morbidity or anastomotic leak rate was present when comparing the first proctored 
cohort of five to the second cohort of non-proctored patients. This suggests that the 
learning effect was not present for adverse outcomes in our training program and 
that therefore five cases seems efficient. However, evaluating a surgical learning curve 
needs higher number of cases (80) to allow a CUSUM analysis.(12, 25-27) Future studies 
will address learning curves within centers that have undergone a structured training 
curriculum.(2, 8, 28, 29) In laparoscopic surgery learning curve ranging from 100-150 
cases as self-taught learning curve and 40-60 with proctoring/teaching programs is 
reported.(25, 28-30) The UK LapCo training program showed the safe widespread 
implementation of supervised training for laparoscopic colorectal surgery.(31) Within 
this program outcomes between experienced consultant trainers and trainees was 
similar regarding adverse events.(31, 32) In addition; a meta-analysis of Kelly et al.(33) 
on 19 studies reporting a total of 14.344 colorectal resections showed no significant 
increase in anastomotic leak rate, conversion or worse pathological outcomes in 
procedures performed by trainees.
In our series the primary end colostomy percentage of 18.8 is lower than the 34% in 
COLOR II.(23) However, compared to the 9% colostomy rate from the TaTME registry 
this seems a high rate.(11) Transanal total mesorectal excision possibly enables an 
increase of the creation of an anastomosis in lower rectal cancer which previously 
would have been subject for end colostomy. In further detail, this (very) low colo-
rectal or colo-anal anastomosis might be suitable for patients without the oncologic 
necessity for an abdominoperineal resection but in whom it is technically impossible 
to create an anastomosis by only transabdominal laparoscopy. For this category the 
preoperative function of the anal sphincter is important in the consideration whether 
to make an anastomosis or an end-colostomy.(11) This can probably be attributed to 




try to avoid major APE surgery for patients and select low rectal cancer for TaTME in 
order to achieve a primary anastomosis.
Long-term oncological outcomes in terms of local recurrences have to be awaited due to 
the limited duration of follow-up in this series. As CRM involvement seems to be a strong 
predictor of local recurrence, the encountered 5.0% is lower compared to 6.3-12.1% as 
reported by the recent Laparoscopic TME RCT’s (Table 6) .(8, 10, 23, 34-37)The quality 
of the specimen as defined by Quirke et al. was incomplete in 0 out of 120 cases, with 
a significant increase of a complete specimen when comparing the proctored cohort 
versus the non-proctored cohort patients: 80% versus 93.3% respectively (p= 0,01).
(18, 34) A non-significant difference of CRM involvement was observed (1.7% vs 8.3% 
p=0.207). This increase of CRM while oppositely improving the quality of specimen might 
be attributed to tumor characteristics which were not captured in this study. It might be 
contributed to a higher proportion of anterior located tumors where, due to tapering 
of the mesorectum towards the pelvic floor, the bowel wall is directly adjacent to the 
mesorectal fascia without any intermediary mesorectal fat. Distal resection margin was 
free in all cases suggesting a high rate of R0 resection in our series.
Some limitations of this study should be mentioned; the small sample size and the 
lack of more than ten patients per center. Nevertheless, the main purpose of this 
study was to show the feasibility and safety of the training and proctoring program; 
the low intraoperative complications and promising pathological outcomes indicates 
that competency to safely perform a TaTME is achieved. By extending the cohort to 
larger numbers per center; too many inclusions could therefore be seen as unethical, 
especially in case if we had encountered major intraoperative complications or R1 
resections in the second half of the patients. We do feel that additional audit, quality 
control and potentially extension of the amount of procedures with a proctor should 
be deliberated in future series. At time of data accrual, all centers who completed the 
program have participated in this study.
CONCLUSION
This study describes the safe introduction of TaTME in the Netherlands within a 
structured training program deemed necessary due to the high complexity of this 
novel surgical approach. Intraoperative complication rate was low and TaTME specific 
complications such as pelvic sidewall injury and urethral transection occurred rarely. 
However, postoperative morbidity and anastomotic leak rate emphasize the need for 
careful implementation and need for randomized data as well as long-term outcomes 
on local recurrences.
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ABSTRACT
Background: Transanal total mesorectal excision (TaTME) has been proposed as an 
approach in patients with mid and low rectal cancer. The TaTME procedure has been 
introduced in the Netherlands in a structured training pathway, including proctoring. 
This study evaluated the local recurrence rate during the implementation phase of 
TaTME.
Methods: Oncological outcomes of the first ten TaTME procedures in each of 
12 participating centres were collected as part of an external audit of procedure 
implementation. Data collected from a cohort of patients treated over a prolonged 
period in four centres were also collected to analyse learning curve effects. The primary 
outcome was the presence of locoregional recurrence.
Results: The implementation cohort of 120 patients had a median follow up of 21.9 
months. Short-term outcomes included a positive circumferential resection margin rate 
of 5.0 per cent and anastomotic leakage rate of 17 per cent. The overall local recurrence 
rate in the implementation cohort was 10.0 per cent (12 of 120), with a mean(s.d.) 
interval to recurrence of 15.2(7.0) months. Multifocal local recurrence was present in 
eight of 12 patients. In the prolonged cohort (266 patients), the overall recurrence rate 
was 5.6 per cent (4.0 per cent after excluding the first 10 procedures at each centre).
Conclusion: TaTME was associated with a multifocal local recurrence rate that may be 
related to suboptimal execution rather than the technique itself. Prolonged proctoring, 




The transanal total mesorectal excision (TaTME) technique has been introduced for 
patients with low rectal cancer, with the aim of improving clinical outcomes, such as a 
greater degree of radical resection, lower rates of anastomotic leakage, more sphincter-
saving procedures, better functional results and, most importantly, similar or lower local 
recurrence rates.(1, 2) Direct visualization facilitates purse-string suture placement. 
The technique has been met with tremendous enthusiasm in the colorectal surgical 
community, and more than 300 centres worldwide have implemented the technique.
(3) In expert centres, TaTME is associated with promising pathological and clinical 
outcomes.(4-8) The first long-term outcome data from two expert centres showed a 
favourable low recurrence rate of 2 per cent after 3 years.(9)
Despite these positive results, it is also acknowledged that TaTME is a difficult technique 
and has a long learning curve with associated morbidity.(10, 11) The international TaTME 
registry(3) and a systematic review(4) have shown that widespread adoption results in 
less favourable clinical outcomes than reported in the initial cohorts treated in expert 
centres. The TaTME registry(3), representing more than 300 centres voluntarily entering 
data, recorded an anastomotic failure rate of 15.6 per cent among 1594 patients, which 
is higher than rates from expert centres. In addition, a population-based study(12) 
documented an overall morbidity rate of 42.3 per cent, anastomotic leakage in 16.0 per 
cent and a circumferential resection margin (CRM)-positive rate of 4.4 per cent. These 
latter studies show that the promise of TaTME has not yet been met on a large scale.
The long-term oncological safety of TaTME remains to be proven. Although the first 
report with long-term outcome data showed a low level of local recurrence, the question 
remains whether such results can be achieved with more widespread adoption of 
TaTME.(9) As TaTME is substantially different from abdominal techniques in terms 
of open access to the tumour, purse-string closure and a subsequent endoluminal 
approach to the mesorectal dissection, it is especially important to assess long-term 
outcomes properly. RCTs such as COLOR III(13) and GRECCAR 11(14) are investigating 
long-term outcomes of TaTME, and are currently including patients. Recently, concern 
has been raised by the first report(15) of national Norwegian data which showed an 
increase in the incidence of local recurrence with an extensive or multifocal pattern 
following TaTME, leading to a national halt to TaTME.(16)
In the Netherlands, a structured training pathway, including proctoring sessions 
by dedicated trainers, has been set up to ensure safe implementation of TaTME 
and minimization of learning curve effects.(17) A collective review of the short-term 
outcomes of the first ten patients in 12 proctored centres revealed a major morbidity 
rate of 19.2 per cent and involved CRMs in 5.0 per cent of patients.(17) The aim of the 
present study was to evaluate the oncological outcomes of the initial patients who 
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underwent TaTME within the structured training pathway. In addition, a cohort treated 
over a prolonged period after the implementation of TaTME in four high-volume centres 
was evaluated to analyse learning curve effects in terms of local recurrence rates.
METHODS
Structured training pathway
The structured training pathway was set up in the Netherlands in 2014 as a programme 
for postgraduate colorectal surgeons in centres with an annual volume of total 
mesorectal excision (TME) surgery for rectal cancer of 20 procedures or more and with 
known proficiency in laparoscopic TME. The clinical data from patients in the structured 
training pathway was collected prospectively, as described previously.(17) The first five 
procedures were discussed with and assisted by an experienced proctor, after which 
the following procedures were performed independently. The first ten patients in each 
of centres that completed the structured training pathway were included to evaluated 
clinical outcomes during the implementation of TaTME.(17) In addition, a larger cohort 
of patients from four centres that continued TaTME after training, with a procedure 
volume greater than 45, was collected to assess learning curve effects. Long-term 
clinical data were obtained as part of an external audit to assure high quality and 
completeness of the data set. The anonymized operative notes and full imaging reports 
of locoregional recurrences were obtained and audited by senior TaTME surgeons. 
All patients consented to a TaTME procedure as required under the Dutch national 
patient–physician relation regulations. The Medical Ethics Review Board of Amsterdam 
UMC, Location VUmc, approved the study and waived the need for additional informed 
consent for the present study
Outcomes
The primary outcome of this study was the incidence of local recurrence confirmed 
by either imaging (MRI, CT or PET–CT) and/or pathology (biopsy, salvage surgery). 
A local recurrence was defined as a mass in the pelvis with a biopsy positive for 
adenocarcinoma, or growth on sequential imaging in the absence of histopathological 
confirmation. A multifocal local recurrence was defined by the presence of two or more 
separate foci of recurrence in the pelvic area, as seen on MRI or PET–CT. Secondary 
outcomes included location of local recurrence and distant metastasis, treatment 
of recurrence and distant metastasis, and overall mortality. All potential risk factors 
were evaluated for an association with recurrence. Pelvic sepsis was defined by the 
occurrence of early anastomotic leakage, early pelvic abscess or late complications 
(leakage, abscess or presacral sinus occurring more than 30 days after operation).
(18) Complications were graded according to the Clavien–Dindo classification.(19) 
Rectal perforation, purse-string failure and an insufficient anastomosis requiring 




cells into the pelvis. A positive CRM was defined by the presence of tumour cells 1 mm 
or less from the circumferential plane.
Statistical analysis
Categorical data are shown as number with percentage, whereas continuous outcomes 
are recorded as mean(s.d.) or median (range). Dichotomous and categorical values were 
analysed using Pearson’s χ2 square test or Fisher’s exact test. Comparison of continuous 
data was done using the independent Student’s t test, or Mann–Whitney U test if the 
data were not distributed normally.
Univariable logistic regression analysis was performed to identify potential risk factors 
for local recurrence. Multivariable analysis was not possible because the event rate 
did not exceed the threshold for entry of multiple univariable significant predictors 
into a multivariable model. Case–control analysis between the present TaTME group 
and the laparoscopic TME group from the original COLOR II study was performed by 
matching sex, age, tumour height, neoadjuvant chemoradiotherapy, type of procedure 
(low anterior resection or abdominoperineal resection) and pathological risk factors, 
R1 and CRM and pT4 category.(20, 21) Patients with a final pT4 category or positive 
margins were excluded to enable evaluation of the technique as a potential individual 
risk factor for recurrence. For all tests, two-sided P ≤ 0.050 was considered statistically 
significant. Statistical analyses were done using SPSS® version 24 for Windows® and 
Mac® (IBM, Armonk, New York, USA).
RESULTS
Baseline characteristics and clinical outcomes
A cohort of 120 patients, comprising the first ten patients in each of 12 centres who 
underwent TaTME between March 2015 and October 2018, was included. Median follow-
up was 21.9 (range 2.0–46.7) months. The median interval between the first and tenth 
procedures in each hospital was 12.5 (range 3.5–35.5) months. Baseline characteristics 
have been published previously and are shown in Table 1.(17)
Short-term outcomes are summarized in Table 2. The overall 30-day morbidity rate was 
45.0 per cent, including an anastomotic leakage rate of 17 per cent and pelvic sepsis 
in 17.5 per cent. The involved CRM rate was 5.0 per cent; no patient had an involved 
distal resection margin. The quality of the specimen was rated as complete in 89.2 per 
cent of procedures and nearly complete in 10.8 per cent; none of the specimens were 
considered incomplete.
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Sex ratio (M : F) 91 : 29
BMI (kg/m2)† 26.9(4.1)
ASA fitness grade
  I 26 (21.7)
  II 77 (64.2)
  III 17 (14.2)
Tumour height from anal verge (cm)† 6.9(3.1)
Clinical tumour category
  ycT1 7 (5.8)
  ycT2 24 (20.0)
  ycT3 89 (74.2)
Clinical node category
  cN0 52 (43.3)
  cN1 44 (36.7)
  cN2 24 (20.0)
Persistent MRF+ after RT‡ 6 (5.0)
Preoperative therapy
  None 43 (35.8)
  RT 41 (34.2)
  CRT 36 (30.0)
Transanal total mesorectal excision
  Low anterior resection 110 (91.7)
  Intersphincteric resection 10 (8.3)
*With percentages in parentheses unless indicated otherwise; †values are mean(s.d.). ‡All patients 
with a persistent theatened mesorectal fascia (MRF+) initially had cT3 tumours (3 anterior, 2 lateral, 








  Purse-string failure 1 (0.8)
  Perforation 1 (0.8)
  Reinforcement 3 (2.5)
30-day mortality 0 (0)
30-day overall morbidity 54 (45.0)
Major morbidity (Clavien–Dindo grade ≥ III) 23 (19.2)
30-day anastomotic leakage 17 of 98 (17)
Pelvic sepsis (early leak, abscess and late sinus* 21 (17.5)
Pathological tumour category
  (y)pT0 11 (9.2)
  (y)pT1 16 (13.3)
  (y)pT2 34 (28.3)
  (y)pT3 59 (49.2)
  (y)pT4 0 (0)
Quality of specimen (Quirke)*
  Complete 107 (89.2)
  Nearly complete 13 (10.8)
  Incomplete 0 (0)
CRM involvement ≤ 1 mm 6 (5.0)
DRM involvement < 5 mm 0 (0)
Values in parentheses are percentages. *All patients (anastomosis and colostomy). CRM, 
circumferential resection margin; DRM, distal resection margin.
Long-term outcomes
Long-term outcomes are shown in Table 3. Twelve of 120 patients (10.0 per cent) 
developed local recurrence, which was multifocal in eight patients. The median interval 
to local recurrence was 15.9 months, ranging from 6.0 to 26.4 months (Table 4). The 
recurrences were located presacrally (2), anterior (1), at the rectal stump (1) or in 
multiple regions in the pelvis (8). Nine of the 12 patients with local recurrence presented 
with or developed distant metastasis, whereas only 14 of 108 patients without local 
recurrence had distant metastases diagnosed (P < 0.001).
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Figure 1 Images from a patient with multifocal recurrence after transanal total mesorectal ex-
cision
a PET images showing multifocal recurrence. b,c T2-weighted axial MRI images showing left lateral 
and presacral local recurrence (b) and recurrence in right seminal vesicle (c).




  Mean(s.d.) 23.4(9.5)
  Median (range) 21.9 (2.0–46.7)
Local recurrence (total) 12 (10.0)
Multifocal local recurrence 8 of 12 (67)
Interval to local recurrence (months)† 15.2(7.0)
Overall distribution of disease (recurrence and metastasis)
  Isolated local 3 (12)
  Local + liver 4 (15)
  Local + lung 2 (8)
  Local + liver + lung 2 (8)
  Local + lung + peritoneal + brain 1 (4)
  Liver + lung 4 (15)
  Isolated liver 5 (19)
  Isolated lung 5 (19)
Disease-free surival 94 (78.3)
Overall survival 115 (95.8)
*With percentages in parentheses unless indicated otherwise; †values are mean(s.d.).
The local recurrences were distributed over the 12 participating sites as follows: three 




was no relationship between the time to include ten procedures and the incidence of 
local recurrence.
Details of the 12 patients who developed local recurrence are shown in Table 5. Two 
patients initially presented with a synchronous liver metastasis which was treated by a 
liver-first approach. One of these developed lung metastasis simultaneous with the local 
recurrence. Pathological examination showed two poorly differentiated tumours, and 
three patients had an involved margin, one due to perineural growth that intersected 
the circumferential plane.
Table 4 Location and treatment of local recurrences
No. of patients
(n=12)
Interval to local recurrence (months)
  Mean(s.d.) 15.2(7.0)
  Median (range) 15.9 (6.0–26.4)
Location
  Presacral 2
  Anterior 1
  Rectal stump 1
  Multiple sites 8
Focality (no. of sites)
  1 4
  2 4
  3 4
Treatment
  Exenteration† 4
  CRS + HIPEC 1
  Abdominoperineal resection + IORT 1
  Palliative chemotherapy 5
  Further CRT; multivisceral resection planned 1
†Also intraoperative radiotherapy (IORT) in one patient. CRS + HIPEC, cytoreductive surgery and 
hyperthermic intraperitoneal chemotherapy; CRT, chemoradiotherapy.
Treatment of recurrences
Of the 12 patients with local recurrence, five with unresectable and/or systemic 
disease received palliative treatment. Six patients had local exenterative surgery with 
curative intent. Four patients underwent exenteration (1 combined with intraoperative 
radiotherapy (IORT)), one had abdominoperineal excision with IORT and one had 
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cytoreductive surgery with hyperthermic intraperitoneal chemotherapy as salvage 
surgery. At the time of writing, the final patient was receiving further chemoradiotherapy 
before salvage surgery.
Risk factors for recurrence
Risk factors for recurrence were identified by univariable logistic regression analysis. 
Prognostic factors associated with local recurrence (12 patients) were: positive CRM 
(odds ratio (OR) 11.67; P = 0.006), intraoperative complication (OR 7.00; P = 0.005), (y)pT3 
category (OR 6.02; P = 0.025) and pelvic sepsis (OR 4.12; P = 0.029) (Table S1, supporting 
information). Risk factors associated with multifocal recurrence (8 patients) were: 
intraoperative complication (OR 12.11; P = 0.013), positive CRM (OR 9.00; P = 0.022), 
pathological N-positive status (OR 6.88; P = 0.022), (y)pT3 category (OR 3.34; P = 0.150) 
and pelvic sepsis (OR 5.59; P = 0.023) (Table S2, supporting information).
Proctoring effect
There were four patients with local recurrence among the first five proctored TaTME 
procedures per centre (4 of 60 overall) and eight occurred in the second five proctored 
TaTME procedures (8 of 60) (P = 0.362). Clinicopathological outcomes for the first and 
second five procedures per centre were an intraoperative complication rate of 3 versus 5 
per cent respectively, an anastomotic leakage rate of 19 versus 16 per cent, and involved 
CRM rate of 2 versus 8 per cent.
Comparative case-matched analysis of transanal versus laparoscopic total 
mesorectal excision
To focus on the procedure itself rather than pathological risk factors for local 
recurrence, case-matched pairing of patients with good-quality specimens and no CRM 
involvement yielded two groups of 109 patients with similar baseline characteristics, 
abdominoperineal resection rate and incidence of anastomotic leakage (Table S3, 
supporting information). The pathological outcomes were comparable in terms of stage, 
and no patient in either matched group had a non-radical resection or incomplete 
specimen. The overall local recurrence rate was higher for TaTME than laparoscopic 
TME: 8.3 per cent (nine patients) and 1.8 per cent (2) respectively.
Long-term outcomes of four hospitals with experience of more than 45 procedures
A prolonged cohort from four hospitals with experience of more than 45 procedures 
included a total of 266 patients who underwent TaTME for primary rectal cancer. Median 
follow-up was 23.8 (range 1.0–62.4) months. The crude local recurrence rate was 15.0 
per cent after the first ten procedures in each centre, 4.2 per cent after procedures 
11–40, and 3.8 per cent for procedure 41 onwards (Table 6). Overall, 15 patients (5.6 per 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 6 Local recurrence according to number of transanal total mesorectal excision procedures 








Centre A 2 of 10 2 of 30 0 of 31 4 of 71 (6)
Centre B 1 of 10 2 of 30 3 of 28 6 of 68 (9)
Centre C 2 of 10 0 of 30 1 of 7 3 of 47 (6)
Centre D 1 of 10 1 of 30 0 of 40 2 of 80 (3)
Overall 6 of 40 (15) 5 of 120 (4.2) 4 of 106 (3.8) 15 of 266 (5.6)
Values in parentheses are percentages.
DISCUSSION
In this study, the local recurrence rate during the learning curve was 10.0 per cent, 
despite the low positive CRM rate and the presence of a structured training pathway, 
including on-site proctoring. The multifocal pattern of recurrence seemed to be 
substantially different from that after abdominal TME (open, laparoscopic or robotic) 
and confirmed the pattern encountered in Norway(15), which calls for further evaluation 
of the safety of TaTME. TaTME has been shown to be a difficult technique with a relatively 
long learning curve and associated morbidity.(10) Therefore, it was expected that 
some learning curve-related problems would be encountered in the present cohort, 
despite the presence of a structured training pathway aimed at minimizing harm during 
implementation.
The effect of the learning curve is demonstrated by the relatively high rate of 
anastomotic leakage and relatively high rate of local recurrences in the longer term. 
The present cohort size in each centre was inadequate for cumulative sum analysis 
with the endpoint local recurrence, but an increased recurrence rate among the first 
ten patients was clearly shown. This could reflect difficulties with poor execution of 
the technique causing unwanted tumour spillage. These data also demonstrate that 
the structured training as set out in this programme was not capable of diminishing 
all adverse outcomes, and should therefore be made more extensive for centres 
implementing this technique in the future. Proctoring of more than ten procedures 
should be advised until proficiency is met according to independent competency 
assessment using video analysis.(22)
Execution of the procedure rather than the technique itself may explain the observed 
recurrences. This is supported by the results of univariable analysis, which identified 
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intraoperative events as the biggest risk factor. Two expert centres reported a 3-year 
local recurrence rate of 2.0 per cent.(9) In the present study, long-term outcomes from 
four centres with experience of more than 45 TaTME procedures after training indicated 
that the first ten procedures (early experience) are more at risk of local recurrence than 
the following 30. The 4.0 per cent local recurrence rate achieved after exclusion of the 
first ten procedures at each centre is more in line with the results reported by Hol et al. 
for the two expert centres starting this technique in the Netherland.(9) Longer follow-up 
is needed to confirm the present recurrence rates, which should be interpreted with 
caution owing to inclusion of more challenging cases.(23)
The learning curve for implementation of new surgical techniques and its influence on 
long-term oncological outcome is an important issue. Data are scarce, but a study of 
laparoscopic TME surgery demonstrated a significantly higher recurrence rate among 
the first 100 procedures compared with the following 200 (10.5 versus 4.9 per cent 
respectively).(24) Robotic-assisted TME surgery is being implemented worldwide, but 
data on the learning curve have focused on duration of operation, involved CRM rates 
and/or complications, and not on long-term recurrence rates. A series by Polat et 
al., reporting the first 77 procedures, documented a recurrence rate of 9.5 per cent 
despite a relatively low positive margin rate. This relatively high local recurrence rate 
was probably related to suboptimal technical execution within the learning curve.(25)
The full report of the National Norwegian audit of 157 TaTME procedures revealed 
12 local recurrences (7.6 per cent) after a median follow-up of 19 months, with an 
estimated local recurrence rate of 11.6 per cent at 2.4 years according to Kaplan–
Meier analysis.(16) Wasmuth et al. stated that TaTME was responsible for the increased 
local recurrence rate, and that poor outcome could not be attributed to the learning 
curve effect because several of these recurrences occurred late in the series.(16) 
However, four high-volume centres performed 152 procedures over 4 years, which 
breaks down to an average annual volume of 9.5 procedures. This raises the question 
of whether the learning curve had been completed owing to the low exposure. A high 
rate of positive margins despite low tumour stage, the high rate of permanent stomas 
and perioperative morbidity may be indicative of suboptimal TaTME procedures. An 
unsupervised learning curve without proctoring, as shown by experienced single-port 
surgeons, takes over 40 procedures.(10, 11)
The crucial difference in the TaTME technique is the endoluminal approach and 
potential direct contact with the tumour, whereas in the other abdominal techniques 
distal closure is assured by stapling below the tumour.(26) Poor tumour handling 
and inadequate closure of the lumen by failing purse strings could lead to tumour 
cells spilling into the pelvic dissection area during the procedure causing (multifocal) 
recurrences. This could be a similar mechanism to that described in early reports 




acknowledgement of tumour cell aerosolization combined with a chimney effect at the 
trocar sites. After implementation of sufficient training and clinical trials, it has now 
been proven that laparoscopy is safe when executed proficiently.
The multifocal local recurrence shown in this series and reported by Larsen and co-
workers seems to be a new pattern.(15) In the Dutch TME trial(28), the multifocality of 
recurrences was not evident on review of the imaging of patients with local recurrence. 
Other data regarding the incidence of multifocal local recurrences are scarce; large 
trials have not reported multifocality as a separate entity. In the present study, seven 
of 12 patients with local recurrence developed distant metastasis, similar to rates 
found in the Dutch TME and COLOR II trials, in which 50–60 per cent of patients with 
local recurrence also had distant metastasis.(21, 29) The question remains whether 
recurrence is related to the biology of the cancer rather than the surgical technique 
driving distant haematogenous spread of the disease.(30)
The explanation for both the high rate of multifocal recurrences and the local recurrence 
rate of 10.0 per cent, despite a relatively low CRM positivity rate of 5.0 per cent in this 
implementation cohort, could be multifactorial. Theoretically, unsuccessful execution of 
a TaTME procedure might result in inadequate purse-string closure of the lumen. During 
the subsequent pelvic dissection, spilled tumour cells might be scattered as a result of 
the continuous high-flow insufflation used in the dissection area in TaTME, leading to 
multifocal local recurrence. A high rate of positive bacterial cultures during TaTME, as 
reported by Velthuis and colleagues(31), might provide support for this hypothesis. The 
authors have preliminary data showing that cancer cells can be cultured from rectal 
wash-out ( J. Tuynman; unpublished observation). Although the exact aetiology remains 
to be proven, all COLOR III sites have been instructed to secure the purse-string closure 
with a second over-running suture after the rectotomy with a secondary wash-out.(32) 
Intraoperative perforation of the rectal tube in conventional TME might be regarded as 
a similar mechanism whereby tumour cells can seed in the pelvic cavity. In the present 
risk analysis, occurrence of intraoperative complications was the strongest predictor 
of multifocal local recurrence and second strongest for overall local recurrence. A 
previous study by Eriksen and colleagues(33) showed a tremendous negative impact 
of perforation on 5-year local recurrence, with the incidence rising from 9.9 per cent to 
28.8 per cent in the presence of perforation (P < 0.001). The relatively high rate of pelvic 
sepsis (17.5 per cent) in the present learning curve cohort might also have contributed 
to the increased recurrence rate. A consistent hypothesis is that pelvic sepsis leads to 
an increased inflammatory reaction, and increased levels of growth factors associated 
with stimulation of adhesion and seeding of tumour cells.(34-36)
A potential weakness of this cohort study is the possible inclusion of some patients 
with advanced-stage disease in the learning curve cohort. Overall, selection bias 
could be present within these data, but all patients who underwent TaTME for primary 
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rectal cancer were included consecutively and the data were audited externally by an 
independent clinical researcher. Furthermore, case-matched analysis of TaTME and 
laparoscopic TME procedures, excluding CRM-positive and T4 tumours, demonstrated 
that TaTME during the learning curve was the only risk factor for local recurrence and 
not the pathology, showing that case selection was not an issue in the present cohort. 
Video analysis with surgical quality assessment could have revealed potential risk 
features for local recurrence. Quality assessment of every procedure is the central 
ingredient in the current COLOR III trial(22), in which all data including MRI and the 
entire video of each procedure are captured centrally.
As stated in the IDEAL framework, a new innovation or technique should be evaluated 
stepwise, and not be implemented broadly before standardized indications and 
procedures have been developed. In this way, adverse effects and consistent 
outcomes can be established during the learning curve, which new centres can set as 
a benchmark.(37) The surgical community should focus on demonstrating oncological 
safety rather than surrogate endpoints for new innovative surgical techniques for 
patients with cancer. High-quality data accrual in a clinical (randomized) trial is key, 
including establishing a safety commission and frequent external data monitoring.(38) 
The international TaTME guidance also states that TaTME should be implemented only 
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ABSTRACT
Introduction: Transanal total mesorectal excision (TaTME) for mid and low rectal 
cancer has shown to result in benefits in short-term outcomes, mostly reflected by lower 
conversion rates and with improved quality of the specimen. However, robust long-
term oncological data supporting the encouraging clinical and pathologic outcomes 
are lacking.
Methods: All consecutive patients undergoing TaTME with curative intent for mid- or 
low rectal cancer in two reference centers in the Netherlands with a complete and 
minimum follow-up interval of 36 months from date of surgery were included. Primary 
outcome was local recurrence rate. Secondary outcome were disease free survival, 
overall survival and development of metastasis.
Results: In this series of 159 consecutive patients operated between January 2012 to 
April 2016, the 3 years local recurrence rate was 2.0% and the 5 years local recurrence 
rate was 4.0%. Median time to local recurrence was 19.2 months. Disease free survival 
at 3 years was 92% and at 5 years was 81%. Overall survival at 3 years was 83.6% and 
at 5 years was 77.3%.
Conclusion: The long-term follow-up of the current cohort confirms the oncological 
safety and feasibility of TaTME in two high volume reference centers for rectal 
carcinoma. However, further robust and audited data must confirm current findings 




Transanal Total Mesorectal Excision (TaTME) has the potential to lower the local 
recurrence rate after radical resection of mid and low rectal cancer. Currently available 
evidence shows an improvement in the quality of the surgical specimen and reduced 
number of R1 resections by lower distal margins in initial cohort studies (1-3). Therefore, 
TaTME has the potential to lower the local recurrence rate after radical resection of mid 
and low rectal cancer. However, long-term data of local recurrence rates confirming the 
encouraging pathologic outcomes are lacking (4). Over the past decades, adaptation 
of Total Mesorectal Excision (TME) as surgical principle has reduced local recurrence 
rates and improved cancer free survival rates (5). Combined with neoadjuvant 
chemoradiation the local recurrence rates have been reduced to 5% as demonstrated 
in a large randomized clinical trial (6).
Even though laparoscopic surgery has improved the short-term results after rectal 
cancer surgery, the expected oncological benefits are modest as shown in large 
randomized trials (6-8). Laparoscopic TME is considered as a difficult technique which 
might influence the results of surgery. Especially the lower part of the rectum is at risk, 
specifically in male patients with a narrow small pelvis in which there is a limited space 
to mobilize the rectum with intact mesorectum. But also neoadjuvant therapy and local 
excision will influence the results of laparoscopic TME surgery.
In TaTME, the rectum is approached both from above and below, preferably at the same 
time (1). Because the distal part of the rectum is approached from below it is more 
accessible and the surgical planes are better visualized. The technique appears to be 
feasible and short-term outcomes seem promising in expert centers. However, the 
learning curve is extensive which might influence the results in low volume centers (3, 
9). Recently, Norway TaTME data revealed 9,5% local recurrences leading to a nationwide 
stop and thorough investigation (10). Nevertheless, the 9,5% local recurrence rate 
disturbed the surgical colorectal community and the results of the official investigations 
are eagerly awaited. Other single center series have reported local recurrence rates 
ranging from 2.3% - 5.7% with median follow up between 15 -32 months (2, 11-15). In 
this study we describe the long-term oncological results after TaTME surgery in a large 
consecutive cohort with a minimal of 36 months follow-up from the two hospitals that 
started TaTME in the Netherlands.
METHODS
Patients
Between January 2012 and May 2016, all patients in the Gelderse Vallei Hospital, Ede, 
the Netherlands and Amsterdam UMC, location VUmc, Amsterdam, the Netherlands 
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with histological proven distal- or midrectal carcinomas, operated electively by TaTME 
approach were included. Exclusion criteria were recurrent and/or locally advanced 
tumors with persistent threatened margins after neoadjuvant radiotherapy, and 
palliative resections.
Preoperative assessment included MRI for local staging, computed tomography of the 
abdomen and computed tomography or conventional x-ray of the thorax for distance 
metastasis detection, and blood analysis with serum CEA analysis. Each patient was 
discussed by a local multidisciplinary cancer board. Patients at medium risk, being 
cT3b+ N0 or cT2–3 N1 tumors received preoperative radiotherapy with 5 consecutive 
days of 5Gy daily dose. Patients with N2 disease or tumors with threatened margins 
(<1.0 mm) to the mesorectal fascia were treated with chemo radiation therapy with 25 
days of 2 Gy daily dose, combined with administration of oral 5-fluorouracil.
Surgical procedure
TaTME was performed as described before (2). The first patients were operated by a 
single surgeon, performing both phases of the procedure sequentially. After the initial 
learning curve the two team approach was introduced, with simultaneous abdominal 
and the transanal dissection. The splenic flexure was mobilized in the majority of the 
patients. Ligation of the inferior mesenteric vein was done near the pancreas.
The transanal phase consists of a thorough washout and the introduction of the anal 
platform, in the majority of the cases the GelPOINT Path Transanal Access Platform 
(Applied Medical, Rancho Santa Margarita California, USA) was used. In the first 
consecutive patients, a regular laparoscopic CO2 insufflator was used. This was replaced 
in all other patient by the AirSeal insufflator (ConMed, Utica, New York, USA). The purse 
strings location changed from the initial position directly behind the dentate line to a 
3 cm higher position above the anorectal junction (if applicable for the location of the 
tumor, in proximal tumors it was placed below the tumor). Dissection was performed 
in a standardized fashion, starting the dissection dorsally and ventrally, thereafter 
dissecting the lateral plane. The abdominal and transanal team joined anteriorly. 
Specimen extraction was performed after wound protection through a Pfannenstiel 
incision. The anastomosis was made preferably side to end using a 31 EEA or 33 EEA 
hemorrhoid stapler (Medtronic, Dublin, Ireland).
Statistics and data collection
Baseline data was collected regarding age, sex, ASA classification, BMI, distance of 
the tumor from the anal verge, preoperative clinical staging, and preoperative chemo 
radiation therapy. Pathological outcome included pathological staging, macroscopic 
completeness of the resection, number of lymph nodes harvested and CRM. All patients 
have had follow-up carried out according to the Dutch National Guidelines for Colorectal 




follow-up was available for all patients. Primary outcome was loco regional recurrence. 
Secondary outcome included distant metastasis disease-free and overall survival. 
Recurrence disease was defined as the presence of loco regional recurrence, distant 
metastases or death from rectal cancer. All data collection and statistical analysis were 
carried out using SPSS Statistics version 24 (IBM, Chicago Illinois, USA). After analysis of 
numbers and percentages or median and range for each variable, a univariate binary 
regression analysis was performed for possible risk factors for local recurrence. Kaplan 
Meier survival analysis was performed for local recurrence free survival rates, disease 
free survival rates and overall survival rates.
Ethics
The study was approved by the participating centers. All procedures performed in 
studies involving human participants were in accordance with the ethical standards 
of the institutional and/or national research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical standards.
RESULTS
Patients characteristics and clinical outcomes
From January 2012 to May 2016 a total of 159 consecutive patients underwent TaTME. 
110 underwent surgery in Gelderse Vallei Hospital, Ede, the Netherlands and 49 in 
Amsterdam UMC, location VUmc, Amsterdam, the Netherlands. The follow-up data 
was complete for all patients. Mean age was 66.9(10.2) years old and 66.7 percent of all 
patients were men. Neoadjuvant radiotherapy was administered in 112 patients (70.4%) 
and 117 received a primary anastomosis during surgery (73.6%). In 39 patients (24.5%) 
encountered postoperative complications graded as Clavien Dindo grade 3 or higher. 
Characteristics and short-term clinical outcomes are summarized in table 1.
Oncologic outcomes
Pathological analysis showed a complete mesorectum in 139 patients (87.4%), nearly 
complete in 16 (10.1%) and an incomplete mesorectum in 4 patients (2.5%). Pathological 
staging showed T0 in 13 patient (8.2%), T1 in 15 (9.4%), T2 in 74 (46.5%), T3 in 55 (34.6%) 
and T4 in 2 (1.3%). N stage was N0 in 118 patient (74.2%), N1 in 28 (17.6%) and N2 in 13 
(8.2%). There was involvement of the circumferential resection margins (<1mm) in 1 
patient (0.6%) and none had involvement of the distal margin (<5mm).
The mean long-term follow up was 54.8 months (range 36-88 months). The overall local 
recurrence rate was 3.8%, median time to local recurrence was 19.2 months (5.9-30.0). 
Figure 1 shows a Kaplan Meier (KM) curve of local recurrence. Local recurrence rate at 
3 years was 2.0% and at 5 years was 4.0%. An overview of all six local recurrence cases 
and treatment can be seen in table 4.
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Table 1. Patient characteristics and clinical outcome
n=159
Sex Male 106 (66.7)
Female 53 (33.3)
BMI (mean) (±SD) 26.4 (4.3)
Age (years) (mean) (±SD) 66.9 (10.2)
ASA I 33 (20.8)
II 100 (62.9)
III 26 (16.4)
Height from AV (cm) mean (±SD) 5.7 (3.5)
median (range) 6 (0-15)
Height from AV <4cm yes 47 (29.6))









Synchronous Metastasis M+ 7 (4.4)
MRF threatened (before RT) No 125 (78.6)
Yes 34 (21.4)
Preoperative therapy RT 112 (70.4)
CRT 43 (27.0)
Anastomosis primary anastomosis 117 (73.6)
end-colostomy 42 (26.4)
Performed operation LAR TaTME 133 (83.6)
ISR/APE TaTME 26 (16.4)
Intra-operative complications rectal perforation 2(1.3)
purse-string failure 1(0.6)
 carbon dioxide (CO2) embolus 1(0.6)
Postoperative morbidity No complications 46 (47.8)
Minor Clavien Dindo 1-2 44 (27.7)
Severe Clavien Dindo ≥3 39 (24.5)
Reoperation 36 (22.6)
Anastomotic leakage 10 (6.3)
Presacral abcess 14 (8.8)
Numbers in parentheses are percentages, unless mentioned otherwise
Abbreviations: BMI = Body Mass Index (kg/m2), SD = standard deviation, ASA = American 
Society of Anesthesiologists, cm = centimeters, AV = anal verge, MRF = mesorectal fascia 
RT = radiotherapy, CRT = chemoradiotherapy, LAR= Low anterior resection, ISR= Intersfincteric 




Table 2. Pathologic and long term outcomes
n =159





Pathologic N-stage N0 118 (74.2)
N1 28 (17.6)
N2 13 (8.2)
Quality of specimen (Quirke) Incomplete 4 (2.5)
Nearly complete 16 (10.1)
Complete 139 (87.4)
CRM + <1 mm 1 (0.6)
DRM + <5mm 0 (0.0)
Follow-up (months) Mean (±SD) * 54.8 (13.1)
Median (range) * 52.0 (36.0-88.0)
Local Recurrence overall no 153 (96.2)
yes 6 (3.8)
Interval to local recurrence (months) Median (range) 19.2 (5.9-30.0)
Distant metastasis no 137 (86.2)
yes 22 (13.8)
Interval to distant metastasis (months) Median (range) 6.9 (1.1-50.4)
Disease recurrence no 133 (83.6)
yes 26 (16.4)
Interval to disease recurrence months 8.2 (1.1-50.4)
Overall survival 124 (78.0)
Deceased 35 (22.0)
Interval to death (months) Median (range) 28.0 (0.5-61)
Numbers in parentheses are percentages, unless mentioned otherwise
* Mean/mediang-range Does not include diseased patients
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Disease free survival at 3 years was 92% and at 5 years was 81%. Figure 2 shows a KM 
curve of disease free survival. Distant metastases were seen in 22 (13.8%) patients and 
were diagnosed after a median of 6.9(1.1-50.4) months. Overall survival at 3 years was 
83.6% and at 5 years was 77.3%. See figure 3 for KM curve of overall survival. Results 
from pathologic examination and long-term results are summarized in table 2.
Risk factors for local recurrence
Univariate binary logistic regression analysis for local recurrence showed no significant 
difference for sex, obesity, low tumor, threatened MRF, preoperative radiotherapy, (y)pT4 
stage, (y)pN2 stage, positive CRM, incomplete mesorectum, intra-operative perforation, 
intra-operative purse-string failure, carbon-dioxide embolus, synchronous metastasis, 
anastomotic leakage and reoperation. There was a significant risk for pathologic stage 
T3 or 4 tumors, RR 0.103 (0.012-0.904), p=0.040, complications grade 3 or higher 
according to Clavien Dindo RR 0.148 (0.026-0.844), p=0.031 and presence of presacral 
abscess RR 0.077 (0.014-0.430), p=0.003. The patient with intra-operative purse-string 
failure did not develop pre-sacral abscess or local recurrence. Results of the univariate 
analysis for risk factors are summarized in table 3.
Years 0 1 2 3 4 5 6 7
No at Risk 159 149 140 133 80 41 14 1










Sex Female 3 53 ref
Male 3 106 2,06 0,401 10,573 0,386
BMI >25 no 4 66 ref
yes 2 93 2,935 0,522 16,522 0,222
Low tumor <4cm from AV no 4 112 ref
yes 2 47 0,833 0,147 4,713 0,837
MRF threatened on MRI no 4 125 ref
yes 2 34 0,529 0,093 3,018 0,473
Preoperative radiotherapy no 2 47 ref
yes 4 112 1,200 0,212 6,787 0,837
pathologic stage T3-4 no 1 102 ref
yes 5 57 0,103 0,012 0,904 0,040
pathologic stage T4 no 6 157 ref
yes 0 2 0,000 0,999
pathologic stage N2 no 5 146 ref
yes 1 13 0,426 0,046 3,943 0,452
CRM+ no 5 158 ref
yes 1 1 0,000 0,000 1,000
incomplete mesorectum no 6 155 ref
yes 0 4 0,000 0,999
Intra-operative perforation no 6 157 ref
yes 0 2 0,000 0,999
Purse-string failure no 6 158 ref
yes 0 1 0,000 1,000
CO2 embolus no 6 158 ref
yes 0 1 0,000 1,000
Synchronous metastasis no 5 152 ref
yes 1 7 0,204 0,021 2,029 0,175
complications CD 3 or higher no 2 120 ref
yes 4 39 0,148 0,026 0,844 0,031
anastomotic leakage no 5 149 ref
yes 1 10 0,313 0,033 2,965 0,311
presacral abscess no 3 145 ref
yes 3 14 0,077 0,014 0,430 0,003
reoperation no 3 123 ref
yes 3 36 0,275 0,053 1,426 0,124
Abbreviations: BMI = Body Mass Index (kg/m2), AV = Anal verge, MRF= mesorectal fascia, 
CRM+ = involvement of the circumferential resection margins (<1mm), CD = Clavien Dindo.
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Years 0 1 2 3 4 5 6 7
No at Risk 159 147 139 133 80 41 14 1
Figure 2: Kaplan Meier curve of disease free survival after TaTME
Years 0 1 2 3 4 5 6 7
No at Risk 159 147 139 133 80 41 14 1
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DISCUSSION
In this series of 159 TaTME procedures for rectal cancer is shown that TaTME is 
associated with low local recurrence rate; the 3 year local recurrence rate is 2.0% 
with complete follow-up and 4.0% after 5 years. The median time to local recurrence 
was 19.2 months (5.9-30.0 months). By our knowledge this is the largest series with a 
complete and long follow-up of more than 3 years after TaTME (4). This report shows 
that TaTME is oncological safe when performed in specialist centers with dedicated 
colorectal surgeons.
The encountered 3 years local recurrence rate in this study is relatively low compared to 
the laparoscopic TME long-term outcome data of the COLOR II, ALaCART and ACOSOG 
Z6051 trials which show a 3 year local recurrence rate of 5% (6-8). In accordance to 
previous literature high tumor stage, severe postoperative complications and presence 
of a presacral abscess were risk factors for local recurrences (16). A multivariate analysis 
was not possible due to the low number of events.
One of the potential benefits of TaTME for mid- and low rectal cancer is better specimen 
quality and better radicality. Incomplete mesorectum is a known risk factor for local 
and overall recurrence (17). In our study 97.5% of the specimens had a good quality 
specimen, which is comparable to our previous study by Velthuis et al. in which 100% 
of the specimens after TaTME had a good quality specimen, while in the traditional 
laparoscopic group 80% had good quality (18).
Despite TaTME was introduced in 2010, ample data on long-term outcome currently 
limited. In contrast, a considerable amount of case-series describing single center 
experiences focus merely on short-term and pathological outcomes (19). Although there 
is a growing interest for TaTME in rectal cancer surgery, it is still not widely implemented 
and concerns persist regarding the adequacy of oncological resection. The results of 
our study adds long-term outcome data to support the potential benefits of TaTME 
for mid- and low rectal cancer: increased quality of the mesorectum, low number of 
positive CRM and corresponding low local recurrence rate.
Although the results from our study are encouraging, it only includes data from the two 
hospitals that started TaTME in the Netherlands which are high volume tertiary referral 
centers. The oncological results of widespread adaptation of TaTME remains to be 
proven. Early adopters of TaTME recognized the high complexity of the procedure (20). 
Therefore, several countries started a nationwide structured training program including 
proctoring to deliver safe implementation of the procedure (21, 22). The technique has 
a learning curve associated with substantial morbidity. Surgeons have to perform at 
least 40 cases in order to reach competency, based on acceptable morbidity or good 




outcome in terms of conversion, severe complications and quality of the mesorectum 
(3). Our results do not support the concern that TaTME leads to an increased risk for 
local recurrence, as suggested by Norwegian data (10). It is to be imagined that poor 
quality TaTME does negatively influence local recurrence rates. A review focusing on 
outcomes of TaTME in low volume centers was associated with relatively high recurrence 
rate of 8.9% versus 2.8% in high volume centers (3). Another possible explanation for 
the higher
This indicates that a learning curve might seriously hamper both short- and long-term 
outcome. Inadequate dissection, perforation and/or insufficient closure of the rectum 
before dissection all have the potential for tumor spill (24).
The IDEAL framework aims to prevent surgical innovation to be implemented too early 
(25). Whilst the technique is still in the developmental stage and no global consensus 
and standardization has been reached, one could argue that the surgical community 
has proceeded to the early exploration with many starting this technique. This means 
exposing patients to potential intra-operative complications and short-term morbidity. 
Furthermore, long-term oncological safety of the technique must be approached with 
caution, comparable to the port-site metastasis setback seen in laparoscopic surgery 
(26). The international TaTME registry showed to be a useful instrument in the aim 
to capture real-time data of the early adaptation of TaTME and has signaled a 15.7% 
anastomotic failure rate (27). The long-term follow up data of the international registry 
are awaited although completeness of data will be a potential problem and bias.
Although the results of our study are promising, oncological safety after TaTME surgery 
remains to be proven in a multicenter international setting. The next crucial step in 
implementing this technique is an international randomized controlled trial such as 
the COLOR III trial, which is currently enrolling and is designed to assure high quality 
evidence by implementing a pretrial showing surgical competency, central review of 
MRI, assessment of procedural video, re-evaluation of the specimen and obligatory 
upload and central review of MRI 3 years after surgery (28).
This consecutive TaTME cohort study in 159 patients with complete follow-up 36 months 
or more shows that TaTME is associated with relatively low local recurrence rate of 2.0% 
after 3 years and 4.0% after 5 years. This shows that in experienced hands with high 
volume TaTME is safe and is associated with good long-term outcome.
161
Long-term oncological results after TaTME for rectal carcinoma
REFERENCES
1. Sylla P, Rattner DW, Delgado S, Lacy AM. NOTES transanal rectal cancer resection 
using transanal endoscopic microsurgery and laparoscopic assistance. Surg Endosc. 
2010;24(5):1205-10.
2. Veltcamp Helbach M, Deijen CL, Velthuis S, Bonjer HJ, Tuynman JB, Sietses C. Transanal total 
mesorectal excision for rectal carcinoma: short-term outcomes and experience after 80 
cases. Surg Endosc. 2016;30(2):464-70.
3. Deijen CL, Tsai A, Koedam TW, Veltcamp Helbach M, Sietses C, Lacy AM, et al. Clinical 
outcomes and case volume effect of transanal total mesorectal excision for rectal cancer: 
a systematic review. Tech Coloproctol. 2016;20(12):811-24.
4. Zhang X, Gao Y, Dai X, Zhang H, Shang Z, Cai X, et al. Short- and long-term outcomes of 
transanal versus laparoscopic total mesorectal excision for mid-to-low rectal cancer: a meta-
analysis. Surg Endosc. 2019;33(3):972-85.
5. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery--the clue to pelvic 
recurrence? Br J Surg. 1982;69(10):613-6.
6. Bonjer HJ, Deijen CL, Haglind E, Group CIS. A Randomized Trial of Laparoscopic versus Open 
Surgery for Rectal Cancer. N Engl J Med. 2015;373(2):194.
7. Stevenson ARL, Solomon MJ, Brown CSB, Lumley JW, Hewett P, Clouston AD, et al. Disease-
free Survival and Local Recurrence After Laparoscopic-assisted Resection or Open Resection 
for Rectal Cancer: The Australasian Laparoscopic Cancer of the Rectum Randomized Clinical 
Trial. Ann Surg. 2019;269(4):596-602.
8. Fleshman J, Branda ME, Sargent DJ, Boller AM, George VV, Abbas MA, et al. Disease-free 
Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection 
of Stage II to III Rectal Cancer: Follow-up Results of the ACOSOG Z6051 Randomized 
Controlled Trial. Ann Surg. 2019;269(4):589-95.
9. Koedam TWA, Veltcamp Helbach M, van de Ven PM, Kruyt PM, van Heek NT, Bonjer HJ, et 
al. Transanal total mesorectal excision for rectal cancer: evaluation of the learning curve. 
Tech Coloproctol. 2018;22(4):279-87.
10. Larsen SG, Pfeffer F, Korner H, Norwegian Colorectal Cancer G. Norwegian moratorium on 
transanal total mesorectal excision. Br J Surg. 2019;106(9):1120-1.
11. Lelong B, Meillat H, Zemmour C, Poizat F, Ewald J, Mege D, et al. Short- and Mid-Term 
Outcomes after Endoscopic Transanal or Laparoscopic Transabdominal Total Mesorectal 
Excision for Low Rectal Cancer: A Single Institutional Case-Control Study. J Am Coll Surg. 
2017;224(5):917-25.
12. Burke JP, Martin-Perez B, Khan A, Nassif G, de Beche-Adams T, Larach SW, et al. Transanal 
total mesorectal excision for rectal cancer: early outcomes in 50 consecutive patients. 
Colorectal Dis. 2016;18(6):570-7.
13. Lacy AM, Tasende MM, Delgado S, Fernandez-Hevia M, Jimenez M, De Lacy B, et al. Transanal 





14. Rouanet P, Mourregot A, Azar CC, Carrere S, Gutowski M, Quenet F, et al. Transanal 
endoscopic proctectomy: an innovative procedure for difficult resection of rectal tumors 
in men with narrow pelvis. Dis Colon Rectum. 2013;56(4):408-15.
15. de’Angelis N, Portigliotti L, Azoulay D, Brunetti F. Transanal total mesorectal excision for rectal 
cancer: a single center experience and systematic review of the literature. Langenbecks Arch 
Surg. 2015;400(8):945-59.
16. Kusters M, Marijnen CA, van de Velde CJ, Rutten HJ, Lahaye MJ, Kim JH, et al. Patterns of local 
recurrence in rectal cancer; a study of the Dutch TME trial. Eur J Surg Oncol. 2010;36(5):470-
6.
17. Nagtegaal ID, van de Velde CJ, van der Worp E, Kapiteijn E, Quirke P, van Krieken JH, et al. 
Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the 
pathologist in quality control. J Clin Oncol. 2002;20(7):1729-34.
18. Velthuis S, Nieuwenhuis DH, Ruijter TE, Cuesta MA, Bonjer HJ, Sietses C. Transanal versus 
traditional laparoscopic total mesorectal excision for rectal carcinoma. Surg Endosc. 
2014;28(12):3494-9.
19. van Oostendorp SE, Koedam TWA, Sietses C, Bonjer HJ, Tuynman JB. Transanal total 
mesorectal excision compared to laparoscopic TME for mid and low rectal cancer—current 
evidence. Annals of Laparoscopic and Endoscopic Surgery. 2018;3(5).
20. Adamina M, Buchs NC, Penna M, Hompes R, St.Gallen Colorectal Consensus Expert G. 
St.Gallen consensus on safe implementation of transanal total mesorectal excision. Surg 
Endosc. 2018;32(3):1091-103.
21. Veltcamp Helbach M, van Oostendorp SE, Koedam TWA, Knol JJ, Stockmann H, Oosterling SJ, 
et al. Structured training pathway and proctoring; multicenter results of the implementation 
of transanal total mesorectal excision (TaTME) in the Netherlands. Surg Endosc. 2019.
22. Abbott SC, Stevenson ARL, Bell SW, Clark D, Merrie A, Hayes J, et al. An assessment of an 
Australasian pathway for the introduction of transanal total mesorectal excision (taTME). 
Colorectal Dis. 2018;20(1):O1-O6.
23. Lee L, Kelly J, Nassif GJ, Keller D, Debeche-Adams TC, Mancuso PA, et al. Establishing the 
learning curve of transanal minimally invasive surgery for local excision of rectal neoplasms. 
Surg Endosc. 2018;32(3):1368-76.
24. Perdawood SK. A case of local recurrence following transanal total mesorectal excision: a 
new form of port-site metastasis? Tech Coloproctol. 2018;22(4):319-20.
25. McCulloch P, Altman DG, Campbell WB, Flum DR, Glasziou P, Marshall JC, et al. No surgical 
innovation without evaluation: the IDEAL recommendations. Lancet. 2009;374(9695):1105-
12.
26. Wexner SD, Cohen SM. Port site metastases after laparoscopic colorectal surgery for cure 
of malignancy. Br J Surg. 1995;82(3):295-8.
27. Penna M, Hompes R, Arnold S, Wynn G, Austin R, Warusavitarne J, et al. Incidence and Risk 
Factors for Anastomotic Failure in 1594 Patients Treated by Transanal Total Mesorectal 
Excision: Results From the International TaTME Registry. Ann Surg. 2019;269(4):700-11.
28. Deijen CL, Velthuis S, Tsai A, Mavroveli S, de Lange-de Klerk ES, Sietses C, et al. COLOR III: 
a multicentre randomised clinical trial comparing transanal TME versus laparoscopic TME 
for mid and low rectal cancer. Surg Endosc. 2016;30(8):3210-5.
163
Long-term oncological results after TaTME for rectal carcinoma
9
10
Transperineal minimally invasive APE: 
preliminary outcomes in a multicenter 
cohort.
SE van Oostendorp, SX Roodbeen, CC Chen, A Caycedo-
Marulanda, HM Joshi, PJ Tanis, C Cunningham, JB Tuynman, R 
Hompes.
Techniques in Coloproctology 2020
ABSTRACT
Background: Abdominoperineal excision (APE) for rectal cancer is associated with a 
relatively high risk of positive margins and postoperative morbidity, particularly related 
to perineal wound healing problems. It is unknown whether the use of a minimally 
invasive approach for the perineal part of these procedures can improve postoperative 
outcomes without oncological compromise. The aim of this study was to evaluate the 
feasibility of minimally invasive transperineal abdominoperineal excision (TpAPE)
Methods: This multicenter retrospective cohort study included all patients undergoing 
TpAPE for primary low rectal cancer. The primary endpoint was the intraoperative 
complication rate. Secondary endpoints included major morbidity (Clavien-Dindo ≥3), 
histopathology results and perineal wound healing.
Results: A total of 32 TpAPE procedures were performed in five centers. A bilateral 
extralevator APE (ELAPE) was performed in 17 patients (53%), a unilateral ELAPE in 7 
(22%), and an APE in 8 (25%). Intraoperative complications occurred in five cases (16%), 
severe postoperative morbidity in three cases (9%). There were no perioperative deaths. 
A positive margin (R1) was observed in four patients (13%) and specimen perforation 
occurred in two (6%). The unilateral extralevator TpAPE group had worse specimen 
quality and a higher proportion of R1 resections than the bilateral ELAPE or standard 
APE groups. The rate of uncomplicated perineal wound healing was 53% (n= 17) and 
three patients (9%) required surgical reintervention.
Conclusions: Transperineal abdominoperineal excision seems to be feasible with 
acceptable perioperative morbidity and a relatively low rate of perineal wound 
dehiscence, while histopathological outcomes remain suboptimal. Additional evaluation 
of the viability of this technique is needed in the form of a prospective trial with 
standardization of the procedure, indication, audit of outcomes and performed by 




Radical surgery with adherence to the principles of total mesorectal excision (TME) 
is the key for local control in rectal cancer surgery (1, 2). A meticulous TME dissection 
avoids involvement of the circumferential resection margin (CRM) which is directly 
related to local recurrence (3-5). For low rectal cancer, achieving a complete TME is more 
difficult, due to tapering of the mesorectal fat surrounding the rectum in combination 
with limited access to the narrow bony pelvis (6-9). To achieve safe oncological margins, 
tumours with threatened margins located in the low rectum are commonly subject to 
an abdominoperineal excision (APE) (10, 11).
Despite more extensive surgery in which the anus and sphincter complex are excised 
en-bloc with the rectum, the clinical and oncological outcomes after APE are far 
from optimal. As shown in the Dutch TME trial, the rate of involved CRM (CRM+) was 
substantially higher for APE compared to anterior resection, 30.4% vs 10.7% (p=0.002) 
respectively (12). Coning of the specimen towards the pelvic floor with a “waist” at the 
puborectal sling was put forward as the main culprit for the higher CRM+ rates and 
formed the rationale for a cylindrical excision (13). In this so called extralevator APE 
(ELAPE), a wider distal dissection route is followed which includes en-bloc excision of 
the levator ani muscles leading to a lower rate of CRM+ and tumour perforation (13-16). 
The wider and thereby more radical excision comes at the cost of a larger defect of the 
pelvic floor and skin (17-20). Previous studies and meta-analyses have reported major 
morbidity rates between 10-30% and perineal wound healing problems from 11 up to 
50% (21-26). Especially in irradiated patients, perineal wound healing is problematic 
and sometimes requires primary or secondary reconstruction with musculocutaneous 
flaps to achieve perineal closure (26-30).
A minimally invasive transperineal approach to the perineal part of an APE has potential 
advantages over the standard technique, although data on this new technique are 
limited [33]. This multicenter series describes the combined initial experience of five 
expert centers in four countries with a transperineal minimally invasive APE technique 
(TpAPE) for locally advanced low rectal cancer. The primary aim was to assess the 
feasibility by reporting on intraoperative complications. Secondary aims were to assess 
the histopathological outcomes and postoperative morbidity including the incidence 
and management of perineal wound complications.
MATERIALS AND METHODS
Patients
A consecutive cohort of patients who underwent TpAPE for primary rectal cancer was 
identified at five centers (two in The Netherlands, one in Taiwan, one in Canada and 
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one in the United Kingdom). This group consisted of patients that had either a bilateral 
ELAPE, an unilateral ELAPE or APE with resection of the entire external sphincter (31, 
32). Intersphincteric APE’s were excluded. A retrospective analysis of prospective 
institutional databases was performed, and individual patient data were provided by an 
anonymized data-sheet. The annual volume of rectal cancer surgery varied amongst the 
participating centers, but all perform over 50 resections (including transanal minimally 
invasive local excision, partial mesorectal excision, low anterior resection, APE, ELAPE, 
and recurrent rectal cancer).
Surgical technique
The patient is placed in a lithotomy position to enable simultaneous abdominal and 
perineal dissection. The abdominal phase is performed by a standard laparoscopic 
medial to lateral mobilization of the left colon. The inferior mesenteric vein is ligated 
near the lower border of the pancreas and the inferior mesenteric artery ligated with 
preservation of the left colic artery. The mesorectal plane is opened with autonomous 
nerve preservation and dissection is continued up to connection with the perineal team. 
The perineal phase commences with a purse string closure of the anus. Afterwards, a 
radial perineal incision at approximately 1 cm from the closed anus is made into the 
subcutaneous fat. A single port can be inserted after creating a 2-3 cm deep opening 
of the ischioanal fat around external sphincter and connected to a continuous high 
flow insufflation and smoke exfiltration system. The most frequently used single port 
devices are the Gelpoint Mini and Gelpointh path (Applied Medical, Rancho Santa 
Margarita, California, USA). Standard laparoscopic instruments including a diathermic 
hook or spatula are needed for the endoscopic perineal phase. Dissection continues 
cephalad until the pelvic floor (levator ani muscle) is reached. Continuation externally 
along the levator ani muscle is tailored on a case by case level. For uni- or bilateral 
ELAPE procedures, the pelvic floor is followed on one or both sides up to the fascia 
of the obturator internus muscle and transected at this level. For a standard APE the 
pelvic floor is usually transected a few centimeters out from the puborectal sling. The 
transection usually starts at the level of the coccyx and thereafter going forward. By 
cutting the pelvic floor muscle, and the overlying pelvic floor fascia connection is made 
with the abdominal team without coning in on the tumor. Identification of the correct 
anterior plane, remains the most difficult step. It is crucial to identify the transverse 
perineal muscles to enter this plane just posteriorly to these muscle fibres to find the 
avascular plane in front of the posterior vaginal wall or prostate and then continuous 
cephalad in front or behind Denonvillier’s fascia pending anterior location of the tumour. 
The specimen is extracted trough the perineal wound. The perineal defect is then 
closed primarily, with a subcutaneous gluteal turnover flap (33) or by aid of (biological) 





The primary endpoint was feasibility of the technique in terms of intraoperative 
complications (34). Secondary endpoints included 30-day major morbidity (Clavien 
Dindo ≥3), perineal wound healing, and histopathological outcomes. CRM+ was defined 
as presence of tumour cells ≤ 1mm of the surgical plane. The specimen quality was 
graded according to Quirke (2). Perforation was defined as a tear or hole from the 
surface of the surgical specimen (mesorectum or at the level of the sphincters) into 
the rectal lumen.
Statistical analysis
All data are presented as N (%) for binary data and for continuous outcome as mean 
±SD and median range as well since normal distribution is not expected in this small 
cohort. To explore the potential impact for the extent of the procedure, which increases 
from APE via an unilateral ELAPE to a bilateral ELAPE, a comparative analysis for these 
procedures was performed. For the comparative analysis, a Fisher’s exact test was used 
for categorical variables and the non-parametric Mann-Whitney U test or Kruskal-Wallis 
test for continuous variables. A p value < 0.05 was considered statistically significant. 
Statistical analysis was performed using SPSS version 24 for Windows (SPSS, Chicago, 
IL, USA).
RESULTS
Baseline characteristics (table 1)
A total of 32 patients were included (24 males, mean age 65.7 [±12.8]) from 5 different 
expert colorectal cancer centers with a case load varying between 1 and 12 procedures. 
The first procedure in this series was performed in June 2014 and the last in July 2018. 
Seventeen patients had cT3 stage rectal cancer and seven were cT4 stage. (Table 1) 
Nodal involvement was diagnosed in 14 patients (44%). In one patient, a suspected 
para-aortic lymph node metastasis was present and, therefore, categorized as distant 
(M+) disease. No other peritoneal, liver or lung metastasis were encountered in the 
preoperative work-up. The majority of cases was found to have a threatened margin to 
the mesorectal fascia (MRF) (n=12, 66%) on baseline magnetic resonance imaging (MRI) 
and the tumour was located at or below the level of the anorectal junction in twenty-
two cases (69%). Extension of low tumours into the sphincter complex was seen in ten 
patients, ingrowth into the levator ani muscles and anterior involvement (prostate or 
vagina) was encountered in four and two cases, respectively. A substantial part of the 
patients received neoadjuvant chemoradiotherapy (n=20, 63%).
169
Trans-perineal minimal invasive APE; preliminary outcomes in a multicenter cohort
Table 1 Patient and tumour characteristics
n=32
Sex Male (%) 24 (75.0)
Female (%) 8 (25.0)
BMI (mean) (±SD) 26.4 (3.3)
Age (mean) (±SD) 65.7 (12.8)
ASA I 1 (3.1)
II 25 (78.1)
III 6 (18.8)
Tumour heigth from ARJ(cm)* mean (±SD) 0.50 (0.87)
median (range) 0 (0-3.0)




N-stage (%) N0 18 (56.3)
N1 8 (25.0)
N2 6 (18.8)
M-stage (%) M+ 1 (3.1)**
Mesorectal Fascia involved Yes 21 (65.6)
No 11 (34.4)
EMVI Yes 8 (25.0)
No 18 (56.3)
Unknown 6 (18.8)
Ingrowth No 16 (50.0)
Spinctercomplex 10 (31.3)
M. levator ani 4 (12.5)
Prostate / vagina 2 (6.3)
Neoadjuvant Radiotherapy (%) No 9 (28.1)
5x5 short interval 3 (9.4)
long course Chemorad 20 (62.5)
Numbers in parenthesis are percentages, unless mentioned otherwise
Abbreviations: BMI = Body Mass Index (kg/m2), SD = standard deviation, ASA = American Society 
of Anesthesiologists, RT = radiotherapy, CRT = chemoradiotherapy, ARJ = anorectal junction





Table 2 Operative details
n=32
Type of surgery APE, levators left in situ 8 (25.0)
Unilateral ELAPE 7 (21.9)
Bilateral ELAPE 17 (53.1)
Beyond TME resection No 24 (75.0)
Prostate / Vagina 6 (18.8)
Seminal vesicles 1 (3.1)
Ovaries 1 (3.1)
Pelvic sidewall 0 (0)
Operative time (min) mean (±SD) 278 (78)
median (range) 249 (175-450)
Bloodloss (ml) mean (±SD) 203 (115)
median (range) 200 (50-400)
Conversion to open perineal dissection 1 (3.1)
to laparotomy 0 (0)
Intraoperative events Urethral injury 1 (3.1)
Pelvic sidewall injury 1 (3.1)
Co2 embolism 1 (3.1)
Rectal tube perforation 2 (6.3)
Omentoplasty performed yes 6 (18.8)
Perineal reconstruction Primary closure 18 (56.3)
Gluteal turnover flap* 3 (9.4)
Gluteus maximus flap** 3 (9.4)
Non-absorbable mesh 1 (3.1)
Absorbable mesh 7 (21.9)
Numbers in parenthesis are percentages, unless mentioned otherwise
*Deepithelialized cutaneous turnover flap, **musculocutaneous flap
A bilateral extralevatory APE was performed in 17 cases (53%), a unilateral ELAPE in 
7 cases (22%), and an APE without resection of the levator ani muscle in 8 patients 
(25%) (table 2). A beyond TME resection (n=8, 25%) was performed for tumours that 
invaded other organs or those at risk of CRM+ and consisted of additional (partial) 
resection of the prostate (n=5), vagina (n=1), seminal vesicles (n=1) and ovaries (n=1). 
An omentoplasty was performed in six patients (19%), all without use of indocyanine 
green, to assess the perfusion of the mobilized greater omentum. The perineal defect 
was predominantly closed by primary closure (n=18, 56%), and in the other 15 cases, 
either a musculo-cutaneous gluteal flap (n=6, 19%), an absorbable mesh (n=7, 22%) or 
a non-absorbable mesh (n=1, 3%) was used for perineal reconstruction.
171
Trans-perineal minimal invasive APE; preliminary outcomes in a multicenter cohort
Primary endpoint
Intraoperative complications occurred in five patients (16%) and consisted of one carbon 
dioxide embolus, one urethral injury, one pelvic side wall injury and two intraoperative 
rectal perforations. No conversions to laparotomy were reported and conversion to an 
open perineal approach was necessary once, due to the inability to progress with the 
dissection, despite abdominal assistance in a two-team approach (table 2).
Secondary endpoints
There was no 30-day mortality. Major 30-day postoperative morbidity was reported 
in three patients (9%). This consisted of a compartment syndrome of the lower leg 
requiring fasciotomy, a deep pelvic abscess due to omental infarction with return to 
theatre and a urinoma following urethral injury which was managed with percutaneous 
drainage (table 3). Perineal wound healing was impaired in 47% (n=15) of patients in this 
cohort; one flap failure (3%), four break through abscesses (deep perineal infection) 
(13%), and ten superficial skin infections (31%). One superficial dehiscence and one 
flap failure were treated by negative pressure therapy, three breakthrough abscesses 
needed packing, and one abscess required drainage followed by secondary healing. 
One patient with a superficial skin infection that was initially not severe developed a 
late perineal hernia with wound dehiscence requiring secondary reconstruction. The 
median time to perineal wound healing was 14 days for those without perineal infection 
and 45 days in complicated perineal recovery (p = 0.002).
Table 3 Postoperative details
n=32
Mortality (30 day) 0 (0.0)
Total post-operative complications CD None 11 (34.4)
Minor (CD I-II) 18 (56.3)
Major (CD ≥ III) 3 (9.4)
Perineal wound healing uncomplicated 17 (53.1)
complicated 15 (46.9)
Nature of healing complicatoins Superficial infection 10 (31.3)
Break through abscess 4 (12.5)
Flap failure 1 (3.1)
Days to heal (days) Median (range) Uncomplicated 14 (5-60)
Complicated  45 (21-140)




CRM+ (R1) upon pathological evaluation was seen in fpir cases (13%) and intraoperative 
specimen perforation occurred in two procedures (6%). The positive margin was 
anterior in three out of the four R1 resections. A complete or nearly complete specimen 
was obtained in the vast majority of cases (n=28, 90%) (table 4.).
Comparative analysis
Comparative analysis based on the extent of the procedure (conventional APE, uni- or 
bilateral ELAPE) revealed that intraoperative complications were higher in the ELAPE 
groups (table 5). There were three severe complications in the unilateral ELAPE (pelvic 
sidewall injury, urethral injury, rectal tube perforation), two in the bilateral ELAPE (CO2 
embolus, rectal tube perforation) and no intraoperative complications in the APE group 
(p 0.071). Severe postoperative complications were distributed equally among the three 
procedures. A composite of optimal pathology, defined as circumferential and distal 
resection margin-without perforation and a complete/near complete specimen, was 
achieved in 84.4% cases in this series. An unsuccessful resection was seen in two out 
of seven (29%) unilateral ELAPE procedures which was higher than in conventional APE 
(13%) and bilateral ELAPE (16%) but did not reach statistical significance.
Table 4 pathological assessment
n=32




Succesfull resection Yes 5 (15.6)
No 27 (84.4)
Quality of specimen (Quirke)* Complete 15 (48.4)
Nearly complete 13 (41.9)
Incomplete 3 (9.7)
CRM involvement (<1mm) Yes 4 (12.5)
No 28 (87.5)
Perforation Yes 2 (6.3)
No 30 (93.8)
Lymphnodes harvested mean (±SD) 13.6 (7.9)
median (range) 12 (2-34)
Pathologic N stage (y)pN0 20 (62.5)
(y)pN1 9 (28.1)
(y)pN2 3 (9.4)
Numbers in parenthesis are percentages, unless mentioned otherwise
*1 missing
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n=8 n=7 n=17 p-value
Baseline
Sex Male (%) 7 (87.5) 6 (85.7) 11 (64.7) 0.488
Female (%) 1 (12.5) 1 (14.3) 6 (35.3)
Age Mean (±SD) 70.3 (7.1) 69.3 (13.7) 62.0 (14.0) 0.241
Median (range) 71 (55-80) 70.0 (47-86) 63.0 (33-83)
BMI Mean (±SD) 28.3 (2.5) 25.0 (3.6) 26.1 (3.3) 0.121
Median (range) 28.2 (25.5-31.5) 24.9 (20.3-30.7) 25.6 (20.2-33.0)
ASA <III 7 (87.5) 4 (57.3) 15 (88.2) 0.202
≥III 1 (12.5) 3 (42.7) 2 (11.8)
Tumour stage (cT) ≤ T3 7 (87.5) 3 (42.7) 15 (88.2) 0.054
T4 1 (12.5) 4 (57.3) 2 (11.8)
Mesorectal Fascia 
threatened
yes (%) 3 (37.5) 6 (85.7) 12 (70.6) 0.146
no (%) 5 (62.5) 1 (14.3) 5 (29.4)
Height with 
respect to ARJ
At or below (%) 6 (75.0) 2 (28.6) 14 (82.4) 0.045




Mean (±SD) 256 (50) 245 (50) 297 (83) 0.250
Median (range) 242 (175-300) 245 (175-300) 300 (180-450)
Intra-operative 
complications
yes (%) 0 (0) 3 (42.9) 2 (11.8) 0.071




Complete 6 (75.0) 5 (71.4) 4 (25.0) 0.022
Nearly 
complete
1 (12.5) 1 (14.3) 11 (68.8)
Incomplete 1 (12.5) 1 (14.3) 1 (6.3)
CRM involvement yes (%) 1 (12.5) 2 (28.6) 1 (5.9) 0.306
no (%) 7 (87.5) 5 (71.4) 16 (94.1)
Perforation yes (%) 0 (0) 2 (28.6) 0 (0) 0.042
no (%) 8 (100) 5 (71.4) 17 (100)
Sucessfull 
resection
yes (%) 7 (87.5) 5 (71.4) 15 (84.4) 0.679
no (%) 1 (12.5) 2 (28.6) 2 (15.6)
Postoperative outcomes
Severe 30 day 
morbidity (CD≥3)
yes (%) 1 (12.5) 1 (14.3) 1 (5.9) 0.781
no (%) 7 (87.5) 6 (85.7) 16 (94.1)
Days to perineal 
wound healing
Mean (±SD) 44.0 (39.0) 25.8 (16.6) 51.2 (36.9) 0.354
Median (range) 33 (5-106) 22 (7-45) 42 (6-140)
Perineal wound 
healing
Uncomplicated 3 (37.5) 4 (57.1) 10 (58.8) 0.709
Superficial 
infection













1 (12.5) 2 (28.6) 1 (5.9)
Flap failure 0 (0) 0 (0) 1 (5.9)
Numbers in parenthesis are percentages, unless mentioned otherwise
CD= Clavien-Dindo, n.p. = not performed
DISCUSSION
This multicenter case series suggests that minimally invasive TpAPE is feasible with 
acceptable intraoperative complications, no short-term mortality and a 9% severe 
postoperative complication rate within 30 days.
The postoperative major morbidity rate of 9% compares favorably to major morbidity 
rates between 10 and 30% and perineal wound infection ranging from 11 up to 50% 
reported in large series and meta-analysis, but the current study is limited by the small 
sample size and inherent case selection bias (21-26). Five intraoperative complications 
were reported, four of which were related to wrong plane surgery with sequential 
perforation, urethral, and pelvic sidewall injury. This illustrates the complexity of this 
technique and further evaluation of safety and development of the technique are 
warranted.
The minimally invasive transperineal approach with the application of a single port 
diminishes the need for a large perineal skin incision to facilitate sufficient exposure to 
complete the extra-sphincteric dissection and resection of the pelvic floor as required. 
The down-to-up approach offers good visualization and access to the extralevator plane 
and does not require rotation of the patient to a prone position and/or resection of the 
coccyx to complete the posterior plane. In addition, the anterior plane between the 
specimen and the prostate or vagina can be dissected endoscopically which prevents 
externalization and rotation of the specimen.
Using the conventional open approach for an APE, perineal wound breakdown is a major 
issue as summarized in a meta-analysis of Musters et al. (35). Impaired perineal healing 
after primary closure occurred in 15.3% of APE and 14.8% of ELAPE procedures, both 
without neoadjuvant treatment, which increased to 30.2% and 37.6%, respectively, 
for APE and ELAPE with neoadjuvant radiotherapy (35). Moreover, in the LOREC APE 
registry (UK), up to 31% perineal wound breakdown for APE and ELAPE was encountered 
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(23). Dehiscence often requires intensive treatment with prolonged wound packing, 
vacuum therapy and in case of pelvic sepsis, image-guided percutaneous drainage 
(36), which is reflected in a substantial increase in length of stay, readmission rate, 
and costs (26, 37). In the current series, in 5 patients (16%), a breakthrough abscess 
or flap failure occurred, and 3 out of 32 patients (9%) needed a surgical reintervention 
under general anesthesia for a perineal wound complication. Interestingly, in addition 
to the aforementioned patients, 12 other patients developed a superficial skin infection 
which could be managed conservatively, i.e. by dressings, antibiotics, or removal 
of sutures. Due to the reduced length of the incision, a superficial infection after a 
minimally invasive transperineal approach is probably less likely to culminate in a 
complete breakdown of the perineal area which seems to occur more frequently after 
a conventional open perineal approach.
The introduction of ELAPE by Holm et al. in 2007 has shown potential to decrease the 
rate of intraoperative tumour perforation and CRM+ rates (13, 14, 19). Randomized data 
only comes from small randomized clinical trials and supports the potential oncologic 
benefit of reduced R1 resection in ELAPE (18, 38). Future larger size trials are awaited 
to add more robust data, especially on tailoring the extent of surgery to uni- or bilateral 
ELAPE. In this series, CRM+ was more frequently encountered in unilateral ELAPE than 
APE or bilateral ELAPE: 29% versus 13% and 6%, respectively, (p= 0.306). Intraoperative 
tumour perforation occurred twice, both in unilateral ELAPE. In three out of four R1 
resections, the positive margin was found in the anterior dissection plane which shows 
that also in an extensive proctectomy, an anterior tumour location is at high risk of 
a positive margin. This is in line with data from the Mercury II study and transanal 
total mesorectal excision (TaTME) registry and, therefore, these cases should not be 
performed early in the learning curve (9, 39). In retrospect, an anterior exenteration 
with en-bloc resection of the posterior vaginal wall or prostate might have been more 
suitable. Eliminating these cases provides an acceptable involved margin rate of 3% 
(1 out of 29).
Comparable results regarding this technique were reported by Yasukawa et al., who 
described a comparative cohort of 21 minimally invasive TpAPE versus 29 conventional 
APE with a positive margin rate (2/21 versus 3/29), a lower severe perineal wound 
infection rate (0/21 versus 5/29) and reduced length of stay (median 14 versus 23 days) 
with no conversion, no mortality, and no increase in major morbidity (31).
The current study is limited by several factors that result from its design. With a total 
of 32 cases from 5 large rectal cancer referral centers, selection bias is indisputably 
present. Furthermore, the learning curve is likely to partly explain the suboptimal 
outcomes (40). Although all the surgeons were highly experienced in TaTME, the 
extension of the down-to-up approach to Tp (EL)APE adds to the procedural complexity. 




and management of complications including variety in follow-up protocols, further 
standardized studies are warranted with appropriate institutional review board 
approval. In particular, since this technique is promising regarding wound healing and 
recovery, standardized registration of time to perineal wound healing is essential. 
However, before initiation of (larger) studies on the potential improvement in perineal 
wound healing, further evaluation should focus on the safety in terms of intraoperative 
morbidity and oncologic safety within a prospective well-designed trial.
CONCLUSION
Tp (EL) APE seems to be feasible with acceptable perioperative morbidity and a low rate 
of perineal wound dehiscence, while histopathological outcomes remain suboptimal. 
High complexity necessitates extensive experience in both TaTME and conventional 
ELAPE. Additional evaluation of this technique is needed, ideally in the form of a 
prospective trial with standardization of the procedure, indications and prospective 
audited data collection to further explore the safety and viability of this technique.
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General summary and future 
perspectives
The aim of this thesis was to explore the current state of transanal minimally invasive 
surgery (TAMIS) in the treatment of rectal cancer. Whilst TAMIS as technique for local 
excision has been accepted and positively evaluated since the introduction of transanal 
endoscopic microsurgery (TEM) by Gerhard Buess in 1988, advancement of the TAMIS 
approach further beyond the rectal wall to achieve a radical transanal total mesorectal 
excision (TaTME) was first published only in 2010.(1, 2) Hence the perspectives in 
forthcoming future of both techniques vary substantially.
The perioperative safety of the TAMIS technique for local excision itself has been 
established over the past decades. Current focus lies in extending the role from 
benign adenomas and early rectal cancer (T1 limited to the most superficial part of 
the submucosa) towards local excision of more advanced rectal tumours potentially 
in combination with (neo)adjuvant chemoradiotherapy in the pursue of organ 
preservation. For TaTME perioperative safety has not been consistently reproduced at 
a comparative level as the standard laparoscopic approach and long-term outcomes 
are scarce and limited to cohort studies.(3, 4)
Despite the absence of high-quality evidence supporting the oncologic safety of TAMIS 
local excision in combination with radiotherapy, various strategies have been already 
incorporated in institutional practices. In chapter 2 we summarized the role of these 
strategies in the available guidelines across the globe. Interestingly, the position of organ 
preserving strategies in the retrieved guidelines diverges from equally safe as primary 
TME resection to only in frail patients unfit for radical surgery. The retrieved variability 
is likely due to absence of robust evidence. However, for pT1 high risk tumours and 
beyond, organ preservation is generally considered experimental and should ideally be 
performed within the setting of a clinical trial.(5) Over the last years, national screening 
programs dedicated to detect colorectal neoplasms in an early stage caused an increase 
in early stage rectal cancer amendable for local excision. Additionally, advancements in 
endoluminal resection techniques enables surgeons and especially gastroenterologists 
to perform a local excision in early cancers more often.(6) Microscopic evaluation of the 
specimen by the pathologist is necessary to identify presence of risk features that would 
require additional surgery to reduce the risk of a local recurrence.(7, 8) Although robust 
data of risk predictors for local recurrence justifying a more radical surgical resection is 
lacking this is considered standard therapy to date, with adjuvant chemoradiotherapy 
as potential alternative treatment to reduce the recurrence risk and intensive follow-up 
and early salvage for those refraining additional treatment.
In chapter 3 we conducted a critical appraisal and meta-analysis of the published 
literature to congregate the local recurrence rate of three strategies following local 
excision of early rectal cancer that show presence of risk factors. First, subsequent 
completion surgery, which is recommended by most guidelines, offers best local control 
but is also associated with high end-colostomy rate and hampered functional and 
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urogenital function. The second strategy concerns patients who refrain from additional 
treatment but undergo surveillance which showed a 3.5 and 7-fold increased risk to 
develop a local recurrence for high risk pT1 and pT2 respectively. This supports the 
current national guideline recommendation of completion surgery upon pathologic 
examination of such tumours that were initially treated by local excision. The third 
strategy involves adjuvant chemoradiotherapy which, based upon the meta-analysis, 
mimics the local recurrence rate of completion TME for high risk pT1 tumours and 
reduces the LR rate for pT2 from 28.9% (no additional treatment) to 15.1% which is 
considerably higher than the gold standard (completion TME pT2 4.1%). Although this 
is an extensive review of the available literature, bias is suspected to be present on 
several levels. First, selection and publication bias of respectively more ideal candidates 
and good outcomes are commonly present in retrospective case series. Secondly, a 
Dutch national database study recently signalled that in a rather large proportion, 
71%(!), completion TME is declined despite presence of an indication for radical surgery 
according to the national guideline.(9) Presumably patient and physician preference play 
a large role in the decision of final treatment strategy. More importantly, these strategies 
are based on, at best, moderate quality of evidence and will be continuing to do so for 
the short future. The prospective TESAR trial, which centrally reviews pathology, offers 
the possibility of organ preservation by adjuvant chemoradiotherapy within the safe 
setting of an audited clinical trial.(10) A third arm of close surveillance was added for 
those declining further treatment which will render prospective audited data. Another 
important domain to explore is the exact location, extension and consequence of 
disease recurrence among the three strategies. In theory, salvage surgery for a local 
recurrence following local excision only or with adjuvant chemoradiotherapy may be 
limited to a “normal” TME resection (low anterior resection or APR). This might be more 
favourable compared to post (completion)TME recurrent rectal cancer which frequently 
needs pelvic exenteration.(11)
In frail and elderly patients with a limited life expectancy a higher risk to develop a local 
recurrence could potentially be tolerated. Especially if these patients are at high risk of 
peri-operative complications due to comorbidity, the trade-off between oncologic (long-
term) safety and immediate procedure related morbidity is different from the trade-off 
in young and fit patients. It might be tempting in those cases to choose local excision 
over radical resection in case of a more advanced rectal tumour (cT2-3). However, local 
excision for larger tumours may yield irradical resection of the primary tumour and will 
leave regional metastatic spread in the mesorectal lymph nodes in situ. Considering the 
unacceptably high local recurrence rate, local excision as palliation should therefore 
be regarded as ineffective as elaborated in chapter 4. For immediate symptom relief 
in frail patients, palliative radiotherapy might be preferable. For patients who are not 
considered terminal, a laparoscopic radical resection by an experienced colorectal 
surgeon proceeded by multidisciplinary prehabilitation will serve patients interest best. 
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If it is anticipated that the patient is unlikely to recover from an anastomotic leakage, a 
non-restorative resection with end-colostomy seems appropriate.
Accurate preoperative staging of rectal cancer is of immense importance to offer 
precise tailored treatment such as organ preservation. Without accurate staging, it can 
lead to prevent potential under and overtreatment. Multidisciplinary teams rely on the 
mandatory preoperative MRI to triage patients with rectal cancer in need of neoadjuvant 
(chemo)radiotherapy. Whilst MRI is excellent to identify enlarged lymph nodes and to 
determine the growth of the tumour beyond the rectal wall, it underperforms in daily 
practice to distinguish T1 stage (limited to submucosa) from T2 stage as shown in 
chapter 5. Therefore large excisional biopsy by local excision is suggested which may 
turn out therapeutic in a proportion of patients. These cases constitute of T1 low risk 
tumours who are thereby spared from a TME resection whilst the large biopsy can 
further direct additional treatment for other than T1 low risk tumours.
The second part of this thesis concerns the Transanal Total Mesorectal Excision (TaTME) 
procedure, which involves a hybrid approach of a transabdominal laparoscopic phase 
and a transanal endoscopic single port phase. The simultaneous access to the pelvic 
cavity from above and below is claimed beneficial in the meticulous dissection along 
the holy plane (inner side of the mesorectal fascia) to achieve a complete specimen 
with clear margins. By completing the most difficult part of the operation which is the 
dissection deep in the narrowing pelvis from below, conversion to laparotomy is seldom 
required as the distal margin can be confirmed by direct endoluminal visualization. 
Additionally, this approach technically enables the construction of a very low stapled 
circular anastomosis due to the diathermic transection with a double purse string 
instead of cross-stapling through a linear stapled transection of the rectal tube. A 
systematic review of twenty-three cohort studies that describe a minimal series of 
fifteen patients that underwent TaTME for primary rectal cancer was conducted to 
congregate the early results of the centres that initially adopted this technique and 
these results were compared to the outcomes from the laparoscopic arm of four large 
randomized controlled trials in chapter 6. The included series of TaTME, all inherently 
limited by selection bias, showed that postoperative morbidity, anastomotic leakage, 
circumferential resection margin involvement and specimen quality were comparable 
to the rates as seen in the laparoscopic arms of the RCT’s. Indisputably the rate of 
conversion to laparotomy was improved from 16% in the laparoscopic TME to 2% in 
TaTME. The end- colostomy rate was not pooled due to anticipated selection bias 
and the local recurrence rate could not be derived due to study design and lack of 
adequately reported follow-up. Nevertheless, this study shows that in the centres from 
the studies involved, which all have a dedicated colorectal cancer program, acceptable 





As suggested by early adaptors and agreed upon in multiple TaTME consensus 
meetings, extensive postgraduate training even for consultant colorectal surgeons 
to start with this highly complex technique is imperative.(12) In the Netherlands a 
structured pathway was set-up to prevent centres making iterative mistakes during 
the implementation of TaTME in their practice; cornerstone was the on-site presence of 
an experienced proctor to coach the apprentice during the first five cases. The short-
term results of the first ten patients in twelve centres that participated in a structured 
training pathway are described in chapter 7. Intraoperative complications were low 
and the pathologic results were good both indicating that the correct planes were 
identified. However, a considerably high morbidity and especially anastomotic leakage 
rate occurred in this multicentre cohort reporting the very early experience.
A disturbing yet honest report coming from Norway on an increased local recurrence 
rate with a multifocal pattern urged an external audit of the local recurrence rate in 
the aforementioned implementation cohort which revealed a similar picture as shown 
in chapter 8. At a median follow-up of 21.9 months, twelve local recurrences (12 of 
120, 10%) occurred of which eight were multifocal. An unexpected high rate, since by 
an involved CRM rate of 5% the expected corresponding LR rate was estimated at 
2.5%. The observed relation of intraoperative events that consisted of some sort of 
open connection between the pelvic cavity and the rectal lumen (purse string failure, 
rectal perforation or defects after firing the anastomosis) and the multifocal recurrence 
pattern hint that tumour spill due to suboptimal execution could be responsible for 
the increased local recurrence rate. Extension of the cohort in four centres with a 
cumulative experience of more than 45 procedures per centre showed that the local 
recurrences of 15 % (6 of 40) were concentrated in the very early experience (case 1-10) 
in each centre and dropped in the succeeding series enormously, thereby bringing 
down the overall local recurrence proportion to 5.4% (15 of 266).
In a cohort of patients that underwent TaTME in the two centres that started this 
procedure in the Netherlands with a minimum interval of 36 months since the operation 
showed the 3-years local recurrence rate to be 2.0% as shown in chapter 9. This 
shows that the technique appears to deliver good long-term outcomes in expert 
hands of high volume rectal cancer programs and supports the previously mentioned 
hypothesis that the long-term outcomes are vulnerable to imperfect execution. To 
indisputably demonstrate long-term oncologic safety of TaTME is non-inferior to 
standard laparoscopic approach a randomized controlled trial is necessary.
Expansion of the principles of the bottom-up principle for an abdominal perineal 
excision (APE) has resulted in a transperineal endoscopic resection of the complete 
sphincter complex and pelvic floor en-bloc with the rectum. The early experience of this 
transperineal (extra levatory) APE technique in five centres are collectively described 
in chapter 10. No postoperative mortality occurred and the major morbidity rate 
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(9%) seems favourable compared to the conventional technique. However, despite 
extensive experience in TaTME, intraoperative complications were reported in 5 of 
32 procedures and a positive CRM was observed in 4 specimens which is somewhat 
disappointing. Especially in the subgroup of unilateral extra levatory tpAPE pathology 
remained suboptimal. Nevertheless, subjective benefits of intraoperative exposure of 
the correct surgical planes and improvements in perineal wound healing justify further 
exploration of this approach in further studies. Further standardization and prospective 
data collection are vital in further assessment of the safety of this tpAPE technique.
Future perspectives
For decades, research in rectal cancer has mainly focused on which approach renders 
an optimal total mesorectal excision, how to minimize associated morbidity following 
TME, increase the restorative procedure rate, minimize anastomotic leakage and assess 
the value of neo-adjuvant radiotherapy to TME in terms of local control.(13-15) Despite 
efforts in decreasing the local recurrence rate to 5% and increasing DFS and OS to 68%, 
long-term functional outcome has not improved leaving at least 50% of the patients 
with urinary, sexual and defecation problems.
Therefore, the last decade more research is focused towards organ preservation for 
patients with rectal cancer. Several institutes have explored the possibility to reduce the 
need for radical resection (TME) in (early stage) rectal cancer by adding (neo)adjuvant 
radiotherapy in combination with transanal local excision thriving for organ preservation 
rather than radical surgery. Both neoadjuvant and adjuvant chemoradiotherapy 
combined with local excision seem promising and are explored. Unfortunately, to date 
only few randomized controlled trials have been conducted to properly assess oncologic 
safety. (16, 17) Although the possibility organ preservation seems appealing for patients, 
in case of insufficient response or signs of regrowth patients qualify for immediate 
completion TME or later salvage TME which then both come at a cost of increased 
morbidity and decreased ability of sphincter preservation compared to a primary TME. 
More direct comparative studies are expected in the coming years including patient 
reported outcomes of quality of life and function. Improvements in endoluminal surgery 
have resulted in advanced techniques, such as endoscopic submucosal dissection 
(ESD) for gastroenterologists and TAMIS for surgeons. Nevertheless, a surprisingly 
high proportion of pT1 (8.1%) locally excised tumours develop a local recurrence as 
demonstrated in chapter 4, even in low risk pT1 this amounted 6.7%. In a cohort of 88 
patients with pT1 cancer treated by TEM endoluminal recurrences were reported in 
more than half of 18 locoregional recurrences despite a radical excision, i.e. absence 
of a positive margin.(18, 19) Lezoche et al. have suggested that quality of the local 
excision, in particular the extend beyond the rectal wall of a full thickness excision 
could be related to incidence of local recurrence.(20) Another explanation analysis 





Also for radical rectal resection, physicians and industry continuously seek technical 
advancements in their aim to improve the quality of surgical cancer care. However, 
history repeats as the current concern on increased local recurrences following TaTME 
reminds of port-site metastases in the early phase after the introduction of laparoscopy.
(21) It seems that the TaTME technique might have been disseminated prematurely 
since long-term outcomes were not yet available. At least than 170 units have started 
this technique according to the latest international TaTME registry paper, and this is 
very likely to be an underestimation since participation in not mandatory and the actual 
number might have reached 300-400 globally.(22)
In 2019, Norway declared a moratorium of TaTME following a disturbing high 
incidence of multifocal local recurrences that were presented to the referral centres 
for recurrent rectal cancer.(23) A national audit revealed a 11.6% estimated local 
recurrence rate in a cohort of all 157 Norwegian patients that were operated by the 
TaTME technique. This indicates that individual hospitals are potentially unable to signal 
unfavourable long-term outcomes and thorough long-term outcome registration was 
lacking. In explanation, signalling was initiated by the centres facing an increase in 
referred recurrent rectal cancer cases, rather than by the centres who performed 
this technique.(24) Also in the Netherlands, external audit was an important aspect 
to track the local recurrence rate in the structured training pathway cohort. (25) In 
daily practice, a substantial proportion of patients are no longer in the follow-up of 
the operating surgeon due to return to a more nearby community hospital for further 
follow-up or referral to a tertiary hospital in case of metastasis or local recurrence. 
In contrast, several dedicated high volume rectal cancer centres that early adopted 
the TaTME technique recently published cohort studies reporting excellent long-term 
outcome data of an expanded experience (N ³ 100) with local recurrence between 2 
and 5%.(26-32) Especially considering that the initial streak in each centre consists of 
an unsupervised and merely autodidact experience, these cohorts rest assure that 
excellent outcomes can be achieved with TaTME. Hompes et al. are commended for 
implementing an international registry which has enabled prospective data collection 
of TaTME procedures performed by any surgeon across the globe.(33) The registry 
has been able to early signal an anastomotic failure rate of 15.7% and an increase of 
positive margins as more centres contributed cases, but has not published long-term 
outcomes to date. The amount of unregistered cases, missing data and loss to follow-
up in this voluntary non-audited database is a limitation that must be acknowledged. 
Pending robust long-term outcome data from large prospective randomized trials 
which are not expected in the next three years, population-based studies are better 
equipped to capture the complete study population by excluding publication bias. 
However, population-based databases are frequently limited to a predefined dataset, 
restricted follow-up (30 days) and are not able to correct for previous experience/
learning curve.(3) Therefore cohort series are the only source of long-term outcome 
data. The difference in the local recurrence rate reported in the cohort series (3-5%) and 
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the external audits in Norway and the Netherlands (10%) puzzles and has placed TaTME 
under a magnifying glass for the foreseeable future. Potentially TaTME could turn out to 
be a non-transferable technique for every surgeon due to the complexity and specific 
required skills. Alternatively, the discrepancy can also be a consequence of selection 
and publication bias of non-audited cohort series in combination with a shorter time to 
overcome the learning curve in more high volume practices that adopted early. Lastly, 
the cohorts report on a prolonged series in which an increased rate of local recurrences 
in the first experience might be present as well but fades out as more cases are added 
enlarging the total amount of cases (denominator).
Patients who are deemed to benefit most from TaTME are obese, male sex, anterior 
tumour location, situated in the distal rectum and/or post radiotherapy. Unfortunately, 
exactly these patients encounter the largest risk of a positive circumferential margin 
following TaTME as can be deducted from the prediction model generated by Roodbeen 
et al. based on 2653 cases from the TaTME registry. Therefore, it is recommended 
to commence with less challenging cases such as a T2 mid rectal tumour in a non-
irradiated female patient when starting TaTME.(12) In the context of the recent data 
from Norway and the Netherlands, from an ethical standpoint it might however be 
questionable to expose “easy cases” to TaTME since these patients could alternatively 
receive curative resection by a conventional laparoscopic transabdominal approach 
without exposure to a surgeons TaTME learning curve. It is relevant to mention here 
that in the Netherlands, the structured training pathway organized by the VUmc is put 
on hold pending reaffirming data on the oncologic safety of TaTME. It is important to 
reiterate that dedicated high volume rectal cancer centres have been able to achieve 
excellent results in recent published cohort series which is reassuring in response to 
the Norway moratorium.(26-32) Continuation of the procedure is therefore appropriate 
but should be performed in the context of a clinical trial to provide reliable data. That 
data is heavily awaited in order to establish the viability of TaTME and secondly identify 
the group of patients that will benefit most from this approach which might result in 
narrowing the indication of TaTME. A contemporary trial incorporates surgical quality 
assurance to ensure the participating sites have completed their learning curve and 
are competent in both TaTME and comparator (laparoscopic TME) in order to make a 
fair comparison. Additionally, central MRI review and collection of procedural videos 
are essential ingredients a well-designed randomized controlled trial with extensive 
quality assurance. The assumption that suboptimal execution can cause serious 
consequences such as described in chapter 8 has amplified the importance of video 
registration to assess the prevalence of intraoperative errors. In such a prospective 
study a potential causal relation with the increased (multifocal) local recurrence rate 
may be demonstrated.
The surgical community will nonetheless have to take lessons from the setback seen 




might be tempted to preliminary adopt new interventions strategies in order to not miss 
the boat. Also patients might pursue new treatment options of which the expectations 
are exaggerated by investigator bias and selection bias. More strict regulation of the 
implementation of innovative procedures by professional associations could prevent 
exposure of too many patients to innovative strategies before safety and efficacy 
is reproducibly established. It is striking that new surgical treatment developments 
lack the strict regulations as to which pharmaceutical companies have to comply to 
when introducing a new drug. (USA: FDA and Europe EMA) Even medical devices, 
although to a much lesser degree than drugs, are regulated by national authorities 
before allowed to be used in healthcare. To remedy this lack of formal regulation, 
the international group of surgeons exploring TaTME thrived to adhere to the IDEAL 
framework for safe stepwise introduction.(34, 35) This includes the aforementioned 
registry and establishment of a highly engaged network of TaTME surgeons sharing 
novel complications as urethral injury, carbon dioxide emboli and videos of other 
potential pitfalls. Continuous adjustments of the technique have been discussed in 
international consensus meetings to improve safety, define indications and minimal 
requirements for effective implementation of the technique.(12, 36-38) Additionally, 
emphasis on the necessity for extensive training of fellow surgeons interested in this 
technique lead to the initiation of various hands-on cadaver courses which are ideally 
followed by proctored implementation and continued mentorship.(39-44) Atallah et al. 
recently argued that the vast majority of participants in training courses in the USA lack 
sufficient case volume to be able to reach sufficient technical competency and made a 
plead for more strict entry criteria and (obligatory) proctoring.(45) Surgical associations 
are likely best equipped to regulate training curriculums including entry criteria, oversee 
the subsequent implementation into daily practice and assess performance disparities 
between individual hospitals and the golden standard of care.
New innovations in this multidisciplinary field are on the foreseeable horizon to improve 
treatment of rectal cancer such as laparoscopic articulating instruments, robotic 
systems, integrated intraoperative navigation, fluorescent labelled tumour markers, 
MRI-guided radiotherapy but also include the exciting area of targeted immunotherapy.
(46) To ensure that new promising options are sustainably incorporated in guidelines, 
thorough scientific evaluation is essential. Alike established (multi)national authorities 
regulating drugs and medical devices, surgical societies may need to implement 
regulative frameworks for novel techniques including appointment of independent 
oversight to protect foremost patients but also innovations itself from too early 
implementation often instigated by too high expectations from patients, health care 
providers and industry.
In the next decade robotic assisted surgery is expected to expand due to expiry of 
the patent of the current monopolist and subsequent entry of alternative platforms 
from multiple companies at more competing costs. Also for robotic assisted colorectal 
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surgery structured training and proctoring programs have been launched but similar to 
TaTME these are not mandatory.(47, 48, 49) Robotic-assisted TME studies have focussed 
on procedural success in terms of primarily conversion and secondary in complications 
and pathologic outcomes (complete specimen and radical margins) whilst long-term 
local recurrence rates are underexposed and randomized data from the ROLARR trial 
is awaited.(15, 50-53) Especially since more units will be able to implement robotic 
assisted surgery in daily practice, robust scientific evaluation of benefits and liabilities 
of the technique, especially in the implementation phase will show the validity and true 
merit of such, relatively costly, equipment.
The outcomes of transanal TME have been scrutinized in detail. An international 
group of engaged surgeons continuously and transparently publish their data. The 
magnifying glass that lies on TaTME by this group exposed caveats of the technique with 
proposed preventive measures and improvements, but has also highlighted the danger 
that comes with a learning curve when implementing a new technique. Throughout 
the surgical literature, the initial procedures of various techniques are well-described 
regarding peri-operative outcomes but are seldom included in studies assessing long-
term safety and efficacy. Prof R.J. Heald acknowledged the importance of focusing on 
oncologic outcome in his landmark paper on TME in the Lancet in 1986:
  ,,In assessment of any new procedure, however, the fundamental yardstick is long-term 
tumour-free survival. This personal series was undertaken in the belief that a reduction of 
the bowel wall margin to conserve sphincters is safe provided that mesorectal excision is 
complete. Since every other consideration is secondary to those of cancer clearance and 
survival the results are presented only in terms of recurrence and mortality.”(54)
Transanal total mesorectal excision should currently be regarded as a promising but 
complex solution for difficult rectal cancer cases. In the coming decade randomized 
controlled trials (55, 56) will have to show definitive oncologic safety and the indication 
for TaTME is likely further refined. Expanding the role of TAMIS local excision will likely 
increase beyond low risk early rectal cancer upon patient request. Whereas shared 
decision making is currently based on suboptimal evidence, several ongoing trials (10, 
57) with prospective oncologic and patient reported outcomes will offer more reliable 
data enabling a better informed trade-off by individual patients between oncologic risk, 
morbidity, function and quality of life.
In summary, introduction of innovations in rectal cancer surgery must follow the IDEAL 
framework to ensure proper and sustainable implementation. Structured training 
pathways, proctoring, quality assurance and external audited data within trials should 
be mandatory before new strategies can be considered standard care. Surgical societies 
may fulfil a more regulative role to ensure new strategies are sufficiently studied to 




itself. Increasing international collaboration facilitates the formation of networks 
capable to collectively produce robust data.
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Het doel van dit proefschrift was om de huidige toepassing van transanale minimaal 
invasieve chirurgie voor de behandeling van een tumor in de endeldarm te analyseren. 
Deze benadering voor de lokale behandeling (TAMIS) van een tumor in een nog vroeg 
stadium is breed geaccepteerd en wordt toegepast sinds de introductie van de TEM-
procedure door Gerhard Buess in 1988. Uitbreiding van de transanale minimaal 
invasieve techniek voor een resectie voorbij de darmwand en met medeneming van 
het omliggende mesorectale vet (TaTME) werd pas 22 jaar later, in 2010, voor het eerst 
beschreven. Hierdoor verschilt het perspectief van TAMIS vs. TaTME ten aanzien van 
de toepassing en ontwikkelingen in de nabije toekomst aanzienlijk.
In de laatste decennia is de perioperatieve veiligheid van TAMIS uitgebreid onderzocht 
en ligt de huidige focus op uitbreiding van de indicatie voor de toepassing van een lokale 
excisie voor verder gegroeide tumoren, al dan niet in combinatie met chemo-radiatie 
voorafgaand of volgend op de lokale behandeling. Voor de TaTME techniek voor de 
radicale resectie van het rectum en drainerende lymfeklieren in het omliggend vet zijn 
de intra-operatieve veiligheid en postoperatieve complicaties echter nog onvoldoende 
gereproduceerd en zijn de oncologische resultaten op de lange termijn nog schaars.
In hoofdstuk 2 worden de adviezen omtrent de toepassing van een lokale excisie 
voor de behandeling van een endeldarmtumor zoals opgenomen in de nationale 
richtlijnen van over de hele wereld samengevat. Ondanks dat er nog geen onomstreden 
bewijs is dat een lokale excisie al dan niet in combinatie met (chemo)radiotherapie op 
de langere termijn even goed is als een radicale resectie, loopt de positie van deze 
zogenoemde orgaan sparende behandelstrategie opvallend genoeg uiteen van een 
gelijkwaardig alternatief in enkele richtlijnen tot alleen toegestaan in studieverband 
of bij patiënten die een grote operatie niet aan kunnen. De algemene opvatting is 
desalniettemin dat voor tumoren van stadium pT1 met hoog risico factoren een orgaan 
sparende therapie nog experimenteel is en idealiter dient plaats te vinden in de context 
van een klinische studie. Door nationale screening programma’s en verbeteringen in 
endoscopische technieken door zowel de MDL-arts als chirurg is er een toename te 
verwachten in de lokale excisie van tumoren. Microscopische analyse door de patholoog 
is essentieel om risicofactoren te identificeren. Wanneer deze factoren aanwezig zijn 
dan bestaat de standaardbehandeling uit het verrichten van een aanvullende radicale 
resectie (totale mesorectale excisie (TME)) teneinde het risico op een lokaal recidief 
te reduceren. Aanvullende bestraling zou het risico op een lokaal recidief kunnen 
reduceren als alternatief voor een majeure operatie. Voor patiënten die een aanvullende 
behandeling afslaan is intensieve monitoring nodig om in geval van een lokaal recidief 
een zogenoemde ‘salvage’ operatie mogelijk te maken.
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In hoofdstuk 3 worden de gepubliceerde uitkomsten van de drie hiervoor 
genoemde strategieën volgend op een lokale excisie van een vroeg rectum carcinoom 
(complementerende TME, adjuvante radiotherapie en geen aanvullende behandeling) 
in een meta-analyse onderzocht. De complementerende radicale resectie, volgens 
de richtlijnen beschouwd als standaardbehandeling, biedt de beste lokale controle 
maar resulteert in een aanzienlijk percentage colostoma’s en functionele en 
urogenitale klachten. Geen aanvullende behandeling maar alleen surveillance laat 
een respectievelijke 3.5- en 7-voudige toename in risico op het ontwikkelen van een 
lokaal recidief zien voor hoog risico pT1 en pT2 stadium tumoren in vergelijking met 
een complementerende TME. Dit ondersteunt de aanbeveling uit de huidige richtlijn 
om een complementerende radicale resectie. De derde strategie, aanvullende 
adjuvante chemoradiotherapie, lijkt voor hoog risico pT1 tumoren de uitkomsten van 
een complementerende resectie te benaderen. Voor pT2 tumoren geeft aanvullende 
bestraling (15.1%) een aanzienlijk mindere reductie op een lokaal recidief ten opzichte 
van de gouden standaard van chirurgie (4.1%) maar is wel ontegenzeggelijk beter dan 
geen aanvullende behandeling (28.9%). De resultaten uit dit uitgebreide systematisch 
literatuuroverzicht zijn gelimiteerd door publicatie- en selectie bias. Positieve resultaten 
worden eerder gepubliceerd en in cohort studies opgenomen. Daarnaast heeft een 
recente Nederlandse populatiestudie door Van Groningen et al. laten zien dat ondanks 
dat er volgens de richtlijn een indictie was voor een aanvullende resectie na lokaal 
behandeling vroeg rectum tumoren, 71% van de patiënten deze behandeling niet 
heeft ondergaan. Hoogstwaarschijnlijk spelen er bij patiënten als ook bij behandelaren 
zwaarwegende motieven om geen aanvullende behandeling te doen. De precieze 
afwegingen in de besluitvorming zijn helaas onbekend maar berusten in ieder geval op 
data van matige kwaliteit. Daarom lopen er momenteel meerdere prospectieve studies 
om deze lacune op te vullen waarbij er wordt gekeken naar behandeling gerelateerde 
oncologische veiligheid, complicaties als ook patiënt gerapporteerde kwaliteit van leven 
en functionele uitkomsten.
Voor oudere patiënten die een beperkte levensverwachting hebben kan mogelijk een 
hoger risico op het ontwikkelen van een lokaal recidief worden geaccepteerd. Een 
lokale excisie wordt daarom ook wel voorgesteld bij meer geavanceerde cT2-3 tumoren 
waarbij de lymfeklieren ongemoeid worden gelaten. Zeker wanneer deze patiënten een 
hoog risico op complicaties rondom de operatie hebben door bijkomende ziekten is 
de afweging tussen oncologisch perspectief en mogelijk complicaties van een grote 
operatie anders dan bij jonge, fitte patiënten. In hoofdstuk 4 beschrijven we dat ook 
bij patiënten die niet als terminaal worden beschouwd een laparoscopische resectie, 
al dan niet met aanleg van een colostoma, door een ervaren colorectaal chirurg in de 
context van een multidisciplinair team om de patiënt optimaal voor te bereiden, de 




Juiste selectie van patiënten met endeldarmkanker is van groot belang om de juiste 
route van behandeling in te gaan. Inadequate stadiëring kan leiden tot zowel onder- 
als overbehandeling. Multidisciplinaire behandelteams gaan primair af op de volgens 
de richtlijn verplichte MRI scan om te bepalen of een patiënt in aanmerking komt voor 
bestraling voorafgaand aan een operatie. Met behulp van de MRI blijkt men goed in 
staat om pathologische lymfeklieren en uitbreiding van de tumor buiten de darmwand 
in het omliggend vet te beoordelen. Daarentegen blijkt zoals beschreven in hoofdstuk 
5 het MRI-onderzoek in de dagelijkse praktijk niet voldoende in staat om onderscheid 
te maken tussen een laag en hoog risico vroeg stadium endeldarm tumor. Een groot 
excisiebiopt middels een hoog kwaliteit lokale excisie kan een waardevolle stap in de 
stadiëring zijn; in geval van een laag risico tumor is de behandeling klaar en in geval 
van een hoog risico tumor dient in principe een aanvullende chirurgische behandeling, 
of adjuvante radiotherapie in studieverband, van de resterende endeldarm en het 
mesorectum te volgen.
Het tweede deel van dit proefschrift beslaat de transanale totale mesorectale 
excisie (TaTME) die bestaat uit een hybride minimaal invasieve (kijkoperatie) met een 
transabdominale fase en een endoscopische transanale fase. Door het kleine bekken 
zowel vanaf boven als beneden te benaderen zou een meer zorgvuldige dissectie langs 
de juiste vlakken bewerkstelligd kunnen worden wat een beter resectiepreparaat met 
vrije marges oplevert. Verder is er vrijwel geen noodzaak meer voor een conversie naar 
een laparotomie (traditionele open buikoperatie) en kan er met de transanale techniek 
op een lager niveau een nieuwe verbinding van de dikke darm en anus worden gemaakt. 
In hoofdstuk 6 presenteren wij een systematisch literatuuroverzicht van publicaties 
met resultaten van de eerste serie patiënten uit centra die deze TaTME techniek 
vroeg hebben omarmd en vergelijken deze met uitkomsten van de laparoscopische 
abdominale techniek uit vier grote gerandomiseerde studies. In de gevonden studies, 
die gelimiteerd zijn door selectie van mogelijk ‘gunstige’ patiënten, waren het aantal 
complicaties, naadlekkages, radicaliteit en kwaliteit van het preparaat vergelijkbaar met 
de resultaten van de gouden standaard. Ontegenzeggelijk was in de TaTME series het 
percentage conversie naar laparotomie lager dan met de laparoscopische techniek: 
2% versus 16%. Uit de geïncludeerde studies kon door het verschil in opzet en duur 
van opvolging na de operatie nog niets geconcludeerd worden over het percentage 
colostoma’s of lokaal recidieven.
De groep chirurgen van over de hele wereld die kort na de eerste demonstratie de TaTME 
techniek hebben geëxploreerd, is het erover eens dat zelfs voor ervaren colorectaal 
chirurgen uitgebreide training geïndiceerd is wanneer men met TaTME wil beginnen 
vanwege de hoge moeilijkheidsgraad. In Nederland is daarom een gestructureerd 
implementatie programma opgezet voor nieuwe centra om te voorkomen dat deze 
dezelfde fouten zouden maken als de pioniers gedurende de implementatie van deze 
operatie. Naast uitgebreide presentaties, live demonstratie en kadavertraining was 
201
Nederlandse samenvatting
het belangrijkste element in het implementatieprogramma de aanwezigheid van 
een collega-chirurg die ervaren is met de TaTME techniek gedurende de eerste vijf 
procedures in het eigen ziekenhuis. De korte termijn uitkomsten van twaalf centra die 
hebben geparticipeerd in dit gestructureerde implementatie programma, beschreven in 
hoofdstuk 7, lieten zien dat er een gering percentage complicaties tijdens de operatie 
was en dat de pathologische resultaten goed waren hetgeen erop wijst dat de juiste 
vlakken werden gevolgd. Echter, er was een aanzienlijk percentage postoperatieve 
complicaties als ook een meer dan verwacht aantal naadlekkages in dit multicenter 
cohort bestaande uit de eerste tien procedures in elk van de twaalf participerende 
centra.
Een alarmerend rapport uit Noorwegen over een hoog aantal lokaal recidieven met 
een ongebruikelijk en uitgebreid patroon gaf aanleiding om onmiddellijk het voorkomen 
van lokaal recidieven te onderzoeken in het cohort van de eerste 10 patiënten uit de 
12 ziekenhuizen. In hoofdstuk 8 had zich bij een mediaan interval van 22 maanden 
sinds de operatie bij twaalf patiënten een lokaal recidief ontwikkeld, een ruw percentage 
van 10%, waarvan het merendeel een multifocaal patroon had. Een zeer onverwacht 
percentage, aangezien het verwachte percentage 2.5% bedroeg bij een positieve 
circumferentiële resectie marge status van 5%. Een correlatie tussen het optreden 
van een situatie tijdens de operatie waarbij er een open verbinding tussen het lumen 
van de darm en het wondbed in het kleine bekken kon zijn (door falen van de tabakszak 
hechting, perforatie van de darm of een defect van de anastomose) geeft een mogelijke 
aanwijzing. Spill van tumorcellen bij een technisch suboptimaal uitgevoerde operatie 
zou mogelijk de oorzaak kunnen zijn voor de verhoogde lokaal recidief kans.
In hoofdstuk 9 wordt beschreven dat in de twee ziekenhuizen die in Nederland 
zijn begonnen met de TaTME techniek in een groep van 159 patiënten die inmiddels 
minimaal 36 maanden na de operatie waren, het 3-jaars lokaal recidief percentage 
slechts 2.0% bedroeg. Dit laat zien dat met de TaTME techniek in een context van 
gespecialiseerde centra in rectumchirurgie met een hoog volume goede resultaten 
behaald kunnen worden, juist ook op langere termijn. Hierdoor bestaat het vermoeden 
dat door de complexiteit van deze procedure de oncologische uitkomsten kwetsbaar 
zijn voor een suboptimale uitvoering van de transanale techniek.
Uitbreiding van het principe van een minimaal invasieve “bottom-up” techniek voor 
de benadering van een abdomino-perineale excisie (APE) waarin ook de kringspier 
en bekkenbodemspier en-bloc met de endeldarm wordt geëxcideerd heeft geleid 
tot de transperineale (extra levatoire) abdomino-perineale excisie. De collectieve 
eerste ervaring met deze techniek bij 32 patiënten uit vijf internationale centra wordt 
beschreven in hoofdstuk 10. Er was geen perioperatieve mortaliteit en het aantal 
ernstige postoperatieve complicaties (9%) is minder dan we kennen van studies met 
de conventionele techniek. Daarentegen trad er tijdens de operatie in vijf gevallen 
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een complicatie op en werd er bij vier patiënten een positief snijvlak gevonden 
ondanks uitgebreide ervaring van de chirurgen met de TaTME techniek. Door de 
operateurs subjectief gerapporteerd beter zicht op de operatievlakken tezamen met 
het grote potentieel in perineale wondgenezing rechtvaardigen verder onderzoek 
naar de toepassing. Echter verdere standaardisatie van de techniek en prospectieve 
datacollectie zijn essentieel in verdere evaluatie van de toepasbaarheid en veiligheid 
van de endoscopische transperineale APE.
Nabeschouwing
Decennia lang heeft onderzoek naar de behandeling van endeldarmkanker zich 
gefocust op met welke benadering (open of laparoscopisch) een optimale TME behaald 
kan worden, interventies om het optreden van naadlekkages en consequenties te 
verminderen, het percentage stoma’s te reduceren en de waarde van radiotherapie 
in het risico op de ontwikkeling van een lokaal recidief. Hoewel het lokaal recidief 
percentage sterk verminderd is tot omstreeks 5% en ook de ziektevrije en algemene 
overleving zijn verbeterd zijn de functionele gevolgen op lange termijn, zoals mictie, 
seksuele en incontinentie problematiek nog altijd aanzienlijk voor patiënten die zijn 
geopereerd wegens endeldarmkanker.
Daarom is er de laatste jaren veel aandacht voor orgaanpreservatie. Verschillende 
instituten hebben de mogelijkheid onderzocht om de radicale resectie van een 
endeldarmcarcinoom te vervangen door bestraling voorafgaand of volgend op een 
lokale excisie van een tumor. Helaas zijn dit geen gerandomiseerde studies maar vooral 
cohort series van mindere kwaliteit. Daarom is toepassing op bredere schaal nog 
prematuur. Vanuit patiënten is er veel interesse in de mogelijkheid van een endeldarm 
sparende behandeling maar men dient zich te realiseren dat de oncologische veiligheid 
op langere termijn nog onzeker is. Daarom adviseren wij om een dergelijke behandeling 
alleen te doen in de context van een klinische prospectieve studie waarbij er een 
gestandaardiseerd follow-up schema is, het bestaan en verschil in uitkomst voor 
mogelijke verschillende subtypen vroeg rectum tumoren wordt onderzocht, en er 
bovendien systematisch patiënt-gerapporteerde kwaliteit van leven en functionele 
uitkomsten worden uitgevraagd.
In het tweede deel van dit proefschrift komt de innovatie van een transanale 
benadering voor de TME resectie, wat sinds de jaren 80 de hoeksteen in de behandeling 
van endeldarmkanker is, uitgebreid aan bod. Helaas lijkt de geschiedenis zich te 
herhalen, want waar in de jaren 90 de laparoscopische benadering (kijkoperatie of 
ook wel sleutelgat chirurgie) gepaard ging met buikwandmetastasen door enting van 
tumorcellen in de toegangspoorten worden recent multifocale lokaal recidieven in het 
kleine bekken na een TaTME operatie gemeld. In Noorwegen is de TaTME tot een halt 
geroepen nadat bleek dat er een onacceptabel hoog lokaal recidief percentage was 
gevonden. Ook in Nederland is er in de eerste serie in ziekenhuizen die participeerden in 
203
Nederlandse samenvatting
een trainings- en implementatieprogramma een verhoogd aantal recidieven gevonden, 
hoewel het risico op zo’n lokaal recidief sterk vermindert naarmate de centra meer 
ervaring opdoen. De twee ziekenhuizen die in Nederland zijn begonnen met TaTME 
hadden bij patiënten die inmiddels minimaal drie jaar na de operatie (n=159) waren, een 
lokaal recidief percentage van 2%. Ook andere expert centra vanuit meerdere landen 
hebben recent bemoedigende resultaten gepubliceerd. Dit ondersteunt de hypothese 
dat de operatie an sich veilig is mits zorgvuldig en technisch perfect uitgevoerd en dat 
mindere uitkomsten mogelijk veroorzaakt worden door suboptimale uitvoering. Patiënt 
selectie, hoog volume, technische uitvoering en adequate training lijken essentiële 
aspecten voor een veilige implementatie. In Nederland is het trainingsprogramma voor 
nieuwe centra gestopt in afwachting van robuuste data uit prospectieve studies die de 
veiligheid van de TaTME benadering ondubbelzinnig aantonen.
Er vallen belangrijke lessen te trekken uit de invoering van orgaan preservatie en zeker 
TaTME door de chirurgische gemeenschap. Zowel artsen als patiënten zijn geneigd 
om een nieuwe behandeling mogelijk prematuur te omarmen. Enerzijds willen artsen 
meegaan in nieuwe ontwikkelingen en niet de boot missen. Anderzijds vragen ook 
patiënten om nieuwe behandelingsopties, met daarbij een te hoog verwachtingspatroon 
gevoed door studies die onderhevig zijn aan selectie- en publicatiebias. Een nieuwe 
chirurgische behandeling wordt niet strikt gereguleerd door een nationale of Europese 
instantie (bijv. FDA in de Verenigde Staten of EMA in Europa) in tegenstelling tot wanneer 
een farmaceutisch bedrijf een nieuwe medicijn of een nieuw chemotherapeuticum heeft 
ontwikkeld en wil introduceren op de markt. Een internationale groep van chirurgen die 
bij de initiële ontwikkeling van de TaTME betrokken zijn heeft dit vroegtijdig herkend 
en een consensus document met daarin een raamwerk opgesteld om handvatten te 
bieden de techniek veilig te implementeren. Daarin staan onder andere aanbevelingen 
omtrent minimale aantallen ingrepen. Echter uit een survey blijkt dat van deelnemers 
van een TaTME cursus in de Verenigde Staten het overgrote deel deze aantallen niet 
haalt en dus te weinig aanbod heeft om zich daadwerkelijk te bekwamen in deze 
techniek. Nationale chirurgische beroepsverenigingen lijken het best toegerust te 
zijn om de implementatie van nieuwe ontwikkelingen te reguleren door middel van 
verplichte trainingscurricula, volume normen en audit van uitkomsten.
In de komende 10-20 jaar zullen technische innovatie binnen de zorg en de (colorectale) 
chirurgie in het bijzonder elkaar snel opvolgen. De implementatie van de TaTME heeft 
mede door de enorme transparantie van een nauw samenwerkende internationale 
groep van chirurgen onder een vergrootglas gelegen en heeft daarmee mogelijke 
valkuilen blootgelegd. Daarbij heeft vroege communicatie er hopelijk voor gezorgd dat 
deze valkuilen door anderen voorkomen konden worden. Bovendien zijn voor TaTME 
de lange termijn (oncologische) consequenties bestaande uit suboptimale uitkomsten 
aangetoond als gevolg van de leercurve voor TaTME. In de chirurgische literatuur 
worden van nieuwe operatietechnieken de technische details en eerste postoperatieve 
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uitkomsten goed beschreven maar de lange termijn uitkomsten van juist de eerste 
patiënten die de nieuwe techniek ondergingen zijn vaak onderbelicht.
Samenvattend zijn er betere richtlijnen nodig om innovaties in de (chirurgische) 
behandeling van endeldarm kanker veilig en met robuuste onderbouwing in de dagelijkse 
praktijk te implementeren. Gestructureerde training, begeleiding, waarborging van 
competentie en externe audit van uitkomsten binnen klinische prospectieve studies 
zouden verplicht moeten zijn voordat een behandeling in de dagelijkse praktijk kan 
worden geïmplementeerd. Een (nationale) chirurgische beroepsvereniging lijkt de 
aangewezen entiteit om een meer regulerende rol te spelen om te voorkomen dat 
veelbelovende behandelingen vroegtijdig wijdverspreid worden toegepast wat niet 
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Als eerste wil ik alle patiënten bedanken die hebben meegedaan, momenteel 
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Professor Bonjer, ik wil u van harte bedanken voor het gestelde vertrouwen en advies 
gedurende mijn promotieonderzoek. Door deel uit te maken van uw team kon ik zowel 
binnen als buiten de trial internationale samenwerkingsverbanden aangaan, wat 
onvergetelijke ervaringen heeft opgeleverd. Het is een enorme eer dat ik heb kunnen 
bijdragen aan een COLOR-trial. Alhoewel u niet elk artikel uit mijn proefschrift heeft 
ge-micro-managed was u er juist wel om bij te sturen op de kritieke punten. U ziet als 
geen ander waar het inhoudelijk of tekstueel wringt bij een nieuw artikel en weet dat 
met enkele aanpassingen glad te strijken. Verder zal ik niet snel uw reactie vergeten 
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tot veel mooie publicaties geleid. Dat het primair om de “message” moet gaan heeft 
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veel dank voor uw tijd, aandacht en de kritische blik die u aan dit proefschrift heeft 
geschonken.
Co-auteurs
In het bijzonder wil ik Colin Sietses bedanken. Bij jou kon ik altijd terecht als ik een extra 
advies of derde mening nodig had . Samen met Thomas en jouw eigen PhD studenten 
Marloes Veltcamp-Helbach en Jeroen Hol hebben we een rits prachtige stukken kunnen 
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proefschrift blijkt te zijn. Het prikbord in jouw hok op G4 met de pdf-jes van je talloze 
publicaties was een inspiratie. Ook Pieter Tanis, Roel Hompes, Sapho Roodbeen en 
Robin Detering, allen enorm bedankt voor de samenwerking!
Beste Leo, toen ik als junior-co assistent gegrepen werd door de chirurgie, heb jij mij 
de kans gegeven om onderzoek te starten. Daarnaast betrek jij mij nog altijd bij nieuwe 
stukken. Het was een leuke afwisseling en ook prettig deze ‘schaduw-promotie’ als troef 
achter de hand te hebben. Hoewel ik Jurriaan meermaals plechtig moest beloven niets 
over tourniquets te schrijven in werktijd.
VUmc
Bij deze wil ik alle mede-onderzoekers op 7F bedanken voor de gezellige tijd. Merijn 
jij specifiek bedankt voor al je secretariële ondersteuning. Nienke, Yasmina, Lisanne 
en Alex dank voor jullie inzet en vasthoudendheid in jullie wetenschappelijke stages. 
Het begeleiden van jullie heeft me geholpen om de opzet van onderzoek beter en 
scherper te formuleren. Ik hoop dat jullie enthousiast zijn geworden voor het doen van 
onderzoek in jullie verdere carrière. Lisanne, thanks voor het overnemen van de TESAR 
en early rectal cancer projecten toen de hoeveelheid mij te veel begon te worden. 
Annabel, enorm veel succes met het volmaken van de Color III, je mag me altijd bellen 
voor hulp. Wendy, Ilse en Ron dank voor jullie hulp bij het regelen van duizend-en-1 
uiteenlopende, maar toch essentiële zaken. Miranda, Sascha, Saskia, Mark, Sander, 
Nina, Lisanne, Larissa, Cirse en alle andere fellows en assistenten die (tijdelijk) bij team 
colorectaal zaten, dank voor de gezelligheid en hulp bij het includeren en follow-up van 
alle patiënten in de verschillende studies.
RKZ
Ahmet, Huib, Piet, Boez, Go, chirurgen, assistenten en alle andere (oud-)collega’s uit het 
RKZ. Ik dacht tijdens het schrijven van dit proefschift nog vaak met heel veel plezier aan 
Beverwijk. Zowel in mijn tijd als co-assistent waar ik sterk in het proces betrokken werd, 
als in de tijd van mijn eerste baan als anios waarin ik écht dokter ben geworden alleen 
maar positieve momenten. Het is een fantastische plek zoals velen, en inmiddels ook 
van Oostendorp junior, weten. Ik ben onwijs gelukkig dat ik mijn opleiding tot chirurg 




Bij deze wil ik ook Steven Oosterling, de vakgroep chirurgie en alle collega arts-
assistenten bedanken voor het warme welkom in het Spaarne Gasthuis. In korte tijd 
heb ik veel kunnen leren en heb ik het enorm naar mijn zin gehad.
Paranimfen
Thomas Koedam. Je hebt uitgebreid de tijd genomen om mij wegwijs te maken in 
onderzoek, de regelgeving en details van de COLOR III en TESAR studies, maar bovenal 
een handleiding “werken voor Tuynman” gegeven waar ik je eeuwig dankbaar voor ben. 
Vooral de tip om altijd je nieuwste resultaten al op een paar slides te hebben, heeft me 
meermaals gered. Jij hebt de basis van de COLOR III gelegd die ik alleen maar hoefde 
uit te bouwen.
Sander Bach. Je bent de persoon met het grootste relativeringsvermogen die ik ooit 
ben tegengekomen en dat in combinatie met je enorm droge humor is een fantastische 
combinatie. Man, wat heb ik gebaald toen je ook een bureau in het CCA kreeg en 
daardoor minder op de gang zat. Tussen al het gekakel door van de resterende collega’s 
op de kamer werden jouw onnavolgbare theorieën en relativeringen in ieder geval 
door mij enorm gemist. Gelukkig konden we regelmatig even pauzeren of richting West 
fietsen om de dagelijkse perikelen van het leven als PhD te bespreken.
De hoge heren
Buijs, Alblas, Milan, Kroese, MacD, Lagaaij, Bolier, Labib en Bus, de afgelopen jaren heb 
ik meer dan eens een vakantie, weekend of avond moeten overslaan maar ik hoop dat 
jullie na het openslaan van dit boekje iets beter begrijpen waarom. Ik hoop op nog vele 
avonden drinken, grappen en lachen om onze hoogoplopende discussies over de (on)
zin van robots, voorkomkunde, gebruik van de fax en waarom datumprikkers en mijn 
rooster niet werken. Ook Jaar 2010 ontzettend bedankt voor jullie vriendschap, tijd, 
hulp en interesse.
Pap en mam, bedankt voor de kansen die jullie me hebben gegeven. Hoewel jullie me 
hebben opgevoed om altijd een bijbaantje te hebben om de waarde van geld te leren 
heb ik mede door jullie support tijdens mijn studententijd het aangename met het 
noodzakelijke kunnen combineren. Dat jullie beiden ook door een vorm van kanker 
zijn geraakt toen ik geneeskunde studeerde heeft mij geleerd dat het contact met een 
patiënt en zijn/haar familie het allerbelangrijkste aspect in het artsen vak is. Ik ben 
enorm dankbaar dat het nu goed gaat en dat jullie dit mee kunnen maken.
Justin, kleine broer, als puber snapte je al helemaal niks van mijn keuze voor de in jouw 
ogen eindeloze studie geneeskunde. Dat je hem uiteindelijk zelf toch ook maar wilde 
gaan doen was daarom een verrassing en ik heb veel respect voor je volharding om 
dat, na 2x uitgeloot te zijn, via het pittige zij-instroom programma alsnog te bereiken. 
Ik ben hartstikke trots dat je mijn pad verder hebt gevolgd en ook in het RKZ bent gaan 
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werken bij de chirurgie. Heel veel succes met de volgende stap in je carrière en ik hoop 
dat je snel tot een goede keuze komt.
Lieve Miek, dankjewel voor je vertrouwen en eindeloze geduld met mij. Op onze 
vakanties mocht ik een half uurtje per dag werken, in ruil voor een half uurtje shoptijd 
voor jou. Zo vinden we samen voor alles altijd wel een oplossing. Je bent echt áltijd 
vrolijk en weet mij met je aanstekelijke enthousiasme en optimisme binnen no time 
weer op te beuren als ik er doorheen zit. Ik hou heel veel van je en heb enorm veel zin 
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